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Abstract 
Both the removal of too much and the failure to remove enough fluid during 
haemodialysis are associated with morbidity and mortality. It has been suggested that 
bioimpedance measurements using the Body Composition Monitor (BCM) and relative 
blood volume (RBV) monitoring can improve fluid management. However, both lack a 
robust evidence base characterising measurements in the clinical setting.  
 
BCM measurements were made in healthy controls to characterise the effect of 
measuring outside standard conditions and were made alongside RBV measurements in 
haemodialysis cohorts with well-defined clinical characteristics that were perceived to 
influence BCM results. 
  
The results suggested that BCM protocols can be flexible regarding measurement paths 
and timing of measurement to ensure as many patients as possible can benefit from the 
technology. The observed tendency for patients with high body mass index (BMI) to 
finish dialysis fluid-depleted does not appear to be related to systematic bias in the 
BCM models, but to a greater tolerance of fluid removal. The tendency for elderly 
subjects to have a degree of excess fluid, as measured by BCM, does appear to be 
associated with changes in tissue hydration linked to sarcopenia. Standard 
measurements in patients with localised lower-limb oedema can lead to attempts to 
remove unrealistic fluid volumes and alternative paths can help optimise targets. 
Feasibility for a trial of interventions to promote fluid mobilisation from oedematous 
tissue was not demonstrated. Simultaneous use of RBV with BCM suggested that 
assumptions underlying current RBV shape analysis use for fluid management can be 
violated and that there is a need for further studies. 
 
BCM can be used across the haemodialysis population, but an understanding of its 
application in individuals with particular characteristics is essential. RBV provides 
complementary information to BCM but there is a need for re-evaluation of RBV 
interpretation, standardisation of measurement categorisation and development of 
intravascular volume measurements. 
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1 Preface 
1.1 Background to the project 
The number of people suffering from renal failure is growing as the prevalence of 
hypertension and diabetes, two of the major risk factors for the condition, increases 
(Stengel et al., 2003). Currently there are around 60,000 people in the UK who regularly 
receive renal replacement therapy (RRT) (Shaw et al., 2013). RRT can be through a 
form of dialysis or a donated kidney. The most commonly used form of dialysis in the 
UK is haemodialysis, typically involving three sessions of about four hours each week 
during which blood is removed from the body, treated and returned. 
  
One of the principal functions of the kidneys is the regulation of fluid levels in the body 
by controlling how excess water is excreted in urine. A healthy kidney will respond to 
changes in fluid intake and output to maintain levels within a narrow range. In 
haemodialysis, fluid status is maintained by removing fluid from the blood using a 
process called ultrafiltration that is controlled by the dialysis machine. 
 
Haemodialysis is burdensome for patients, both practically - the treatment typically 
takes three half days out of their week - and clinically. The process of repeated fluid 
accumulation and removal can put a large stress on the heart, and both under- and over-
hydration have associated cardiovascular complications (Jaeger and Mehta, 1999). 
There is a startling increase in the risk of cardiovascular mortality at all ages in patients 
receiving haemodialysis as compared to the general population. Foley et al. showed that 
a 30 year old dialysis patient in the USA had the life expectancy of a typical 80 year old 
(Foley et al., 1998, Wabel et al., 2009). Five-year survival has improved from 41% for 
patients who started dialysis in 1997 to 53% for those who started in 2007 (Pruthi et al., 
2013) but it is still lower than for most common cancers. Reducing cardiovascular risk 
is considered to be the most important challenges in clinical nephrology today and 
optimising fluid management is an essential element of meeting this challenge. 
  
Managing how much fluid to remove at each treatment is not trivial. Clinical 
assessment has remained central to fluid management and there has been little 
advancement on established indicators of fluid status, such as blood pressure, oedema, 
cramping and dizziness. However, there is increasing acceptance that the use of 
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technology – and in particular bioimpedance and relative blood volume (RBV) 
monitoring - can form a vital part of fluid management (Covic and Onofriescu, 2013, 
Balter et al., 2015). 
  
Bioimpedance analysis is based on measuring the impedance of the body to small 
electric currents. The test can give information on fluid volumes in the body (Kyle et 
al., 2004). Bioimpedance measurements are simple, non-invasive, harmless and 
inexpensive. The technology has long played a role in fluid assessments of dialysis 
patients in the research setting, but has not gained acceptance as a routine tool in fluid 
management. One of the principal reasons has been the need to reference the fluid 
volumes from these measurements to results in healthy controls, leading to problems in 
a patient population in which abnormal body composition (particularly low muscle 
mass) is common. However, recent developments in body composition modelling 
(Chamney et al., 2007) have allowed the assessment of hydration status with 
bioimpedance analysis independent of comparisons to controls. A device based upon 
this new model, the Body Composition Monitor (BCM) (Fresenius Medical Care, Bad 
Homburg, Germany), has been developed and the fluid information it provides has been 
well validated against gold standard body composition measurements (Wabel et al., 
2009). The ability to quantify over- or under-hydration has allowed easily interpretable 
bioimpedance data to be obtained by a device that can be used at the bedside with 
minimal training (Wabel et al., 2007a). 
 
1.2 Unmet health need 
It is well established that there is a need to improve fluid management strategies for 
haemodialysis patients. Current approaches have scarcely developed in decades and 
there is a growing evidence of the complications associated with current management 
approaches (Huang et al., 2015). At the same time, there is an increasingly strong case 
that using BCM to guide populations to fluid status targets can improve outcomes 
(Covic and Onofriescu, 2013) and a growing realisation of the dangers of excessively 
reducing plasma volumes (McIntyre, 2010), which reinforces the need for RBV 
monitoring. Despite this, there remains a great degree of scepticism about the benefits 
of BCM and RBV as routine tools and there is relatively infrequent use of them as part 
of standard patient care.  
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This in part is due to the lack of a strong evidence base for measurement in the clinical 
setting. For BCM, the standard wrist-ankle protocols cannot always be used, as there is 
a high prevalence of anatomical and physiological abnormalities in the dialysis 
population (O'Hare et al., 2003, Ferreira-Filho et al., 2012). There is an unmet need to 
develop a knowledge base to make BCM measurement more flexible and effective. For 
RBV, there are inadequate descriptions for the many factors that impact upon results 
and how these can be managed. 
 
This project was based in a team with over six years’ experience of using BCM and 
RBV as part of routine fluid management and that has undertaken a number of studies 
to try to address some of the concerns about the devices. The BCM was validated for 
paediatric use (Lindley et al., 2010). The need for alternative measurement paths was 
identified in response to the challenge of measuring bilateral amputees from our patient 
population and the use of hand-to-hand measurements was validated for these 
individuals (Keane and Lindley, 2015). A strong association between BCM-measured 
overhydration (OH) and BMI (Lindley et al., 2012) was demonstrated. Finally, a project 
was undertaken to evaluate the introduction of BCM into a unit that had never used the 
technology (Lindley et al., 2014) in collaboration with the NHS Technology Adoption 
Centre, and a guide for implementing BCM in hospital units (NTAC, 2013) developed.  
 
This project aims to develop this work by characterising fluid status measurements 
across different paths, in healthy controls and haemodialysis patients, to improve our 
understanding of how best to use the diagnostic information generated by BCM across 
the dialysis population. It is also evident that there are groups of patients with certain 
clinical characteristics in which BCM measurements need further validation or 
characterisation. There is uncertainty about the validity of BCM at extremes of body 
habitus (Carter et al., 2005) and there is a lack of guidance on how to manage patients 
with abnormal distribution of fluid, such as those with lower-limb oedema. Combined 
use of RBV with BCM allows the association between fluid status and intradialytic 
changes in blood volume to be investigated.   
 
It is hoped that the knowledge generated in this study will facilitate the translation of 
BCM use from being primarily used in research to a technology that can be used and 
interpreted by staff on dialysis units. A more individualised approach to making and 
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interpreting BCM measurements can help to benefit patients across the whole 
haemodialysis population. An increased knowledge base and wider dissemination of 
this knowledge will ultimately improve fluid management strategies throughout the 
NHS and the evidence suggests this will be a significant step towards improved 
cardiovascular outcomes in this patient group (Wizemann et al., 2009).  
 
1.3 Research questions 
Hypothesis: Improving the knowledge base around bioimpedance measurements and 
their relationship with RBV will allow improved and individualised fluid management 
strategies that can be applied across the haemodialysis population. 
 
Research question 1: Can characterisation of alternative measurement paths and timing 
for the BCM, and the use of simultaneous RBV monitoring, lead to more individualised 
and effective fluid management? 
 
Research question 2: Is the tendency for high BMI haemodialysis patients to finish 
dialysis fluid depleted according to the BCM associated with an artefact in the 
mathematical model or with systematic differences in the prescription and delivery of 
treatment? 
 
Research question 3: Is the presence of malnutrition associated with BCM-measured 
fluid overload? 
 
Research question 4: (a) Can BCM measurements be used to assess and monitor 
localised oedema and (b) Can easily administered, non-invasive interventions mobilise 
persistent localised oedema so that it can be recruited into the circulation? 
 
1.4 Structure of the report 
In line with the stated aims of this project, the thesis is structured around an overarching 
narrative which is underpinned by four specific research questions.  
 
This preface, chapter 1, briefly sets out the rationale behind the work and the hypothesis 
examined. 
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The background to the research is then examined in detail in chapter 2. The 
consequences of kidney failure and the role of renal replacement therapies are explored 
in the context of fluid homeostasis. Approaches to fluid management in haemodialysis 
are critiqued and the need for objective measures outlined. Finally, the technical aspects 
of the work are outlined in chapter 3 in sufficient detail to understand method sections 
in subsequent chapters. 
 
The four specific research questions will be evaluated individually in chapters 4-7. Each 
chapter includes an introduction, a methods section, results, discussion, limitations and 
implications for clinical practice. 
 
The conclusion of the thesis, chapter 8, draws together the findings of each of the 
studies, puts them into the context of the central aim of the work, looks at the 
limitations of the studies and considers what further work is needed. 
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2 Introduction 
2.1 Fluid balance 
2.1.1 Fluid balance in health 
Water is the major constituent of the human body and plays a part in numerous 
functions, including regulation of oxygen and carbon dioxide, transport of nutrients and 
waste products, heat regulation and chemical distribution (Tortora and Derrickson, 
2009). The body regulates fluid levels primarily through the kidney’s ability to control 
how excess water is excreted in urine. 
 
Due to the important functions relating to waste removal and regulation, the kidneys 
receive almost 25% of the cardiac output, meaning that in adults around 1200 ml/min of 
blood can pass through the kidneys (Tortora and Derrickson, 2009). The blood splits 
into many arteries which supply around two million nephrons, and these form the 
functional units of the kidneys. Here, the glomeruli create a hydrostatic pressure 
gradient which forces water and solutes from the blood plasma into the renal tubules. In 
the tubules, two processes occur which are central to the homeostatic functions of the 
kidney. Selective reabsorption causes about 99% of the filtered fluid and many useful 
solutes to return to the blood via reabsorption at the tubule cells (Tortora and 
Derrickson, 2009). Conversely, tubular secretion acts to remove further waste products 
into the filtered fluid, which is then collected and passed to the ureter as urine. 
  
There are two main control systems that regulate urine production: osmoreceptors 
monitor the serum osmolality and baroreceptors monitor intravascular volume. The 
osmoreceptors are cells in the hypothalamus that monitor changes in extracellular 
tonicity. As sodium accounts for the majority of extracellular fluid (ECF) tonicity, the 
cells are essentially monitoring sodium concentration (Verbalis, 2007). Changes in 
sodium concentration indirectly indicate fluid balance disturbances through the effect of 
dilution or concentration and the osmoreceptors act to address the disequilibrium. 
Baroreceptors exist in the right atrium and great veins and monitor intravascular volume 
via transmural pressure. The numerous receptor points reflect the fact that there can be 
varying volume status across the vasculature (Louden, 2012). Pressure increases or 
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decreases indicate hyper- or hypo-volemia respectively and stimulate actions to restore 
normal pressure. 
 
Antidiuretic hormone (ADH) and the renin-angiotensin-aldosterone system (RAS) 
provide the principal responses to fluid disturbances. ADH increases the permeability of 
distal tubules and the collecting duct to increase reabsorption of water without sodium, 
thereby causing excretion of concentrated urine (Abbrecht, 1980). It is produced in 
response to hypovolemia-induced reductions in pressure at the baroreceptors and 
osmoreceptor stimulus from high tonicity. The RAS is triggered in response to stimuli 
from baroreceptors only. It is a cascade reaction, based on renin secretion by the 
kidneys, renin-facilitated formation of angiotensin I and angiotensin II and finally the 
production of aldosterone. The chain of events acts to preserve fluid, by increasing 
sodium reabsorption in the distal tubular cells of the kidney, increasing plasma 
osmolality and stimulating ADH release and the thirst mechanism (Abbrecht, 1980). 
 
The different receptors and response mechanisms have quite different characteristics. 
Plasma osmolality is one of the most tightly controlled parameters in human physiology 
and the osmoreceptors are very sensitive to small changes in tonicity (Verbalis, 2007), 
whereas it is not until there is an approximate 10% drop in blood volume that 
baroreceptors are triggered (Guyton and Hall, 2006). However, the ADH response 
triggered by the baroreceptors is much stronger and long lasting than that from 
osmolality changes (Louden, 2012). 
 
2.1.2 Fluid balance in disease 
2.1.2.1 Fluid balance in chronic kidney disease 
Chronic kidney disease (CKD) is an umbrella term encompassing many different 
disease processes and is defined by the presence of abnormal kidney structure and/or 
function. CKD is classified into five stages based on the glomerular filtration rate 
(GFR), with decreasing GFR indicating worsening CKD. 
  
As kidney function declines, individuals will need to consider a form of RRT. Currently 
there are nearly 60,000 people in the UK who regularly receive RRT (Rao et al., 2015). 
RRT can be through a form of dialysis or a donated kidney, with transplanted kidneys 
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accounting for more than half of the people receiving RRT and haemodialysis being the 
most commonly used form of dialysis in the UK. 
 
When somebody is receiving RRT, fluid balance is generally managed by the particular 
RRT technique in addition to residual renal function - where present - which can be 
augmented by the use of diuretics. In CKD patients who have yet to reach the need for 
RRT, fluid balance is largely maintained by the remaining function of the kidney with 
the use of diuretics and sometimes dietary advice to limit fluid intake. 
 
2.1.2.2 Fluid balance in haemodialysis 
The kidneys fail in different ways; some haemodialysis patients have sufficient renal 
function to maintain their hydration close to normal, others pass no urine at all and are 
dependent on the treatment and their ability to manage their salt and fluid intake to 
control their fluid status. 
 
Excess fluid tends to accumulate in the ECF, across both the intravascular fluid (IVF) 
and interstitial fluid (ISF) compartments. Up to a certain point, the fluid will 
proportionately increase the volume of each compartment, but eventually the blood 
volume will plateau and the greater compliance of the interstitium means that fluid will 
almost exclusively accumulate there, manifested as oedema (Guyton and Hall, 2006). 
 
The accumulated fluid is removed using a process called ultrafiltration during 
haemodialysis. Ultrafiltration for thrice weekly haemodialysis can be equivalent to the 
whole plasma volume being removed during a four hour session (Thijssen et al., 2013). 
This puts a huge strain on the cardiovascular system and the body reacts with 
compensatory mechanisms to try and maintain haemodynamic stability. These 
mechanisms include vasoconstriction in arterioles and venules to increase systemic 
vascular resistance and ensure that central blood volume is maintained (Prakash et al., 
2002).  
 
Ultrafiltration removes fluid from the blood volume alone, so the excess fluid in the 
interstitium must be able to pass into the blood before it can be removed, a process 
called vascular refilling. The capillary walls act as the main barrier between the IVF and 
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ISF where fluid exchange takes place (Korthuis, 2011). The forces driving the fluid 
exchange were first described by Starling (Starling, 1896). The net filtration pressure 
across the capillary wall is the sum of the difference in hydrostatic pressure in the 
capillary and the interstitium and the difference in oncotic pressure between the 
capillary and interstitium (Korthuis, 2011). As fluid is removed from the blood volume, 
there is a reduction in the hydrostatic pressure gradient from the capillaries to the 
interstitium and, given that plasma proteins are too large to pass through dialyser 
membranes, an increase in the oncotic pressure gradient across the capillaries (Chamney 
et al., 1999). Both these changes have the effect of refilling the vascular space with fluid 
to replace that lost in ultrafiltration.  
 
There are many factors that affect the refilling rate. There are treatment related factors - 
ultrafiltration rate, plasma sodium concentration, dialysate temperature (Palmer and 
Henrich, 2008) and patient related factors, including the response of vasoactive 
substances and vascular tone adjustment, body size and plasma volume, fluid overload, 
regional blood flow distribution, plasma protein concentration and transcapillary 
pressure gradient (Schneditz et al., 1992, Santoro et al., 1998). Many of these factors are 
patient specific and can vary from session to session. This makes it difficult to tailor 
ultrafiltration rates according to refilling rate and a standard approach to ultrafiltration is 
often taken across whole patient groups. 
 
Unless refilling from the interstitial volume can compensate for ultrafiltration, blood 
volume will drop and this can cause intradialytic hypotension (IDH). This is defined as 
an acute drop in blood pressure; it is a common and serious complication of 
haemodialysis (van der Sande et al., 2000). The body’s response to a drop in blood 
volume is stimulated by the baroreceptors, since ultrafiltration removes isotonic fluid. 
However, the pathophysiology of IDH is still not well understood. The body’s 
autonomic response to a drop in blood volume can be compromised in haemodialysis 
patients, who may have congestive heart failure and diastolic dysfunction, autonomic 
neuropathy or disturbed acid-base and electrolyte balances (Thijssen et al., 2013). IDH 
is also related to decreased venous compliance, decreased systemic vascular resistance, 
decreased stroke volume and cardiac index (Kooman et al., 1992, Converse et al., 1992, 
Nakamura et al., 1991, Boon et al., 2004), all of which inhibit the body’s response to 
haemodynamic stress. The problems associated with ultrafiltration and IDH can also be 
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compounded by excessive interdialytic fluid gains (IDFG) - related to salt intake, social 
drinking, sodium loading during haemodialysis or short haemodialysis sessions – and 
haemodialysis treatment itself can cause heat accumulation and induce vasodilation in 
cutaneous blood vessels (Schneditz and Levin, 2001). 
 
Interventions for prevention of IDH include a number of different approaches. These 
include optimisation of the ultrafiltration rate - such as treatment duration and 
frequency, ultrafiltration profiles or RBV biofeedback systems - or interventions to 
improve the cardiovascular response to ultrafiltration and plasma osmolality changes – 
such as use of midodrine, dialysate temperature changes or dialysate sodium profiling.  
 
As well as the cardiovascular complications linked to fluid removal, more recent work 
has demonstrated the damaging effects of ultrafiltration related circulatory stress and 
reductions in perfusion of a number of other end organs, leading to structural and 
functional abnormalities of the brain (Eldehni and McIntyre, 2012), ischemic damage to 
the gut resulting in endotoxin translocation into the circulation (McIntyre et al., 2011) 
and a reduction of residual renal function in the kidney (Hur et al., 2013). 
 
2.1.2.3 Fluid management in haemodialysis 
In haemodialysis, the removal of fluid is managed by giving a patient a `target weight'. 
This is the weight after dialysis that minimises the cardiovascular risks due to fluid 
overload without causing discomfort or compromising residual renal function. The 
accumulation of fluid in the body is assessed before each dialysis session using changes 
in body-weight and the dialysis machine is programmed to restore the patient to their 
target weight. Routine fluid management of dialysis patients includes dietary advice and 
the use of antihypertensive medications, but is fundamentally related to the patient's 
target weight. If this is too high, patients will be systemically overhydrated throughout 
the interdialytic period (Kuhlmann et al., 2005). If the target weight is too low, patients 
will be excessively dehydrated and at risk of IDH complications, loss of any residual 
renal function and increased post-dialysis fatigue (Lindley and Keane, 2014). 
  
Historically, a patient's target weight was defined on the basis of clinical assessments 
and changed in response to symptoms during dialysis (Jaeger and Mehta, 1999). 
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Hypertension, puffy tissue or breathlessness can indicate overhydration, whereas 
hypotension, cramping, dizziness or nausea are frequently used as signs of dehydration. 
Unfortunately these indicators can result from conditions that are unrelated to hydration 
and patients can be fluid overloaded with no obvious symptoms. The result is that the 
management of fluid status can be reduced to a somewhat `trial and error' approach. 
 
The clinical examination has been the cornerstone of fluid management in patients with 
kidney failure. Yet it is widely accepted as being far from adequate (Ishibe and Peixoto, 
2004). Evidence shows that clinical examination has poor sensitivity and specificity in 
identifying fluid imbalance (McGee et al., 1999, Chung et al., 1987). Part of the 
problem with the clinical examination is the reliance upon parameters that are indirectly 
linked to fluid status and affected by other physiological effects. Blood pressure, for 
example, is a fundamental part of clinical assessments, but has been shown to have very 
poor correlation with fluid status in this population (Lindley and Keane, 2014). The 
drive for normalisation of blood pressure as a central aspect of fluid management 
invariably leads to a focus on reducing target weights to try to reduce fluid overload and 
blood pressure. This idea is the basis of the ‘probing’ approach to fluid management, 
which involves systematic reduction of target weight until the point when the patient 
experiences symptoms relating to IDH (Canaud and Lertdumrongluk, 2012). This 
approach would invariably use the term ‘dry weight’ in place of target weight, stressing 
the approach of drying patients out as much as possible. While shown to be successful 
at normalising blood pressure and reducing cardiovascular risk (Charra et al., 1992), this 
approach clearly puts patients more at risk of the complications relating to excessive 
fluid-depletion. 
 
A number of novel techniques have been developed to be used in addition to clinical 
examinations: 
- Lung comets: When excess fluid accumulates in the lungs, the air-fluid interface 
at the alveoli produce a pronounced hyperechoic artefact known as a ‘comet’ on 
ultrasound assessments. It has been shown that the number of comets observed 
is directly related to the degree of excess lung water and also to survival, both in 
patients with lung congestion (Zoccali et al., 2013) and in haemodialysis patients 
(Siriopol et al., 2013). There is currently a large multinational trial assessing the 
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effect of using lung comets as a method of fluid management in haemodialysis 
patients (Zoccali et al., 2011). 
- Biomarkers: Atrial natriuretic peptide (ANP) is secreted in response to fluid 
overload as stimulated by increased atrial transmural pressure (Ishibe and 
Peixoto, 2004) and as such ANP levels can be used as an indicator of fluid 
status. However, there is significant variability in results (Kouw et al., 1993) and 
it also has the drawback of not being able to differentiate fluid depletion from 
normal hydration. There is no evidence that it can be used in clinical practice. 
Brain natriuretic peptide (BNP) has also been given much attention, particularly 
in heart failure patients, but suffers from similar limitations as ANP. Both 
markers have good prognostic power for left ventricular hypertrophy and 
dysfunction and mortality (Zoccali et al., 2001), but the ability to be used in 
routine clinical management and improve results is lacking (Nishikimi et al., 
2001, Ishizaka et al., 1994). 
- Inferior vena cava diameter: The intravascular volume can be indirectly 
assessed by ultrasound measurements of the diameter of the inferior vena cava 
(IVC), which have been shown to correlate well with central venous pressure. 
This assessment can also be supplemented by measuring changes in the IVC 
diameter during deep expiration, known as the collapsibility index. The use of 
these indices for target weight assessment has been shown to be able to 
differentiate patients under-hydrated at the end of haemodialysis with those who 
are normo- or hyper-hydrated (Cheriex et al., 1989). Furthermore, it has been 
shown that IVC diameter can detect clinically unapparent volume depletion and 
that using the results to inform target weight changes improved blood pressure 
and heart rate (Leunissen et al., 1993). However, measurements post-dialysis do 
not account for fluid redistribution from the extravascular space, so it is 
important to keep in mind that the technique is based on intravascular fluid, not 
whole body excess fluid. There are also problems in interpreting IVC diameter 
in patients with heart failure (Ishibe and Peixoto, 2004).  
- Bioimpedance and blood volume monitoring: The most established techniques 
for aiding traditional, clinical examination-based fluid management are 
bioimpedance and blood volume monitoring. These techniques are considered in 
detail in sections 2.3 and 2.4. 
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2.1.2.4 Fluid balance and oedema formation 
In some tissues the hydrostatic pressure gradient exceeds the osmotic pressure gradient 
along the length of the capillary bed, causing a large net fluid loss due to filtration and 
the need for filtered fluid to be returned to the blood via lymphatics (Taal et al., 2012). 
Oedema forms when the capillary filtration rate exceeds the lymphatic drainage rate 
(Topham and Mortimer, 2002). The lower limbs are subject to higher hydrostatic 
pressures due to gravity, increasing transcapillary filtration into the interstitium (Stick et 
al., 1993b) and this is one of the reasons that oedema is often found in the lower limbs. 
 
At normal hydration the interstitium is relatively non-compliant such that small 
increases in ISF will produce large increases in interstitial hydrostatic pressure, 
opposing further fluid leakage from the IVF to the ISF. However, as the tissue becomes 
oedematous, the compliance of the ISF drastically increases, allowing it to 
accommodate significant amounts of excess fluid (Korthuis, 2011). The increased 
compliance reduces the compensatory hydrostatic pressure increases in the ISF and so 
reduces the rate of refilling, making oedematous fluid more difficult to remove during a 
short dialysis session. 
 
Venous and lymphatic function is dependent on the muscle pump for return of fluid 
from the extremities. The movement of the limbs drives the venous pump and the 
pressure changes in the tissue provides a rhythmic opening of the lymphatics, increasing 
lymph transport.  
 
2.2 Body composition assessment 
2.2.1 Body composition models 
To allow quantitative analysis of body composition it is necessary to generate models 
that describe relationships between specific body components in a numerical way. The 
basis of such modelling is that there are properties of the human body that are constant 
across all individuals. For many years, most research was based on the two 
compartment model of fat-mass (FM) and fat-free mass (FFM), however these were 
based on observations on a small, ethnically uniform, male group of individuals (Wang 
et al., 2008). When it became clear that the assumptions that underpinned this approach 
were insufficient, more components were added to the models to help to improve the 
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prediction ability, leading to 6-compartment models based on fat, water, bone mineral, 
protein, soft-tissue minerals and glycogen (Wang et al., 1998). 
 
Figure 2-1: Five levels of body composition. ECF is extracellular fluid and ECS is 
extracellular solids. Adapted from (Wang et al., 1992) 
 
In an attempt to provide a framework for consistent description of multi-compartment 
body composition models and to facilitate research in the area, Wang described a 
comprehensive five level model of body composition (Wang et al., 1992). The five 
levels run from the descriptions at the atomic level through to descriptions of the body 
as a whole (fig. 2-1) and provide definitions and equations to quantitatively relate 
different constituents with the unit weight, body weight.  
 
Level I, the atomic level, describes the body in terms of the fundamental building 
blocks which make it up. Atoms combine together to form thousands of different types 
of molecules in the body, and the description of these molecules make up level II, the 
molecular level. Due to the number and complexity of the molecules in the body, it is 
necessary to categorise them into related molecular species: water, lipid, protein and 
other. Level III represents the cellular level, which organises molecules into the 
functional components of the living body, cells. The model describes the body at this 
level with cells, ECF and extracellular solids.   The components of level III are grouped 
into tissues which make up the tissue-system level, IV. Finally, level V indicates the 
whole-body level which looks at body size and shape. 
 
The practical application of this framework lies in the ability to quantify the relationship 
between known compartments that are tightly controlled, measure specific 
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compartments directly or indirectly and deduce the size of further compartments by 
simple arithmetic equations for body weight. An example of this is the measurement of 
FM from a measurement of ECF, using the two compartment model for FM and FFM 
based on the level II molecular level: 
 It is well described that total body water (TBW) is tightly controlled at 73% of 
FFM 
 There are a number of common methods for measuring TBW (e.g. tracer 
dilution), allowing the estimation of FFM 
 The two compartment model defines body weight as the sum of FM and FFM, 
meaning that from a measure of TBW and body weight, estimates of FM and 
FFM can be made. 
 
Deciding which body composition level to use in practice is very much dependent on 
the purpose of the body composition measurement. Level V, whole body, includes some 
of the simplest and most used assessments such as height, weight and body mass index 
(BMI). These are often used for population based research and categorisation, but it is 
well known that BMI, for example, is flawed as a measure of fat due to the fact that 
individuals of the same sex, height and weight can have markedly different fat and 
muscle masses. At the other end of the spectrum, level I, atomic level models tend to be 
applied to sophisticated tests, such as neutron activation, and used primarily in research 
and as reference measurements (Heymsfield et al., 1997). 
 
2.2.2 Body composition in kidney disease 
Because fluid status is frequently perturbed in patients on haemodialysis, many of the 
body composition models and measurements that are related to fluid status are invalid. 
If we consider the example described above, excess fluid in haemodialysis patients 
accumulates in the FFM so the assumption of 73% hydration of FFM is invalid and will 
cause overestimation of FFM and underestimation of percentage FM. 
 
To overcome this, body composition in haemodialysis was often described using a 
Level III, cellular approach by measuring ECF and TBW. Target weights could then be 
reviewed based on reference ranges for ECF normalised by intracellular fluid (ICF) or 
TBW. However, this approach is limited due to the fact that there are inter-individual 
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differences in lean and adipose tissue compartments which alter the normalised ECF 
independent of fluid status.  
 
One approach to account for differences in lean and fat proportions was to consider the 
volume of excess fluid in a patient as a separate compartment. Kraemer proposed a four 
compartment model, consisting of the excess fluid, fat, muscle and remaining ‘basic’ 
components (Kraemer, 2006). This introduced the concept of normo-hydrated weight - 
being the weight of the body when all the tissues have normal fractions of ICF and ECF 
- and overhydration (OH) - which is the fluid volume above or below that of a norm-
hydrated subject, for positive and negative values respectively. Chamney et al. refined 
this idea and proposed a 3-compartment model (Chamney et al., 2007). This model is 
centred on the concept that, in health (when kidney disease is not present), lean tissue 
and adipose tissue compartments are normally hydrated and, crucially, they have fixed 
proportions of ICF and ECF across all individuals. On this basis, it is relatively 
straightforward to show that simply by measuring ECF and ICF and knowing body 
weight and height, simultaneous equations can allow the quantification of normally-
hydrated lean tissue mass, normally-hydrated adipose tissue mass and OH (for details 
see (Chamney et al., 2007)).  
 
Figure 2-2: Estimation of the fractional hydration of ECF and ICF in lean and adipose 
tissue, by extrapolation of regression lines based on dilution based fluid volumes and 
DEXA body fat 
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This model theoretically allows the measurement of OH over a wide range of body 
compositions, as long as the assumption about constant fractions of ECF and ICF in the 
lean and adipose tissue compartments is valid. The values for these fractions were 
determined experimentally. Simultaneous measurements of DEXA body fat, ECF with 
bromide dilution and TBW with deuterium dilution (allowing an estimate of ICF by 
subtraction of ECF) were made. Percentage body fat was plotted against ECF and ICF 
and a regression line allowed an estimation of the fractional ECF and ICF at the 
hypothetical states of 0 and 100% body fat - i.e. the percentage ECF and ICF for lean 
and adipose tissue (see fig.2-2). 
 
The model is commonly used with bioimpedance assessments of ECF and ICF for 
measuring normo-hydration weight and OH in particular, but also for lean and adipose 
tissue. There are a number of studies that have attempted to validate the measurements, 
(Wabel et al., 2009, Wabel et al., 2007b) but, for normo-hydration weight and OH, this 
is very difficult as no gold-standard exists. There is a growing body of evidence 
supporting a link between measurements of OH using this model and outcomes 
(Wizemann et al., 2009, Moissl et al., 2013, Onofriescu et al., 2014), which further 
supports the clinical validity of the values from the model. However, it must be 
acknowledged that all measurement techniques have their limitations and even the 
criteria methods used in the development of this model have a certain degree of 
uncertainty which will feed into that of the model. This should be considered for each 
application of the model.  
 
2.2.3 Body composition measurement 
Table 2-1 summarises some of the most common body composition measurements (Siri, 
1993, Duren et al., 2008, Heymsfield et al., 2005). We can broadly describe them as 
being direct or indirect. Direct measurements include dilution methods and neutron 
activation, whereas indirect measurements rely on the results of a direct measurement. 
By definition, indirect methods will have greater uncertainty due to the inter-individual 
variance in biological assumptions which underpin the direct or criterion methods that 
they rely on (Duren et al., 2008). However, it must be noted that no body composition 
measurements are free from comparison to a reference and, as such, a set of 
assumptions about the biological conditions of an individual. This biological variability 
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must be considered alongside the experimental error when evaluating any technique 
(Siri, 1993). 
 
Technique Examples Type Use Biological 
uncertainties 
Measurement 
uncertainties 
Anthropometry Weight; BMI; 
skinfold thickness 
Direct; 
Indirect 
Nutritional 
status 
Population 
specific; direct 
measures cannot 
distinguish fat 
and lean tissue  
Equipment 
calibration; inter-
user variability 
Bioimpedance BIA 
BIS 
Direct; 
Indirect 
Fluid volumes BIA is 
population 
specific. Both 
BIA/BIS are 
dependent on 
assumptions 
about shape, and 
resistivity 
fluid distribution; 
electrode 
positioning 
DEXA Pencil beam; fan-
beam 
Direct Fat, lean and 
bone  
Attenuation 
properties of 
different tissues 
in 
reconstruction 
algorithms  
Beam hardening 
Densitometry Under-water 
weighing; 
Air displacement 
plethysmography 
Indirect Fat mass Assumes 
reference body 
composition for 
all components 
except variable 
adipose tissue 
Assumptions on 
the amount of air 
in the body; 
requires 
compliant subject 
Dilution Deuterium; 
bromide 
Direct Fluid volumes Assumptions on 
tracer kinetics 
Assay 
uncertainty 
Whole body 
counting 
40K counting; 
Neutron 
activation 
Direct Level I, 
atomic 
compartments 
Assumptions on 
40K abundance 
Reliance on 
highly technical 
equipment.  
Imaging  CT; MRI Direct Level IV 
tissue 
compartments 
Relationships 
between tissue 
type and pixel 
values 
Finite resolution; 
attenuation 
correction; 
Table 2-1: Comparison of different body composition measurements. BIA is bioimpedance 
analysis, BIS is bioimpedance spectroscopy, DEXA is dual energy x ray absorptiometry, 
40K is the isotope potassium-40, CT is computed tomography, MRI is magnetic resonance 
imaging. 
 
 
2.3 Bioimpedance 
2.3.1 Introduction 
Bioimpedance is defined as the ability of biological tissue to impede electric current 
(Grimnes and Martinsen, 2011) and refers to the measurement of the electrical 
properties of biological tissue. It is used in an extremely wide range of applications, 
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from measuring the characteristics of individual cells through to optimising 
performance in sports science and monitoring body composition and physiology.  
 
Figure 2-3: Cole-Cole plot 
 
The principle that underpins clinical applications is the relationship between impedance 
and the volume of fluid - the conducting material - in the tissue under investigation. 
This relationship can be characterised empirically, allowing estimation of body fluid 
volumes from a measurement of bioimpedance, and this simple approach has been and 
remains the basis of most devices. However, as far back as the early twentieth century, 
pioneering work around the physical and chemical properties of tissue that underpin 
bioimpedance was underway. Kenneth Cole and his brother Robert investigated the 
frequency-dependent impedance of capacitively coated spheres in suspension (Cole, 
1928) and described the circular arc, now commonly known as a Cole plot (see fig. 2-
3), that is found if impedance at different frequencies is plotted on an Argand diagram. 
As technology improved in the latter part of twentieth century, measurement processes 
improved and bioimpedance could be applied to body composition analysis. Thomasset 
developed the concept of differentiating ECF and TBW with needle electrodes by 
measuring at low and high frequency respectively (Thomasset, 1963), which was then 
replaced by the less-invasive surface electrode measurement technique (Hoffer et al., 
1969).  
 
There is now a bewildering array of bioimpedance analysers available for health-related 
applications, from cheap devices designed for home monitoring of body composition up 
to expensive and complex systems for specialist and niche fields. 
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2.3.2 Electrical properties of tissue 
2.3.2.1 Defining bioimpedance 
Impedance (Z) is a complex quantity composed of a resistive component (R) and a 
reactive component (X), as defined by equation 2-1 (where i denotes the square root of -
1). Following normal mathematical handling of complex numbers, this allows 
impedance to be displayed graphically on an Argand diagram, where resistance and 
reactance describe the real and imaginary parts of impedance respectively (fig. 2-4), and 
allows the calculation of the real terms impedance magnitude (|Z|) and phase difference 
(φ) based on equations 2-2 and 2-3. 
 
Figure 2-4: Argand diagram showing the relationship between impedance (Z), resistance (R), 
reactance (X) and phase angle (∅) 
 
Equation 2-1                                                       𝒁 = 𝑹 + 𝒊𝑿 
Equation 2-2                                                    |𝒁| =  √𝑹𝟐 + 𝑿𝟐 
Equation 2-3                                                      ∅ = 𝒕𝒂𝒏−𝟏 (
𝑿
𝑹
) 
Bioimpedance specifically refers to measuring the impedance of biological tissue. If an 
electric current is introduced into tissue and the potential difference is measured, the 
impedance magnitude |Z| can be calculated based on Ohm’s law as the ratio of the 
potential difference and the current. If the phase difference between the current and 
potential difference is measured, the resistance and reactance can be calculated.  
Impedance can equally be described by its inverse term, admittance, which is composed 
of the real term conductance (how easy it is for a current to flow) and susceptance (how 
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susceptible a material is to polarisation). These terms can be used to help describe 
bioimpedance theory, but measurement processes tend to use the term impedance and 
its constituent terms. 
 
2.3.2.2 Conductive properties of tissue 
When a current is introduced to tissue, it is conducted through the body by the 
movement of ions. At the cellular level, the body can be described as a bath of fluid 
containing cells. Cell membranes are formed by a phospholipid bilayer which acts as an 
insulator separating a volume of conducting fluid outside the cell, the ECF, and a 
volume of conducting fluid inside the cell, the cytoplasm. The arrangement of an 
insulating layer separating two conductive regions defines a capacitor in an electric 
circuit. As such, the impedance of the body can be considered as composing of a 
viscous resistance to ion movement, which is described electrically as a resistance, and 
from the interaction of ions with cell membranes acting as capacitors, forming the 
reactive part of impedance.  
 
 
Tissue 
Conductivity (S/m) Φmax 
at <10 MHz 
 
Anisotropy 1 Hz - 10kHz 1MHz 
Human skin, dry 10-7 10-4 80° ? 
Human skin, wet 10-5 10-4 30° ? 
Bone 0.01 - 20° ? 
Fat 0.02-0.05 0.02-0.05 3° Small 
Lung 0.05-0.4 0.1-0.6 15° Local 
Brain 0.1 0.15 15° ? 
Liver 0.2 0.3 5° ? 
Muscle 0.05 0.6 30° Strong 
Whole Blood 0.7 0.7 20° Flow dependent 
Urine 0.5 0.5 0° 0 
Saline, 9% at 20oC 1.3 1.3 0° 0 
Saline, 9% at 37oC 2 2 0° 0 
Table 2-2: Typical electrical properties of tissue, data adapted from (Grimnes and 
Martinsen, 2011). Φmax defines the maximum phase difference 
 
At the tissue level, impedance of the body is extremely non-uniform and anisotropic. 
Table 2-2 shows typical conductivity values (inversely proportional to resistivity) for 
different tissues, with corresponding phase angles and the degree of anisotropy 
displayed. The disparity highlights the significant effect body composition has on any 
bioimpedance measurement; for example, the conductivity of muscle is around ten 
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times that of fat. The effects of anisotropy are particularly notable for muscle tissue, 
which can have values of conductivity up to ten times greater parallel to muscle fibres 
as compared to perpendicular, dependent on measurement frequency (Epstein and 
Foster, 1983). 
 
2.3.2.3 Frequency dependence of bioimpedance 
 
Figure 2-5: Idealised version of the typical frequency dependent permittivity of biological 
tissue. Adapted from (De Lorenzo et al., 1997) 
 
Bioimpedance is heavily dependent on the frequency of the applied current. This is 
primarily related to the fact that cell membranes are poor conductors but good 
capacitors. Zero-frequency current, known as direct current (D.C.) is not able to pass 
through a dielectric, such as cell membranes, and so the impedance is based solely on 
the resistive properties of the ECF. Alternating current (A.C.) signals stimulate a 
changing potential over cell membranes, causing them to store and discharge electric 
charge, allowing the passage of electric current into the ICF and generating the reactive 
component of impedance. 
 
Permittivity is a measure of how easily bound charges are moved or polarised in the 
presence of an electric field and is related to reactance (Dean et al., 2008). Because 
tissue contains many different charged ions and molecules that have their own response 
to an alternating electric field, biological tissue displays a frequency dependent 
distribution of permittivity values known as dispersion (Schwan, 1957). The 
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characteristics and mechanisms responsible for each region were described by Schwan 
as alpha, beta, delta and gamma regions (fig. 2-5) (Schwan, 1993). Most bioimpedance 
measurements are based on the region of beta-dispersion (tens of kHz to 100MHz) 
where dispersion is due to the cellular structure of tissue and the dielectric properties of 
cell membranes discussed above. At lower frequencies, in the alpha region, electrode 
polarisation is very high and the dispersion mechanisms are not well understood. The 
gamma and delta regions are related to the polarisation of water molecules and do not 
allow the investigation of cellular level body composition (Dean et al., 2008). 
 
 
Figure 2-6: The change in reactance with A.C. signal frequency 
 
Within the region of interest to bioimpedance measurements, the relationship between 
reactance and frequency can be seen in figure 2-6: increasing the frequency reduces the 
time between discharge of the membranes and the build-up of charge on the membranes 
which opposes current flow. 
 
2.3.2.4 Cole-Cole model 
Kenneth Cole performed pioneering work around the electrical properties of cell 
membranes. His work looking at the bulk properties of a cell suspension showed 
empirically that when resistance is plotted against negative reactance over a range of 
frequencies it produces an arc of a circle with centre below the axis. The depressed 
centre is due to the fact that cell membranes are imperfect capacitors and also the 
variation in cell type gives different time constants (Cornish et al., 1993). The equation 
describing the empirically determined impedance locus, known as the Cole equation, is 
defined as: 
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Equation 2-4                                                 𝒁 = 𝑹∞ +
𝑹𝟎−𝑹∞
𝟏+(𝒊𝝎𝝉)𝜶
 
Where: R0 is the resistance at zero frequency; R∞ is the resistance at infinite frequency; 
ω is the angular frequency (where ω=2π x frequency); τ is the time constant - the 
constant of a capacitive circuit describing the rate of charge accumulation and 
discharge; and α is a parameter relating to the dispersion characteristics of the tissue. 
 
2.3.2.5 Equivalent circuit of a cell 
 
 
Figure 2-7 Equivalent circuit model of biological tissue. R1 represents the resistance of the 
ECF, R2 the resistance of the ICF and C1 the capacitance of the cell membranes 
 
Various models have been proposed to simulate the electrical properties of tissue and 
the empirical observations outlined by Kenneth Cole. The most commonly employed 
model consists of a parallel circuit with a resistor in one arm and a resistor and capacitor 
in the other arm, corresponding to the ECF and ICF respectively (fig. 2-7). The response 
of this modelled circuit with changing frequency describes an arc as predicted by Cole’s 
model 
 
As frequency increases, the reactance of the cell membranes decreases (see fig. 2-5) and 
the effective conducting volume increases as current penetrates into the cells, reducing 
the resistance. Reactance is zero for D.C. currents, begins to increase with frequency - 
as current begins to interact with the cell membranes - before reaching a plateau when 
this effect is balanced by the reducing absolute reactance. Continued increases in 
frequency reduce the reactance further until, at infinite frequency, the rate of charge and 
discharge at the cell membranes becomes so high that the effect of the cell membrane 
becomes insignificant and the reactance will once more be zero. At this point the current 
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will pass through the ECF and ICF in proportion to the relative volumes and 
conductivities of each compartment (De Lorenzo et al., 1997). The intersection of the 
low frequency impedance loci and the resistance axis is R0 and represents the resistance 
of the ECF while the intersection of the high frequency loci and the resistance axis, R∞, 
represents the resistance of the TBW (figure 2-8). The frequency at which reactance is a 
maximum, the peak of the Cole-Cole plot, is known as the characteristic frequency, fc. 
.  
 
Figure 2-8: Cole-Cole plot showing the changes in reactance 
 
This equivalent circuit model of cell properties allows the Cole equation (equation 2-4) 
to be given in more physiological terms. The measured frequencies, R0 and R∞ can be 
related to compartmental resistances. The resistances of the intracellular and 
extracellular spaces, RE and RI are summed in parallel to get the resistance of the total 
body water, R∞. Using the formula for adding parallel resistances, R∞ can be given in 
terms of RE and RI (equation 2-5). 
 
Equation 2-5:                                                    𝑹∞ =  
𝑹𝑬𝑹𝑰
𝑹𝑬+𝑹𝑰
 
Equation 2-6                                                    𝝉 = (𝑹𝑬 + 𝑹𝑰)𝑪𝒎 
The time constant of the circuit, τ, is given by the cell membrane capacitance, Cm, 
multiplied by the sum of RE and RI (equation 2-6) (Cornish et al., 1993). If equations 2-
5 and 2-6 are substituted into equation 2-4, the Cole equation can be re-written in terms 
of fluid compartment resistances and cell membrane capacitance (equation 2-7). 
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Because the calculation of RI incorporates the uncertainty of measuring R0 and in 
measuring R∞, whereas the calculation of RE is based only on measurement of R0, there 
is greater uncertainty associated with RI and the physiological parameters based upon it.   
 
Equation 2-7                     𝒁 = (
𝑹𝒆
𝑹𝒆+𝑹𝒊
) × (𝑹𝒊 +
𝑹𝒆
𝟏+(𝒊𝝎𝑪𝒎(𝑹𝒆+𝑹𝒊))
𝜶) 
 
2.3.3 Measuring bioimpedance 
2.3.3.1 Measurement approach 
Clinical applications of bioimpedance can be categorised based on the approach to 
recording the impedance data. There are temporal measurements which monitor and 
analyse impedance changes; the primary example of this approach is the use of 
impedance derivatives measured across the thorax to calculate haemodynamic 
parameters such as cardiac output (Moshkovitz et al., 2004). Alternatively, electrical 
impedance tomography uses bioimpedance as an imaging tool, for example in the 
assessment of lung volume and ventilation (Kotre, 1997). By attaching electrodes 
around the circumference of a body segment and applying currents between different 
poles, tomographic images based on differences in conductivity can be formed.  
 
For assessment of body composition, instantaneous bioimpedance measurements are 
made across a single path. Within this field of measurement, there are many different 
approaches, based on the different anatomical regions of investigation, different 
properties of the applied signal and different methods of analysis of the data obtained. 
 
2.3.3.2 Measurement site 
For all non-implantable bioimpedance devices, surface electrodes on the skin are used 
to provide a conducting path to the tissues. ‘Bi-polar’ arrangements refer to 
measurement between two single electrodes which are used to inject current and 
measure the potential drop. ‘Tetrapolar’ arrangements refer to measurements in which 
two pairs of electrodes are used, one pair to inject current and one pair to measure the 
potential drop (fig. 2-9). Tetrapolar arrangements have an advantage in that the 
separation allows a more uniform current density in the region of the measurement 
electrode (Khan et al., 2005). 
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Figure 2-9: Standard tetrapolar electrode arrangement for a whole body bioimpedance 
measurement between wrist and ankle. (Used with permission from LTHT Medical 
Illustration). 
 
The positioning of the electrodes defines the region of the body to be measured. 
‘Whole-body’ techniques indicate the extrapolation of information based on certain 
segments of the body to generate information on whole-body composition. This is most 
commonly based on measurement between wrist and ankle (fig. 2-9), but can also be 
measured between each wrist or between each ankle. The use of foot to foot 
measurements are common in commercial devices designed for home use; pressure 
contact electrodes on foot pads can be incorporated into bathroom scales to allow a 
body composition measurement by simply standing on the device (Khan et al., 2005). 
Similarly, the practical ease of measuring from hand to hand has led to the development 
of cheap devices that have plate electrodes built into handles on a device which can be 
held with outstretched arms for a simple measurement.  
 
Whole-body measurements do have limitations. Modelling the body as a series of 
cylinders (see chapter 2.4.4.1) is based on the knowledge of the length of these 
cylinders, but for practical ease height is universally used as a surrogate for the circuit 
length. This is sometimes corrected for by a factor which uses standard anthropometric 
ratios (De Lorenzo et al., 1997), but will add some uncertainty into results. Also, the 
trunk only accounts for 10% of impedance of the body despite accounting for 50% of 
body mass (Kyle et al., 2004), whereas the forearm only accounts for about 1% of body 
mass yet contributes 25% to whole body impedance (Fuller and Elia, 1989). This means 
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that changes in body composition in the trunk will not be well reflected in whole-body 
measurements, whereas changes in the arm and leg will be overly reflected in whole-
body parameters.  
 
These limitations can be avoided by use of segmental bioimpedance, which allows the 
isolation of one or more segments for measurement. This can give information about 
one segment alone or several segments can be measured individually and summed 
together to give an equivalent estimate to whole body approaches (Zhu et al., 1999). 
Avoiding some of the limitations of whole-body measurements, segmental approaches 
generally give a more precise estimation of the properties of each segment and can 
allow the assessment of regional fluid distributional changes during haemodialysis. 
Electrodes can be positioned at the segment boundaries, with measurements of the 
distance between them defining path length, or alternatively using standard whole-body 
electrode placements on both sides of the body (8-electrode technique) and making 
variations on which electrodes are used for current and voltage (Gibson et al., 2008). 
This, in effect, isolates individual regions of tissue. However, standardisation of 
electrode positioning remains a concern in all segmental approaches (Lorenzo and 
Andreoli, 2003). 
 
2.3.3.3 Measurement signal 
The measurement of impedance is dependent on the interaction between a current 
passing through the tissue under investigation and the voltage measured across this 
tissue. Measurements can be based on applying a voltage and measuring current, or 
applying a current and measuring voltage change. Bioimpedance devices tend to use a 
current with amplitudes in the range of 20 µA to 10mA which is below minimum levels 
of harm (Khan et al., 2005). A high input impedance is necessary to avoid effects due to 
the skin impedance and the variable impedance at the electrode-skin interface due to 
different contact pressures (Khan et al., 2005). 
 
The frequency of the applied signal has a significant effect on what information can be 
inferred from a test. Low frequency signals are restricted to the ECF while high 
frequency signals pass through both ICF and ECF. By increasing the number of 
measurement frequencies, it becomes possible to get more information on differences in 
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ECF and ICF. Bioimpedance devices can be based on measurements at a single 
frequency, dual-frequency or multi-frequency. 
 
Single frequency: Given that measurements at zero frequency relate to the ECF only 
while at infinite frequency they relate to the TBW, most single frequency devices use a 
frequency somewhere in between in an attempt to make a measurement including ECF 
and ICF. Hoffer showed that the resistance index (height squared over resistance; H2/R) 
using 100 kHz measurements is proportional to TBW (Hoffer et al., 1969) and this 
proportional relationship is the basis of most regression based prediction equations used 
for single frequency devices. 
 
Often 50 kHz is used as the measurement frequency, as it is usually close to the 
characteristic frequency where the reactive component is at a maximum. However, in 
reality, fc can have quite a range of values – usually between 30 and 60 kHz but 
including up to 130 kHz in healthy adults (Stahn et al., 2012). At 50kHz, the signal does 
not fully penetrate the cell and so the device cannot truly express the resistance of the 
ICV (Kyle et al., 2004). However, the high correlations between ECF, ICF and TBW 
mean that relationships between impedance and any of these volumes can be defined 
and used for analysis (Matthie et al., 1998). This means that in theory, any frequency in 
the beta dispersion range could be used to predict ECF, ICF and TBW. 
 
Dual-frequency: The dual frequency approach acknowledges the fact that the resistivity 
of the ICF and the ECF are different and the two volumes can be differentiated by 
measuring at high and low frequency based on the parallel circuit model. Typically, the 
relationship between resistance index and fluid volume is used separately for the 
calculation of ICF and ECF.  
  
Multi-frequency: To fully characterise the impedance spectrum it is necessary to 
measure at many frequencies and this approach is known as bioimpedance spectroscopy 
(BIS). Typically, a sufficient number of measurements are made across the beta 
dispersion range to allow a Cole-Cole plot to be fitted to the data and allow the 
extrapolation of R∞ and R0 from an impedance locus. For the BCM, measurements are 
made at 50 frequencies. 
 
30 
 
 
 
2.3.4 Analysing bioimpedance data 
2.3.4.1 Fundamental concepts of analysis 
The resistance of an object of uniform resistivity is related to its shape and ability to 
carry charge. It can be described using a length (L), cross sectional area (A) and 
resistivity (ρ) by equation 2-8, and knowing that the volume of a cylinder is area 
multiplied by length we can generate an equation to relate the volume of conducting 
material to resistance (equation 2-9) (Kyle et al., 2004). This relationship underpins the 
relationships between bio-electrical and physiological parameters. 
 
Equation 2-8                                                           𝑹 =  
𝝆×𝑳
𝑨
 
Equation 2-9                                                           𝑽 =  
𝝆×𝑳𝟐
𝑹
 
This relationship, along with the fact that FM and fat free mass (FFM) have very 
different electrolyte content and resistivities (Kushner and Schoeller, 1986), makes it 
relatively simple to generate some equations to estimate body composition 
compartments from bioimpedance measurements. However, these concepts are 
underpinned by a number of assumptions which are important for a good understanding 
of the limitations of bioimpedance.  
 
 
Figure 2-10: For many approaches to analysing bioimpedance, the body is assumed to 
consist of a series of cylinders (left) and in whole-body measurements, height is generally 
used as a surrogate for the length of conducting material 
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Geometry: Equation 2-8 is based upon measurement of a cylinder of uniform 
conducting material. For most approaches to analysing bioimpedance, the human body 
is assumed to comprise five cylinders: two arms, two legs and the trunk (fig. 2-10). The 
length of the tissue under investigation tends to be estimated by height for whole body 
measurements and can be measured directly for segmental measurements. Also, in 
reality, the limbs are not cylinders but more like a series of truncated cones and the 
disparity between limb and trunk CSA means that, for whole body measurements, the 
majority of the impedance comes from the limbs and little for the trunk (section 
2.1.3.2).  
 
Models for whole body bioimpedance expressly, or as part of the predictive equations, 
will account for these geometrical factors. This is based on estimating the effects on a 
“standard person” or as part of a reference population. Van Loan et al. calculated a 
factor, kb, for BIS measurements to account for differences in shape of human body 
segments from cylinders (Van Loan et al., 1993). This was done by anatomical 
measurements of length and circumference of limbs and corrected the relationship in 
equation 2-8 to give rise to a modified equation: 
 
Equation 2-10                                                      𝑽 =
𝒌𝒃𝝆𝒉
𝟐
𝑹
 
 
Here, Kb is a constant at 4.3 and h is the height of the subject. However, for any 
individual, this approach is only valid for proportional changes in geometry as 
compared to the reference. If there is the case of highly localised changes, inaccuracies 
will be introduced into the results. Examples of localised changes include abnormal 
limb lengths with reference to height, or preferential build-up of fat in the abdomen 
(increasing the CSA of trunk but not limbs). 
 
Resistivity: The value of ρ used for analysis tends to come from empirical estimates, but 
will have some variability and, as such, will impact upon the accuracy of body 
composition parameters. Different values have been put forward for sex-specific ECF 
and ICF resistivities (Van Loan et al., 1993, De Lorenzo et al., 1997), which could be 
explained by differences in limb shape and composition between sexes. The resistivity 
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of ECF is close to that of saline, but ρ  for the ICF is dependent on the type of cell and is 
estimated with less certainty (Jaffrin and Morel, 2008).  
 
It is also assumed that the tissue under investigation is a uniform body of conducting 
material, which is clearly not the case for the human body. Hanai looked at how 
resistivity of a fluid changed when it contains non-conducting spheres, due to the fact 
that current must flow around these spheres rather than travelling directly through the 
fluid (Hanai, 1968). This work, known as “mixture effects”, showed that if spheres take 
up a fractional volume of C then the overall resistivity of the fluid is described by 
equation 2-11. 
 
Equation 2-11                                                𝝆𝒂 =
𝝆
(𝟏−𝑪)𝟑/𝟐
 
 
Where ρa is the apparent resistivity, accounting for mixture effects, and c is the fraction 
of non-conducting material. Applying this theory to bioimpedance, cells and other 
bodies are modelled as non-conducting spheres in a bath of fluid. However, section 
2.1.2.5 shows that the volume of conducting material is dependent on the frequency: at 
low frequencies the conducting volume is the ECF and the non-conductors are the cells 
containing ICF and other bodies; whereas at high frequencies the conducting volume is 
the TBW - that is ECF plus ICF - and the non-conductors are limited to the other bodies 
in this volume (De Lorenzo et al., 1997). 
 
Body composition also has a significant effect on resistivity due to the highly insulating 
properties of body fat. Gender (Kyle et al., 2001), age (Tengvall et al., 2009) and 
ethnicity (Deurenberg et al., 2002) are also associated with differences in FFM/FM 
ratios which will affect the resistivity. Zhu et al showed that resistivity is different 
between segments, which is likely related to differences in fat and fat-free mass content 
of the segments (Zhu et al., 2006). 
 
2.3.4.2 Bioimpedance analysis 
Bioimpedance analysis (BIA) generally refers to analysing single or dual-frequency 
measurements using regression equations that relate impedance to a physiological 
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parameter based on data obtained from a control population. This technique makes use 
of the principle described in equation 2-9 which links the volume of a conducting 
material, to its length and, resistance and resistivity. A regression equation is generated 
from gold standard measures of fluid volumes in a population alongside bioimpedance 
measures of the resistance of the body at a specific frequency (e.g. equation 2-12 (Cox-
Reijven and Soeters, 2000)).  
 
Equation 2-12                                   𝑻𝑩𝑾 = 𝟎. 𝟎𝟖 +
𝟎.𝟒𝟓𝟖×𝒉𝟐
𝑹
+ 𝟎. 𝟎𝟔 × 𝒘 
 
Here, h is height and w is weight. 
 
Because of the high intercorrelation between ECF, ICF and TBW it is possible to 
generate equations to predict any of these volumes from an impedance measurement 
(De Lorenzo et al., 1997). However, simple regression is very much affected by 
population factors, so equations are population specific. Many propose different 
equations for males and females but it is not common to have different equations for 
other important characteristics that vary between populations. Caution is warranted in 
the use of these equations in altered body composition or fluid status. 
 
2.3.4.3 Bioimpedance spectroscopy 
By making use of some of the known electrical properties of tissue, analysis techniques 
have been developed that have a stronger theoretical basis than BIA techniques. 
Bioimpedance spectroscopy (BIS) refers to making impedance measurements at many 
frequencies, allowing an approximation of the Cole plot and estimation of the Cole 
parameters, in particular RE and RI. The most common approach to extrapolating the 
measured impedances to obtain the Cole parameters is to use non-linear least squares 
iterative fitting to generate a Cole plot based on the measured data. 
 
The measured data will often have artefacts due to stray capacitances that are 
particularly noticeable at high frequencies and interfere with the analysis of the data. 
This effect had been attributed to the time delay introduced from the measurement 
cables and a function was introduced to the Cole equation on this basis (De Lorenzo et 
al., 1997). More recently, it has been proposed that the time delay compensation does 
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not adequately explain or correct this effect and a function based on correcting for stray 
capacitances has been proposed (Buendia et al., 2010). This is the basis of the term used 
in the BCM (equation 2-13), which is multiplied by the Cole equation (described in 
section 3.2). ω is the angular frequency and Cs is the stray capacitance. 
 
Equation 2-13:                                                         𝒆−𝒊𝝎𝑪𝒔 
 
Knowing RE and RI it is possible to calculate each volume directly if we know the 
resistivity of the two compartments, corrected for Hanai’s mixture theory. Calculation 
of ICF is less accurate than ECF, due to the accumulation of errors in estimating R0 and 
R∞ for estimation of ICF and the greater uncertainty in ICF resistivity compared to ECF. 
 
More simply, RE and RI can be used as indicators of the relative amount of ECF and 
ICF without the need for any volume equations and all the assumptions that they 
involve (Chanchairujira and Mehta, 2005). This does however mean that the problems 
in differentiating body composition and fluid status associated with BIA must be 
considered here also. 
 
2.3.4.4 Bioimpedance vector analysis 
The limitations of using empirically based regression equations (as in BIA), or complex 
models (as in BIS) are avoided in bioimpedance vector analysis (BIVA). This is a single 
frequency technique, typically measured at 50 kHz using a whole-body approach. 
Rather than attempting to convert the impedance data into body composition 
parameters, the raw measured resistance and reactance values, normalised to height, are 
plotted as bivariate vectors on a graph (figure 2-11). The graphs contain reference 
ellipses at 50%, 75% and 95% based on gender and sex specific reference populations 
(Piccoli et al., 1994, Piccoli et al., 2002).  The vector of an individual can be compared 
to the normalised plot and a judgement made relating to fluid and nutritional status. 
 
The advantage of this method is that it relies on few assumptions about the underlying 
basis of impedance and the bio-electrical properties of tissue, but adopts a simple, 
empirically-based, graphical method that can be used to indicate abnormal hydration 
status and monitor changes in hydration status as the vector moves. However, the 
35 
 
 
 
method relies on reference data that are population specific and, similar to BIA, it is not 
able to differentiate fluid status and body composition. For example, a vector below the 
bottom left of the ellipse could equally be a normally hydrated obese individual or a 
muscular person with fluid overload. 
 
 
Figure 2-11: ‘Piccoli’ nomogram showing the bivariate distribution of the impedance 
vector, displayed as height normalised R and X values, in a reference population. Used 
with permission: Piccoli A, Pastori G: Department of Medical and Surgical Sciences, 
University of Padova, Padova, Italy. 
 
 
2.3.4.5 Phase angle 
Phase angle is one of the raw electrical parameters generated in a bioimpedance 
measurement and so, as with BIVA, it is free from assumptions and models inherent in 
the more complex analyses. By definition, phase angle is a measure of the lag between 
current and voltage, introduced by the storage of electric charge in cell membranes due 
to their dielectric properties. This makes the parameter inextricably linked to the 
reactance and also to the body cell mass - the intracellular mass of the body - and has 
been proposed as a useful marker of nutrition (Małecka-Massalska et al., 2015). 
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Figure 2-12: The effect of fluid status and fluid management on the ability of phase angle 
as a marker of cellular health or nutrition. The graph on the left shows a single patient 
with pre-dialysis BCM measurements less than two months apart. The graph on the right 
shows the same patient with BCM measurements pre- and post-dialysis on the same day. 
The line of identity defines the phase angle of 8ᵒ, proposed as an indicator of poor survival 
(Abad et al., 2011) 
 
However, because the reactance is not only dependent on the body cell mass, but also a 
function of the ECF (the greater the ECF compartment, the less likely current will 
interact with membranes), direct interpretation of the parameter can be confounded by 
variability in the ECF compartment (Baumgartner et al., 1988). Figure 2-12 displays 
data from measurements on one patient plotted on the same R-X graph that is used to 
display a Cole-Cole plot. The plot on the left shows a measurement on the 30th 
September where OH was -0.9 litres pre-dialysis, suggesting an excessively low target 
weight. This was increased and a repeat measurement made less than two months later, 
when OH was 3.8 litres. There was no suggestion that nutritional state had changed and 
the move from a region of good prognosis to poor prognosis is likely to be entirely 
related to the way target weight was set. The plot on the right shows the same patient 
measured pre- and post-dialysis, clearly showing the change in phase angle over a four 
hour dialysis treatment that is due solely to fluid removal, taking the individual from the 
poor prognosis region to the good prognosis region. 
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2.3.5 The use of bioimpedance in haemodialysis 
2.3.5.1 Introduction 
The sensitivity of bioimpedance to changes in fluid status and the need for objective 
measurements to guide fluid management in haemodialysis have inevitably led to a 
large body of work assessing the use of bioimpedance in haemodialysis. This has 
predominantly been confined to the research setting and had gained little acceptance as 
a routine tool in fluid management. Historically, one of the principal reasons for this has 
been the need to reference the fluid volumes from these measurements to results in 
healthy controls - leading to problems in a patient population in which abnormal body 
composition (particularly low muscle mass) is common. 
 
2.3.5.2 Historical overview 
Early attempts at utilising bioimpedance for fluid management were based on 
measuring ECF using BIA volumes and comparing them to matched controls with 
normal kidney function. Increased ECF indicated a degree of fluid overload (Kouw et 
al., 1993). This approach was refined by Chamney et al. who used BIS to measure ECF 
in a group of normally hydrated controls and used the results to define normal ECF 
volumes as a proportion of body weight (Chamney et al., 2002). This relationship was 
used to define the dry weight as the point at which a subject’s ECF intersected the slope 
defined by normality (fig. 2-13). However both of these approaches neglect to account 
for differences in body composition, which can mean two individuals of the same 
ECF/weight ratio can have wide range of fluid status, due to different lean tissue and fat 
tissue combinations.  
 
Lopot took a similar approach by considering hydration state to be described by an 
ECF/TBW ratio  (Lopot et al., 2002). He described the association between ECF/TBW 
and age due to increased body fat percentage with ageing and suggested the use of an 
age normalised ratio for patient management. Although this did account for some 
population based confounding factors, the confounding due to subject specific body 
composition was still not addressed. 
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Figure 2-13: Objective definition of target weight based on BIS measured ECF and the 
idealised ECF/weight relationship based on a reference population. Adapted from 
(Chamney et al., 2002).  
 
This problem was resolved by re-thinking body composition models for patients who 
have altered fluid status (see section 2.2.2). The model developed by Chamney et al. has 
allowed the assessment of hydration status with bioimpedance analysis independent of 
comparisons to controls and population normalised body composition (Chamney et al., 
2007). A bioimpedance device based upon this new model, the Body Composition 
Monitor (BCM) (Fresenius Medical Care, Bad Homburg, Germany), has been 
developed and the fluid information it provides has been well validated against gold 
standard body composition measurements (Wabel et al., 2009). 
 
Segmental bioimpedance techniques are also being developed to avoid many of the 
problems relating to geometry. Zhu and colleagues have outlined in a series of papers 
that the use of bioimpedance measurements of the calf can offer a more accurate method 
of measuring fluid volumes (Zhu et al., 2006, Zhu et al., 1999), but it is not clear yet 
how this can be applied in routine fluid management. 
 
2.3.5.3 Current applications and consensus opinions 
The development of more appropriate models for analysis and devices with better 
specifications have led, for the first time, to a more widespread acceptability by 
clinicians of the technology and better engagement with bioimpedance as a routine part 
of fluid management strategies (Covic and Onofriescu, 2013). A number of studies have 
produced data to support this approach. Moissl et al performed a cohort study that 
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attempted to optimise fluid status with the BCM over a three month period and showed 
improved fluid status, quality of life, blood pressure and symptoms (Moissl et al., 
2013). In addition, three randomised controlled trials have been performed using BCM 
to guide fluid management which have shown improvements in hard end points such as 
mortality, hospitalisation and blood pressure (Onofriescu et al., 2014, Hur et al., 2013, 
Onofriescu et al., 2012). Despite this, the BCM device is not universally accepted and is 
still used much more in research than in patient management. The BCM has been 
available in the UK since 2008 but very few centres are using it. Anecdotally, this is 
often because units given a device for evaluation have considered the results to be 
unrealistic, probably due to lack of training in the identification of poor readings or the 
surprisingly degree of dehydration that is often observed in large patients. 
 
2.4 Blood volume monitoring 
2.4.1 Introduction 
Being the accessible compartment used for haemodialysis, the blood volume is acutely 
reduced during a haemodialysis session and the ability of the body to respond to this 
and maintain the blood volume is a key determinant of achieving good fluid balance. It 
is therefore no surprise that measurement and monitoring of the blood volume during 
haemodialysis is used widely to aid fluid management strategies. 
 
2.4.2 Measurement of blood volume 
Measurement of absolute blood volume is not simple. Tracer dilution is established as 
the gold standard but is not suitable for routine assessment (Puri et al., 2014). More 
recently, a method has been developed for absolute blood volume measurement in 
haemodialysis patients based on measuring changes in haematocrit (Hct) after 
administration of a bolus of saline (Kron et al., 2014, Schneditz et al., 2014). The 
simplicity of the measurement and the fact that the technology is now readily available 
on dialysis machines suggests this could allow widespread assessment of absolute blood 
volume, but further work is needed to look at the clinical significance and utility of 
these measurements.  
 
However, the assessment of RBV during haemodialysis is an established technique. 
RBV is defined as the instantaneous blood volume at a specified time during a dialysis 
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session, expressed as a percentage of the blood volume at the commencement of 
treatment.  
 
If we consider any element of the blood volume that is constant throughout 
haemodialysis, the concentration at the start of treatment (C0) and at time t (Ct) can be 
used to calculate the RBV at time t as a percentage:  
 
Equation 2-14                                               𝑹𝑩𝑽𝒕 =
𝑪𝟎
𝑪𝒕
− 𝟏 
 
A number of different parameters have been proposed as suitable for monitoring, 
including haemoglobin (Hb), Hct, plasma proteins and plasma conductivity (Santoro et 
al., 1996). The apparatus for measuring Hb and Hct tend to use optical absorbance or 
transmission based on the Lambert-Beer law (Santoro et al., 1996), whereas for total 
plasma proteins, measurement is based on the speed of ultrasound in blood (Schneditz 
et al., 1990, Johner et al., 1998). 
 
2.4.3 Principles of measurement and common artefacts 
The measurement of RBV is based on the concept that the degree of 
haemoconcentration reflects the change in blood volume. There are two fundamental 
assumptions that underpin this technique: that the amount of substance being measured 
is constant throughout the measurement session; and that there is uniform mixing 
throughout the blood volume, or that the distribution of the substance is constant 
throughout the session (Dasselaar et al., 2005). These assumptions need some 
consideration. 
 
The main factors that can affect the amount of the substance being measured are 
haemolysis, blood leaks or blood transfusion during haemodialysis, although these are 
not common. However, the distribution of red blood cells and plasma proteins during 
haemodialysis is a more complicated and variable issue. The concentration of Hb in the 
capillaries is lower than in larger blood vessels – referred to as the Fahraeus effect 
(Goldsmith et al., 1989) – which means that the venous or arterial Hct measured by 
RBV is higher than whole-body Hct (Chapdelaine et al., 2011). The difference in these 
two Hct values is known as the F-cell ratio. During ultrafiltration it has been shown that 
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the F-cell ratio rises due to fluid shifts from the microcirculation to the 
macrocirculation, which is thought to be a compensatory mechanism to maintain central 
blood volume (Mitra et al., 2004). This causes a reduction in measured Hct and increase 
in RBV, such that most commonly used devices overestimate change in RBV at modest 
changes and underestimate it at large RBV changes (Chapdelaine et al., 2011). 
 
There are other redistribution effects that are important to consider. Postural changes 
from supine to standing can cause fluid to shift from the circulation to the interstitium 
due to gravitational forces with an associated rise in whole-body Hct. However the 
haemoconcentrated blood in the limbs is relatively slow in mixing such that measured 
increase in Hct is underestimated (Lundvall and Bjerkhoel, 1995). Furthermore, if there 
is a rapid return to supine position the haemoconcentrated blood is rapidly mixed, 
increasing systemic Hct despite the increase in blood volume, before reducing as 
refilling from the interstitium occurs (Lundvall and Bjerkhoel, 1995). Eating causes 
blood to be moved from the central circulation to the splanchnic bed, where the Hct is 
lower, causing a drop in measured RBV (Dasselaar et al., 2005). Despite that this effect 
is redistribution rather than a true drop in blood volume, the shift away from the central 
circulation can lead to IDH and this would be independent of vascular refilling. A large 
proportion of the blood volume resides in the splanchnic and splenic vascular beds and 
this forms a reserve which is used to buffer changes in blood volume in the central 
circulation (Ribitsch et al., 2015). There has been a demonstrated link between 
norepinephrine and reduced RBV, but it was unclear whether this was related to 
increased plasma protein content or reduced plasma water (Nette et al., 2006). 
 
2.4.4 Use of RBV in haemodialysis 
The appeal of RBV monitoring in HD is the potential to identify IDH before it occurs, 
thereby reducing the number of events and associated adverse effects. In theory this 
should also aid setting more appropriate target weights (Lopot et al., 1996).  
 
Interpretation of RBV data can largely be split into analysis of the magnitude of RBV 
changes during haemodialysis and the shape of the RBV curve. Typically, the 
magnitude of RBV changes is defined in a number of ways, be it the absolute change in 
RBV over a single session, or the change over a period of the treatment. Alternatively, 
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Lopot et al identified very early in the use of RBV that the shape of a curve had 
diagnostic significance (Lopot et al., 2007) (figure 2-14). When plotting RBV against 
time over a single treatment, curves that were relatively flat were assumed to indicate 
plasma refill rates exceeding ultrafiltration rates, suggesting the presence of fluid 
overload. Curves with a linear decrease in RBV, or a period with a flat-line followed by 
a linear decrease were interpreted as being close to dry weight. A fourth characteristic 
curve shows an early linear decrease followed by a period with a flat-line. This is not 
well explained but must be due to redistribution as the decline can be much higher than 
the ultrafiltration rate.  
 
 
Figure 2-14: Characteristic shapes of RBV curve 
 
Unfortunately, it appears that the potential of this technology has not been realised in 
clinical practice. Part of the difficulty in the use of RBV is that inter- and intra-patient 
variability makes interpretation non-trivial and there are no single, typical criteria that 
can reliably predict IDH in an individual. It has been shown that the plasma refilling 
coefficient varies markedly between patients undergoing haemodialysis (Iimura et al., 
1996, Santoro et al., 1998), with a removal of 2 litres over 1 hour giving anywhere 
between 0.7% and 21.9% reduction in RBV (Koomans et al., 1984). It then follows that 
critical RBV limits will also vary between subjects, and this has been reported (Andrulli 
et al., 2002). Removing the inter-subject variability by defining individual critical RBV 
limits improves the reliability and this has, in one study, been shown to predict IDH 
events with a variation of less than 5% RBV (Barth et al., 2003), but there remains 
significant intra-individual variation in the RBV response to ultrafiltration (Krepel et al., 
Close to 
dry weight
Not well explained
Fluid overload
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2000). This variation will in part be related to the fact that RBV does not account for 
initial fluid status or absolute blood volume. Maduell et al showed a clear association 
between OH measured by BCM and RBV change (Maduell et al., 2013) and novel 
techniques for measuring absolute blood volume are highlighting the significance of this 
parameter (Kron et al., 2015). To try and avoid these issues, a critical Hct has been 
suggested as better predictor of IDH than the change in blood volume measured by 
RBV (Steuer et al., 1994).   
 
This variability also seems to be present in analysis of RBV curve shape. For example, 
Lopot et al. suggested that less than 1% of cases typically show curves with a linear 
decrease followed by a flat-line (Lopot et al., 2000), whereas a different centre reported 
that after analysing 2240 curves, 91% had this shape (Dheu et al., 2009). Furthermore, 
clear definitions of the different shapes are lacking. The flat-line shaped curves are 
defined as being a change in RBV of less than 5% (Steuer et al., 1994), 3% (Reddan et 
al., 2005) or 1.5% (Agarwal et al., 2009) per hour. 
 
Alternatively, the rate of change in blood volume has been proposed as a useful tool in 
managing patient’s target weights. It has been shown that as dry weight is approached, 
the rate of decay moves from an exponential pattern to a linear decay, due to a switch 
from two-pool kinetics based on interstitial and intravascular volumes, to single-pool 
kinetics when the interstitial volume is depleted (Ishibe and Peixoto, 2004, Mitra et al., 
2002). 
 
The use of RBV as a diagnostic monitoring tool usually results in changes to the 
dialysis prescription for future sessions, but a potentially more powerful application of 
the technology is the continuous response of the dialysis machine to the instantaneous 
RBV data – so called biofeedback. This involves directly linking RBV results into an 
automated management programme which  responds to changes in RBV by adapting the 
UF rate or dialysate sodium, to either increase or reduce fluid removal as necessary 
(Chapdelaine et al., 2011). This works on the assumption that the physiological 
variations occurring during haemodialysis necessitate different Na and ultrafiltration 
rates at different times. The user pre-defines limits for changes in blood volume and the 
device will alter ultrafiltration rate and dialysate sodium concentration to maintain the 
RBV slope along the defined trajectory while attempting to achieve the target 
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ultrafiltration volume within the treatment time. This typically involves starting a 
session with the maximum ultrafiltration rate that the user allows, to compensate for 
potential reductions in ultrafiltration rates later in the session. 
 
2.4.5 Current applications and consensus opinion 
Attempts to use a Hct threshold for guiding fluid management have shown mixed 
results (Hecking et al., 2013), possibly because of the high intra- and inter-patient 
variability. The Crit-Line Intradialytic Monitoring Benefit (CLIMB) study showed a 
negative result (Reddan et al., 2005) but there has been considerable discussion about 
the design of this study (Chapdelaine et al., 2011).  Further trials are underway to 
evaluate the use of biofeedback controlled ultrafiltration on IDH (Leung et al., 2014, 
Hecking et al., 2012). 
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3 Methods 
3.1 Introduction 
The research presented in this thesis centres on two measurement techniques used as 
part of fluid management strategies – BCM and RBV. This chapter will detail the 
common methods of use for each technology and also detail statistical software used 
and research governance arrangements. 
 
3.2 Bioimpedance measurements 
3.2.1 Standard BCM measurement 
The Body Composition Monitor (BCM; Fresenius Medical Care, Bad Homburg, 
Germany) is a whole-body, bioimpedance spectroscopy device. Measurements of 
resistance, reactance and phase angle are made between the wrist and ankle after 
injection of a current of around 50-800μA at 50 frequencies, logarithmically spaced 
between 5 kHz and 1 MHz (FMC, 2009). The device then uses a curve fitting routine 
based on the Cole-Cole model (see section 2.3.4) to fit a curve to the measured data 
points, allowing estimation of the Cole parameters. The extracellular resistance (RE) and 
intracellular resistance (RI) are used in the fluid model described by Moissl et al (Moissl 
et al., 2006) to calculate ECF and ICF and these parameters are used in Chamney’s 
body composition model (Chamney et al., 2007). 
 
Healthy controls had height measured using a stadiometer and weight measured using 
calibrated scales. They were positioned in a supine position for a minimum of 3 minutes 
before a measurement was taken. Haemodialysis patients were positioned supine, or as 
close to supine as was comfortable. Pre-dialysis measurements were made on the non-
fistula side after the patient had been supine for at least 3 minutes; post-dialysis 
measurements were taken immediately after the needle sites had stopped bleeding and 
been dressed.  
 
For all measurements, voltage measuring electrodes were positioned on the dorsal 
surface of the hand and foot at the wrist bone and ankle and the current injecting 
electrodes positioned about 10 cm distal to the voltage electrodes, across the knuckles, 
to ensure uniform current density at the measurement electrodes (FMC, 2009). 
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Measurements were checked visually for artefacts, and repeated until the difference in 
the measured OH was no greater than 0.2 litres between readings. In almost all cases 
only two readings were required and the discrepancy between the first and second was 
usually no more than 0.1 litre. 
 
3.2.2 8-lead BCM measurement 
For the purposes of research, the manufacturers of the BCM, Fresenius Medical Care, 
developed a modified version of the device, known as the 8-lead BCM, which is not 
commercially available. This device has two additional cables which allow 8 leads to be 
connected to both hands and both feet, with a voltage and a current lead at each site (fig. 
3.1). This allows the possibility of making BCM measurements across a number of 
paths and also allows the isolation of individual segments for measurement as described 
in section 2.3.3.2.  
 
# Voltage Current Segments measured  
 
 
1 RH-RF RH-RF Right arm, right trunk, right leg 
2 LH-LF LH-LF Left arm, left trunk, left leg 
3 RH-LF RH-LF Right arm, R-L trunk, left leg 
4 LH-RF LH-RF Left arm, L-R trunk, right leg 
5 RH-LH RH-LH Right arm, top trunk, left arm 
6 RF-LF RF-LF Right leg, low trunk, left leg 
7 RH-LF RH-RF Right arm, right trunk 
8 LH-RF LH-LF Left arm, left trunk 
9 LH-RF RH-RF Right leg, right trunk 
10 RH-LF LH-LF Left leg, left trunk 
11 RH-RF RH-LH Right arm 
12 LH-LF RH-LH Left arm 
13 RH-RF RF-LF Right leg 
14 LH-LF RF-LF Left leg 
15 LH-LF RH-RF Right trunk 
16 RH-RF LH-LF Left trunk 
17 RH-RF 
LH-LF 
RH-RF 
LH-LF 
Full whole body 
Figure 3-1: Specifications of an 8-lead BCM measurement. Illustration used with 
permission from Medical Illustration, Leeds Teaching Hospitals Trust. 
 
For 8-lead measurements, electrodes were positioned as in the standard BCM 
measurements only on both hands and both feet. Measurements of resistance, reactance 
and phase angle were made at the same 50 frequencies as in the standard BCM, for 
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seventeen combinations of voltage and current (for full details, see appendix 9.1) which 
allows body composition measurements of the segments detailed in fig 3-1. The 8-
electrode device does not display Cole-plots or body composition data to allow real-
time assessment of artefacts or consistency, so measurements were taken in singular and 
the raw impedance values were extracted. 
 
 
Figure 3-2: Flowchart showing how the data from 8-lead measurements was analysed. Re 
is extracellular resistance, Ri is intracellular resistance, Cm is the cell membrane 
capacitance, α relates to the dispersion characteristics of the tissue and Cs is the stray 
capacitance 
 
Programmes were written in Matlab (v. 2014a; Mathworks In, MA, USA) to process 8-
lead BCM data. The analysis is described in fig. 3-2. Measured data were stored as a 
matrix of complex impedance data at 50 frequencies for 17 measurement paths. The 
data from each measurement, Zmeasured, were analysed by fitting a Cole plot (equation 3-
1) to the measured data. The equation used to fit the data is a combination of the Cole 
equation (equation 2-7) and a stray capacitance exponential term (equation 2-13) as 
discussed in section 2.3.4.3. The programme used some initial values for the Cole 
8-lead BCM 
measurement
Impedance matrix:
[17 paths * Zmeasured]
Fminsearch function minimises the 
difference between Zmodel and 
Zmeasured
Starting values for
Re, Ri, Cm, α, Cs
Zmodel
Re, Ri, Cm, α, Cs, error
KECW, KICW Height; weight
ECW, ICW
Tissue hydration parameters; 
age; sex
OH, LTM, ATM
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parameters which were altered through a series of iterations to minimise the difference 
between the measured data and modelled data (Zmodel). The error was calculated as the 
sum of the squared error of (Zmeasured – Zmodel) at each point, normalised to the mean 
error across all frequencies, for both real and imaginary components of Z. The Matlab 
algorithm “fminsearch” was used to minimise the error. RE and RI were then used with 
the volume and body composition models (Moissl et al., 2006, Chamney et al., 2007) 
using optimised tissue hydration parameters (courtesy of Fresenius R&D) to calculate 
OH, lean and adipose tissue compartments.  
𝑍𝑀𝑜𝑑𝑒𝑙 = (
𝑅𝑒
𝑅𝑒 + 𝑅𝑖
) × (𝑅𝑖 +
𝑅𝑒
1 + (𝑖𝜔𝐶𝑚(𝑅𝑒 + 𝑅𝑖))
𝛼) × (𝑒
−𝑖𝜔𝐶𝑠) 
Equation 3-1: Modelled Cole equation for parameter optimisation 
 
The analysis programme was validated by re-analysing data that had been used in 
standard BCM measurements. The raw data from twenty measurements on subjects 
with a wide variety of body composition and fluid status (mean (range) of BMI: 29 (16 
to 50) kg/m2; and of OH 0.5 (-3.8 to 5.9) litres) were analysed with the programme and 
the agreement between the body composition parameters can be seen in figure 3-3. For 
OH, the bias was 0.1 litres with 95% limits of agreement of around -0.1 to 0.3, showing 
very good agreement and verifying that the programmes are working similarly to 
commercial device analysis. For lean tissue and adipose tissue, biases of -0.4 and 0.3 
litres were observed with larger confidence intervals. This is likely to be related to 
known issues in modelling RI which has a larger influence on lean tissue and adipose 
tissue than OH. However, for the purposes of the study lean tissue and adipose tissue 
are secondary outcome interests and the agreement was deemed sufficient. 
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Figure 3-3: Validating the data analysis programme against commercial analysis for OH 
(ĭ), lean tissue (ĭi), adipose tissue (ĭii) using Bland-Altman analysis 
(i) 
(ii) 
(iii) 
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3.3 Blood volume measurements 
3.3.1 Measurement technique 
Relative blood volume measurements were made using the Crit-Line III Monitor 
(Hema-metrics, Kaysville, UT, USA). A sterile, disposable cuvette was positioned 
between the arterial blood line and the dialyser blood inlet and the sensor clip placed 
onto the cuvette. The sensor emits optical light at specific wavelengths and monitors the 
absorption and reflection of the light as it passes the whole blood in the cuvette. This 
allows it to make a measure of haematocrit content and percentage change in blood 
volume, relative to the start of the measurement period. The results of each 
haemodialysis session were downloaded and imported into Microsoft Excel (Microsoft 
Corporation) to allow analysis. Device calibration was checked using a verification 
filter monthly, as recommended by the manufacturer.  
 
3.3.2 RBV classification 
RBV measurements were classified based on the shape of the curve as advocated for 
informing fluid management and also were used as the basis of a novel approach to 
classifying the refilling characteristics of patients.  
 
The basis of using shape classification of RBV slopes is outlined in section 2.4.4. The 
shape of each blood volume curve was defined as one of four characteristic shapes 
described in figure 3-4.  
 
Figure 3-4: Characteristic shapes of RBV curves 
time
RBV
A
BC
D
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A) Flat-line: ‘A’ slopes are characterised by a flat line throughout a haemodialysis 
session, with a maximum slope of 3% per hour. 
B) Late reduction: ‘B’ slopes are characterised by a flat slope over an initial period 
of the haemodialysis session (<3% per hour for at least one hour) followed by a 
more rapid reduction in blood volume for the remainder of the session (average 
slope >3% per hour). 
C) Linear reduction: ‘C’ slopes are characterised by a linear reduction in blood 
volume throughout the haemodialysis session (average slope >3% per hour) 
D) Early reduction: ‘D’ slopes are the inverse of ‘B’ slopes and are characterised by 
an initial rapid blood volume slope (average slope >3% per hour for at least one 
hour) followed by a flat slope for the rest of the session (average slope <3% per 
hour) 
 
The concurrent use of RBV and BCM measurements allowed a novel method of 
classifying patients based on their refilling ability. The drop in RBV over the full 
dialysis session reflects the difference between the volume of fluid removed from the 
blood by ultrafiltration and the refilling volume. However, the refilling volume is 
dependent on the pre-dialysis fluid overload, which can be measured by BCM. As such, 
patients can be classified as exhibiting good or poor refilling capacity based on the RBV 
drop over a dialysis session, for a given ultrafiltration volume and pre-dialysis OH. The 
cut-off values chosen here were based on experiences of using the two technologies 
locally and can be seen in Table 3-1.  Sessions which indicated good refilling are 
denoted as 1 and those with poor refilling denoted as 0. 
 
 UF < OH UF < OH + 1 litre UF > OH + 1 litre 
UF < 2 litres 5% 10% 10% 
UF > 2 litres 10% 15% 20% 
Table 3-1 Critical drop in blood volume over a 4-hour dialysis session that indicates 
inadequate refilling, based on a dialysis session of 4 hours, pre-dialysis OH (OH) and 
ultrafiltration volume (UF). 
 
Consequently, each individual haemodialysis session is given a classification based on a 
combination of a 0 or a 1 with a letter A, B, C, D. 
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3.4 Haemodialysis treatments 
All haemodialysis subjects included in these studies had prescriptions for standard 
regimes of three sessions of four hours per week. Dialysate temperature was 36ᵒC and 
sodium was 137mmol/l as standard. All haemodialysis patients come from units where 
BCM use is standard as part of fluid management and informs target weight decisions 
alongside clinical examination. RBV measurements are available on some, but not all of 
the dialysis machines used in the dialysis units and is rarely used as part of routine care.  
 
3.5 Statistical analysis 
Bland Altman analysis was done using Analyse-it for Microsoft Excel (version 2.26). 
All other analysis was done using the statistical software package ‘R’ version 3.0.2 (R 
Foundation for Statistical Computing, Vienna, Austria).  
 
3.6 Research governance 
This work was undertaken in accordance with the principles of the Declaration of 
Helsinki and ethical approval was granted by a local ethics committee (References: 
13/YH/0148 for the work in chapter in 4; 12/YH/0497 for the work in chapter 5; and 
14/YH/1091 for the work in chapter 6). 
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4 Characterising BCM and RBV measurements 
in haemodialysis 
 
4.1 Objective 
Bioimpedance and RBV monitoring are considered as promising tools for improving 
fluid management in haemodialysis patients (Rosner and Ronco, 2014) and have started 
to be implemented in routine practice in some centres. However, despite some 25 years 
of research into both these technologies in haemodialysis there lacks a sufficiently 
robust evidence base in the clinical setting to allow users to make management 
decisions with confidence. This study aims to characterise some important features of 
BCM and RBV use in normal clinical practice to allow users to make measurements 
and interpret the results with confidence in a range of clinical scenarios. 
 
Research question 1: Can characterisation of alternative measurement paths and timing 
for the BCM, and the use of simultaneous RBV monitoring, lead to more individualised 
and effective fluid management? 
 
4.2 Introduction 
4.2.1  Bioimpedance 
Many of the limitations around bioimpedance relate to assumptions made during data 
analysis, including assumptions about temperature, resistivity, limb shape and fluid 
distributions (Hoenich and Levin, 2003). Assessing these limitations as applied to the 
technology as a whole is not easy. Bioimpedance devices use many different forms of 
analysis and the impact of these assumptions upon a clinical measurement is very 
dependent on the form of measurement and analysis. Despite the fact that many groups 
have reported on these factors (Huang et al., 2000, Zhu et al., 1999, Zhu et al., 1998, 
Moissl et al., 2006), the sheer number of measurement and analysis techniques and lack 
of understanding of the differences between them make it difficult to interpret the 
literature in this area. 
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The important factors affecting bioimpedance measurements can be split into two types: 
those on the microscopic scale, such as temperature, ionic concentrations, tissue 
resistivity; and those on the macroscopic scale, such as body composition, body 
geometry, fluid distribution and measurement path. This investigation aimed to evaluate 
the effect of some of the macroscopic assumptions on BCM measurements.  
 
BCM manufacturer’s guidance states that measurements should not be made on an arm 
with peripheral vascular access (FMC, 2009). However, in practice this requirement 
would exclude a large number of patients from having BCM measurements. Patients 
can, over time, end up with multiple vascular access sites over both sides of the body, or 
in some cases it may not be possible to avoid a vascular access site, e.g. patients with 
amputations, bandaged limbs, localised fluid. It is also advised that measurements 
should be made pre-dialysis and that the patient should be recumbent for at least 2 
minutes before measurement (FMC, 2009). This is due to the effect that ultrafiltration 
(Abbas et al., 2014) and posture (Zhu et al., 1998) have on fluid distributions in the 
body. Due to the different shapes and sizes of the limbs, shifts in fluid from one 
compartment to another can have significant effects on the whole body impedance.  
 
In order to allow greater understanding of the effect of making measurements outside 
the manufacturer’s protocol, the effect of changing measurement path and time of 
measurement on body composition parameters was characterised.  
 
4.2.2 Relative blood volume measurements 
The principle obstacle to RBV monitoring gaining acceptance as a simple, user-friendly 
diagnostic tool is the inter- and intra-subject variation in the blood volume response to 
ultrafiltration (Krepel et al., 2000). In any one measurement session, the RBV slope will 
be a function of a large number of variables as outlined in table 4-1.  
 
Real changes in blood volume can be simplistically described as the difference between 
ultrafiltration removing fluid from the blood and refilling of the blood. The 
ultrafiltration rate is dependent on the amount of fluid to be removed and the time taken 
to remove it, along with any profiling used to introduce variable ultrafiltration rates. The 
refilling rate is more complicated and is described in more detail in section 2.1.2.2. 
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However, it is fundamentally affected by differences in hydrostatic and oncotic 
pressures in the blood volume and the interstitium and by the integrity of lymphatic 
return. 
 
Response Variable Factors 
Real changes 
in blood 
volume 
Ultrafiltration rate 
Treatment time 
Ultrafiltration volume 
Ultrafiltration rate profiling 
Refilling rate 
Fluid status 
Absolute blood volume 
Venous and interstitial compliance 
Dialysate sodium concentration 
Body size 
Plasma protein 
Antihypertensive medications 
Integrity of lymphatics 
Apparent changes 
in relative 
blood volume 
F-cell ratio 
Postural changes 
Ingested food and drink 
Dialysate and core temperature 
Exercise 
Haemolysis Haemodialysis equipment 
Table 4-1: Factors affecting RBV measurement 
 
In addition to these real blood volume changes, there are a number of situations that can 
lead to apparent RBV changes as recorded by monitors. These are described in section 
2.4.3, but generally relate to changes in the local and global haematocrit concentrations 
during the measurement period.  
 
Some of the variables can be controlled to some degree – ultrafiltration rates can be 
manipulated, patients can be advised not to eat etc. – but others, such as interstitial 
compliance, are very difficult to investigate, never mind control. This has led to a 
prevailing lack of consensus on how to use the technology, and of the hard evidence to 
justify its use (Hecking et al., 2012). There are studies advocating the use of RBV that 
have controlled some of these factors for the research (e.g. with fluid restrictions, 
enforced treatment times, standardised prescriptions etc.) and in this situation, RBV 
technology has been shown to be associated with a reduction in IDH and symptoms 
(Steuer et al., 1996, Balter et al., 2015), but this is not likely to be generalizable to 
routine management of a whole group of patients. Cohort based, controlled studies 
looking at clinically important outcomes are lacking. 
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One of the parameters associated with both inter-subject and intra-subject variation in 
RBV changes is initial fluid status (Maduell et al., 2013). For a long time there has been 
no simple measure of fluid status, so it has not been incorporated into most algorithms 
for interpreting RBV data. OH measured using BCM can provide a simple assessment 
of initial fluid status that could inform RBV interpretation in routine practice. 
 
4.3 Methods 
4.3.1 Subjects 
Two cohorts of subjects were involved in the study. The inclusion criteria for each 
group are detailed here. 
 
Healthy control subjects: 
 48 subjects stratified by age-decade between 20 and 70+ and by sex 
 No history of kidney disease or heart failure 
 No visible localised fluid accumulation such as oedema 
 Ability to be weighed 
 No limb amputations 
 
Haemodialysis patients: 
 48 subjects over 18 years old 
 No more than one recorded episode of IDH within the preceding two months 
 No visible localised fluid accumulations  
 Ability to achieve target weight, defined by a clinician with access to BCM 
results 
 
Pilot work comparing BCM measurements from hand to hand and from hand to foot 
showed standard deviations of the mean difference in hydration values of around 1.0 
litres (Keane and Lindley, 2015). Recruiting 48 subjects into each cohort would allow 
differences of 0.3 litres to be measured between the primary two paths at the level of 
5% type I error with 80% power using a two sided t-test. This is deemed an acceptable 
sample size; differences below 0.3 litres will fall below the limits of reproducibility of 
57 
 
 
 
the device (Wieskotten et al., 2013). Further research questions investigated will be 
exploratory and will not be powered for a particular outcome. 
 
4.3.2  Procedure 
For healthy volunteers, standard and 8-lead BCM measurements were made as 
described in chapter 3. Height and weight were recorded immediately before BCM 
measurements. 
 
For haemodialysis patients, height was taken from their clinical notes and pre- and post-
dialysis weights were obtained as part of normal care. A standard BCM and an 8-lead 
BCM measurement were made before and immediately after dialysis and RBV was 
monitored (see Chapter 3). Planned and achieved ultrafiltration volumes were recorded. 
Repeat measurements were made between 2 weeks and 4 weeks after the initial 
measurement. 
 
4.3.3 Analysis 
4.3.3.1 Model generation 
Data were analysed using linear mixed-effects models. For healthy controls, subject was 
taken as the random effect and path, sex and age were taken as fixed effects. For 
haemodialysis patients, the same model set up was used, only with the addition of pre-
/post-dialysis as an interaction term if it significantly altered the model or as a normal 
predictor variable if not. For healthy controls, measurement from hand-to-foot on the 
dominant side of the body was taken as the reference path, whereas for haemodialysis 
patients, measurements from hand-to-foot on the contralateral side of the body to the 
most recently used vascular access (VA) was taken as the reference path. 
 
To present the data, results for a 60 year old female acted as a reference and the 
adjustments for age and sex are detailed. The mean value for the dependent variable 
from the reference path was presented alongside the bias, p-values and 95% confidence 
intervals associated with making measurements on each of the whole body paths. 
Significance levels were set at 0.05. 
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To examine the model, plots of standardised residuals against fitted values were used to 
check the assumption of homoscedasticity and a Q-Q plot of the residuals was used to 
assess normality. 
 
4.3.3.2 Characterising BCM measurements of body composition 
The raw data from the 8-lead BCM were processed as outlined in chapter 3 to give 
estimates of OH, lean tissue and adipose tissue for each path. The difference in 
estimated OH, lean tissue and adipose tissue respectively between the 6 primary paths 
(see figure 4-1) was characterised. Extracellular resistance (RE) was taken from the 
modelled impedance data for each of the five body segments to investigate segment 
specific changes in RE.  
 
Figure 4-1: Primary 6 measurement pathways. VA is vascular access and the 
configurations here are shown for a person with left sided VA 
 
To consider the repeatability of the model for haemodialysis patients, the repeat 
measurements were re-analysed in the same way and a qualitative description of the 
differences in the two analyses was made. 
 
Arms LegsCross 2
Cross 1Non-VA VA
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4.3.3.3  Characterising changes in body composition parameters during HD 
To investigate the validity of post-dialysis measurements, the agreement between 
change in BCM-measured OH from the reference path and change in weight was 
assessed using Bland-Altman analysis. Furthermore, the consistency of lean tissue and 
adipose tissue from the start to end of dialysis was assessed using paired t-tests. 
 
4.3.3.4 Characterise RBV measurements 
The RBV chart from each session was defined based on its shape, as outlined in 
previous literature, and based on the novel method of categorising refilling 
characteristics (see chapter 3). The intra-subject repeatability for curve shape was 
assessed by comparing the proportions in each category at the first and second 
measurement session using Cohen’s kappa. The relationship between RBV curve shape 
and fluid status was explored by plotting the pre- and post-dialysis BCM-measured OH 
for all subjects with each RBV shape category. Furthermore, quantitative comparisons 
were made between mean pre- and post-dialysis OH in the RBV slope groups using 
one-way analysis of variance. Because there are numerous criteria for categorising 
curve shape, sensitivity analysis was undertaken to re-classify all the curve shapes based 
on a conservative definition of a ‘flat line’ of 1.5% per hour (Sinha et al., 2010). 
 
4.4 Results 
4.4.1  Mixed effects regression model 
 Healthy controls HD patients 
Age (years) 49 (17) 60 (16) 
Height (m) 1.71 (0.11) 1.70 (0.12) 
Weight (kg) 73 (14) 81 (23) 
BMI (kg/m2) 25 (4) 29 (7) 
Sex (males) 24 28 
HD vintage (months) - 30 (6) 
Most recent VA (left sided) 
Albumin (g/L) 
Diabetes 
Number of comorbidities:  - 1 
                                            - 2 
                                            - 3 
- 
- 
- 
- 
- 
- 
38 
38 (2.8) 
14 
12 
4 
3 
Table 4-2: Subject demographics. Data are mean (standard deviation) for normal data 
and number of subjects for categorical data. Comorbidities present included acute 
coronary syndrome, heart failure, cerebrovascular disease, liver disease, peripheral 
vascular disease and smoking. 
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The results from the mixed effects regression models are presented based on the results 
from a 60 year old female as reference, with age and sex adjustments detailed in the 
table legend. In each case, the mean result from the reference path for a 60 year old 
female is given and the bias associated with measurements on the other paths. 
 
For the models investigating OH and adipose tissue, age and sex were non-significant 
predictors in either healthy controls or haemodialysis patients. For lean tissue, age and 
sex were significant predictors in both healthy controls and haemodialysis patients. For 
dialysis patients, including pre-/post-dialysis as an interaction term made a significant 
difference to the model (p=0.02), so data are presented as such. 
 
  
 
 
Figure 4-2: Plot of residuals (left) and a ‘Q-Q’ plot of the residuals (right) for mixed-
effects model of OH in healthy controls (above) and haemodialysis patients (below) 
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For the model investigating OH, plots of residuals against fitted values and Q-Q plots 
can be seen in figure 4-2, while those for lean tissue and adipose tissue are in the 
appendix (see section 9.2). Visual inspection of the residual plots suggested random 
scatter. Although Q-Q plots showed some dispersion from normality; sensitivity 
analyses were done by checking the outliers for errors, but no clear problems with the 
data were found. These outliers were predominantly examples of increased discrepancy 
between hand-to-foot and foot-to-foot measurements in some individuals. 
 
4.4.2 Characterising BCM measurements of body composition 
4.4.2.1 Healthy controls 
The data from healthy controls show that there is no difference in BCM-measured OH 
measured between all the whole-body paths other than the foot to foot measurement, 
which had a bias of 0.8 litres (table 4-3). Considering lean tissue and adipose tissue, 
there was a significant bias on most of the paths other than some of the cross 
measurements, including higher lean tissue and lower adipose tissue in the dominant 
arm and in the hand-to-hand path as compared to the reference path.  
 
Measurement  
Path 
OH  
(litres) 
Bias  
(litres) 
 
p-value 
Approx. 95% 
CI 
Healthy 
controls 
Dominant -0.12 - 0.74 -0.86 to 0.61 
Non-dominant - 0.09 0.24 -0.06 to 0.25 
Cross1 - 0.002 0.98 -0.15 to 0.16 
Cross2 - 0.10 0.20 -0.05 to 0.26 
Arms - -0.02 0.81 -0.17 to 0.14 
Legs - 0.80 <0.01 0.64 to 0.95 
Table 4-3: Model for OH in healthy controls. Data are presented for a 60 year old female, 
where the adjustment for age was -0.003 per year (p=0.65; 95% CI: -0.02 to 0.01) and for 
sex was 0.28 for male (p=0.22; 95% CI: -0.17 to 0.74) 
 
 
Measurement  
Path 
LTM  
(kg) 
Bias  
(kg) 
 
p-value 
Approx. 95% 
CI 
Healthy 
controls 
Dominant 45 - <0.01 39 to 50 
Non-dominant - -1.5 <0.01 -2.5 to -0.4 
Cross1 - -0.43 0.41 -1.4 to 0.59 
Cross2 - -1.1 0.05 -2.1 to -0.03 
Arms - -2.7 <0.01 -3.7 to -1.7 
Legs - 4.4 <0.01 3.4 to 5.4 
Table 4-4: Model for lean tissue mass (LTM) in healthy controls. Data are presented for a 
60 year old female, where the adjustment for age was -0.17 per year (p<0.01; 95% CI: -
0.28 to -0.07) and for sex was 19 for male (p<0.01; 95% CI: 15 to 22) 
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Measurement  
Path 
ATM  
(kg) 
Bias  
(kg) 
 
p-value 
Approx. 95% 
CI 
Healthy 
controls 
Dominant 23 - <0.01 12 to 35 
Non-dominant - 1.4 <0.01 0.36 to 2.4 
Cross1 - 0.44 0.40 -0.57 to 1.5 
Cross2 - 0.95 0.07 -0.06 to 2.0 
Arms - 2.7 <0.01 1.7 to 3.7 
Legs - -5.2 <0.01 -6.3 to -4.2 
Table 4-5: Model for adipose tissue mass (ATM) in healthy controls. Data are presented 
for a 60 year old female, where the adjustment for age was 0.11 per year (p=0.33; 95% CI: 
-0.11 to -0.32) and for sex was -2.7 for male (p=0.44; 95% CI: -9.7 to 4.2) 
 
4.4.2.2 Haemodialysis patients: alternative paths 
Haemodialysis patients showed different pre-dialysis patterns than subjects with normal 
renal function. In particular, there was a significant difference in BCM-measured OH 
between measurements made on the side of the body where vascular access is situated 
as compared to the contralateral side (table 4-6). Unlike controls, there was no 
difference in lean tissue or adipose tissue between the sides, despite the fact that 
vascular access is usually on the non-dominant side.  
 
 
Measurement  
Path 
OH  
(litres) 
Bias  
(litres) 
 
p-value 
Approx. 95% 
CI 
Pre-
dialysis 
Non-VA side 1.7 - <0.01 0.66 to 2.7 
VA-side - 0.42 0.02 0.08 to 0.76 
Cross1 - 0.02 0.91 -0.32 to 0.36 
Cross2 - 0.41 0.02 0.07 to 0.75 
Arms - -0.21 0.23 -0.55 to 0.13 
Legs - 1.7 <0.01 1.4 to 2.1 
Post-
dialysis 
Non-VA side -0.12 - 0.82 -1.2 to 0.90 
VA-side - 0.13 0.61 -0.36 to 0.61 
Cross1 - 0.02 0.93 -0.46 to 0.50 
Cross2 - 0.10 0.68 -0.38 to 0.59 
Arms - 0.35 0.16 -0.13 to 0.84 
Legs - -0.56 0.03 -1.0 to -0.07 
Table 4-6: Model for OH in dialysis patients. Data are presented for a 60 year old female, 
where the adjustment for age was 0.012 per year (p=0.38; 95% CI: -0.02 to 0.04) and for 
sex was 0.001 for male (p=0.99; 95% CI: -0.88 to 0.89) 
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Measurement  
Path 
LTM  
(kg) 
Bias  
(kg) 
 
p-value 
Approx. 95% 
CI 
Pre-
dialysis 
Non-VA side 25 - <0.01 19 to 30 
VA-side - 0.58 0.45 -0.90 to 2.0 
Cross1 - -0.38 0.61 -1.9 to 0.97 
Cross2 - 1.2 0.12 -0.30 to 2.8 
Arms - 1.3 0.08 -0.14 to 3.1 
Legs - 1.5 0.04 0.07 to 3.0 
Post-
dialysis 
Non-VA side 24 - <0.01 19 to 30 
VA-side - -0.43 0.69 -2.5 to 1.7 
Cross1 - 0.14 0.90 -1.9 to 2.2 
Cross2 - -0.89 0.41 -3.0 to 1.2 
Arms - -0.25 0.82 -2.3 to 1.8 
Legs - 0.15 0.89 -1.9 to 2.2 
Table 4-7: Model for LTM for dialysis patients. Data are presented for a 60 year old 
female, where the adjustment for age was -0.40 per year (p<0.01; 95% CI: -0.56 to -0.25) 
and for sex was 17 for male (p<0.01; 95% CI: 12 to 22) 
 
 
Measurement  
Path 
ATM  
(kg) 
Bias  
(kg) 
 
p-value 
Approx. 95% 
CI 
Pre-
dialysis 
Non-VA side 32 - <0.01 19 to 45 
VA-side - 0.58 0.45 -0.90 to 2.0 
Cross1 - -0.38 0.61 -1.9 to 0.97 
Cross2 - 1.2 0.12 -0.30 to 2.8 
Arms - 1.3 0.08 -0.14 to 3.1 
Legs - 1.5 0.04 0.07 to 3.0 
Post-
dialysis 
Non-VA side 32 - <0.01 19 to 45 
VA-side - -1.0 0.19 -2.6 to 0.48 
Cross1 - 0.36 0.64 -1.0 to 1.8 
Cross2 - -1.6 0.04 -3.1 to -0.13 
Arms - -1.1 0.15 -2.6 to 0.38 
Legs - -3.4 <0.01 -4.8 to -1.9 
Table 4-8: Model for ATM in dialysis patients. Data are presented for a 60 year old 
female, where the adjustment for age was 0.22 per year (p=0.22; 95% CI: -0.14 to 0.58) 
and for sex was 2.4 for male (p=0.68; 95% CI: -9.0 to 14) 
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4.4.2.3 Haemodialysis patients: changes over a dialysis session 
 
Figure 4-3: Bland Altman analysis of the agreement of change in weight (∆weight) and 
change in OH (∆OH) 
 
There was good agreement between change in BCM-measured OH on the reference 
measurement path ([pre-dialysis OH] – [post-dialysis OH]) with change in weight (fig. 
4-3; bias 0.3 kg, 95% CI -1.9 to 1.3 kg). In theory, lean tissue and adipose tissue should 
not change over dialysis and the mean difference in the measured changes was not 
different to the null of zero (lean tissue: mean difference: -0.28 kg; p=0.7; 95% CI:-1.8 
to 1.2; adipose tissue: mean difference: 0.56 kg; p=0.5; 95% CI: -0.92 to 2.1). 
 
Considering the distribution of changes in BCM-measured OH, the only measurement 
path that has a significantly different change in OH compared to the reference path is 
that of the legs. This path shows around 0.6 litre greater change in OH than the 
reference path over dialysis, indicating that there is a more pronounced change in fluid 
status in the legs than in the other segments. This was supported by analysis of the 
changes in raw impedance values from each segment individually, showing greatest 
reduction in extracellular resistance in the legs and smallest in the arms (table 4-6).  
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Table 4-9: Segmental changes in ECF resistance (RE) over dialysis. ‘ref’ indicates a 
segment from the reference path and ‘opp’ from the opposite side. 
 
4.4.2.4 Haemodialysis patients: repeatability 
Of the 48 HD patients recruited, 36 had follow up measurements. The model for follow 
up measurements showed no pronounced differences considering the different sample 
sizes used, suggesting that the effects from the model are reproducible (see appendix, 
section 9-3). 
 
Figure 4-4: Characteristic shapes of RBV curves 
 
4.4.3 Characterising RBV measurements 
Of the 48 subjects recruited, RBV measurements were recorded in at least one of the 
sessions for 47 of them. Based on the criteria outlined in chapter 3, of these 47 the most 
common characteristics from the first measurement session were of shape ‘A’ or ‘D’ 
(figure 4-4) and the vast majority displayed good refilling characteristics (table 4-10). 
For those that had follow up measurements, almost a third had a different RBV slope 
category at the repeat measure and 10% had a different refilling score (full RBV results 
table in appendix table 9-4). Cohen’s kappa was calculated to assess the repeatability of 
RBV shape between first and second measurement sessions, with the single ‘B’ 
time
RBV
A
BC
D
Segment Mean pre  
RE (ohms) 
Mean post  
RE (Ohms) 
Mean % change  
in RE (Ohms) 
Arm_ref 288 326 13 
Arm_opp 283 316 12 
Trunk 23 25 6 
Leg_ref 248 295 19 
Leg_opp 247 294 19 
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categorised measurements being left out of the analysis as it would invalidate the 
analysis due to low counts (table 4-11). A kappa value of 0.3 suggested there is no 
evidence of good repeatability between the 1st and second measurements.  
 
  Shape 
  A B C D 
Refilling 
0 0 0 4 7 
1 16 1 10 9 
Table 4-10 Shape and refilling characteristics of the first measurement session with RBV 
recorded for each patient. 
 
  2nd session 
  A B C D 
1st  
session 
A 4 0 3 4 
B 0 0 0 0 
C 1 1 4 1 
D 4 0 1 9 
Table 4-11: Comparison of RBV shape in first and second measurement sessions 
 
The plots of pre- and post-dialysis BCM-measured OH by RBV shape category do not 
highlight a clear difference in OH patterns between groups, by visual inspection and 
that across all categories there are subjects who finish dialysis fluid depleted. (fig. 4-5). 
There was no difference in pre-dialysis OH between the different slope groups, other 
than the sensitivity analysis of the second session where the small sample of patients 
with an ‘A’ curve had the unusual characteristic of being fluid depleted pre-dialysis. 
Patients from all shape categories finished dialysis with similar fluid status, including in 
the sensitivity analysis which used a conservative definition of a flat line. Mean 
ultrafiltration volumes and ultrafiltration volume normalised to ECF were highest in 
those patients classified as B&C, although the shape definition is dependent on the 
ultrafiltration volume to some extent. The subjects were divided into tertiles by BMI 
and each tertile displayed in a different colour in figure 4-5. D shaped curves were less 
likely to come from the highest BMI tertile. 
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A B & C D 
p-
value 
Primary 
analysis 
n 16 15 16 1.0 
Good refilling (%) 100 69 56 0.01 
Pre-dialysis mean OH) (l) 1.0 2.2 1.6 0.1 
Post- dialysis mean OH (l) -0.9 -0.1 -0.1 0.3 
Mean UF volume (l) 1.8 2.5 1.6 0.02 
UF/ECF (%) 11 13 9 0.05 
 BMI (kg/m2) 29.9 27.4 28.3 0.6 
Sensitivity 
analysis 
N 8 22 17 0.04 
Good refilling (%) 100 82 59 0.06 
Pre-dialysis OH (l) 1.0 1.9 1.5 0.3 
Post- dialysis OH (l) -0.9 -0.2 -0.3 0.6 
Mean UF volume (l) 1.5 2.3 1.6 0.02 
UF/ECF (%) 9 13 9 0.01 
BMI (kg/m2) 28.4 28.6 28.6 0.6 
 
Table 4-12: Patient characteristics and treatment features by shape category groups with 
a p-value from one-way analysis of variance between the three groups. UF refers to 
ultrafiltration volume. 
 
 
Figure 4-5:  Pre and post OH measurements for patients with RBV plots of different curve 
shape. Blue plots are from the lowest tertile of BMI from this cohort (16.5-24.9 kg/m2), 
black plots are the middle tertile (25 to 29.9 kg/m2) and red plots are the highest tertile (30 
to 46 kg/m2). 
 
Because there is discrepancy in how a flat line slope is defined, sensitivity analysis, 
using the most conservative definition of a flat line from the literature (1.5% per hour, 
Mean UF = 1.8 l                    Mean UF = 2.5 l                   Mean UF = 1.6 l
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(Agarwal et al., 2009)) examined whether the conclusions were still justified when 
different definitions of a flat-line were used. This showed that of the 16 subjects initially 
classified as having a flat-line (‘A’ slope), 8 of these were still classified as being flat-
lines and half of these still finished dialysis fluid depleted (mean post-dialysis BCM-
measured OH: -0.6 litres, range: 1.8 to -1.9 litres) (full dataset in appendix table 9-4). 
 
 
Figure 4-6: Pre and post OH measurements for patients with RBV plots of different curve 
shape as part of sensitivity analysis with a stricter definition of what constitutes a flat-line. 
Blue plots are from the lowest tertile of BMI from this cohort (16.5-24.9 kg/m2), black are 
the middle tertile (25 to 29.9 kg/m2) and red plots are the highest tertile (30 to 46 kg/m2). 
 
4.5 Discussion 
4.5.1 Bioimpedance  
At a population level, it is becoming well accepted that using BCM as an aide in 
guiding haemodialysis patient’s fluid management improves outcomes (Onofriescu et 
al., 2014, Moissl et al., 2013). In an uncomplicated individual with relatively common 
characteristics, generic measurement protocols and decision making algorithms are 
likely to be beneficial. Yet there is a lack of data to support use of BCM outside this 
idealised case and there remains a great deal of uncertainty in utilisation of the 
technology in certain individuals. By making 8-lead BCM measurements before and 
after dialysis the impact of making alterations to the standard measurement 
configuration is defined which will allow these measurements to be made with greater 
confidence. 
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4.5.1.1 Alternative measurement paths 
There is a need for alternatives to the standard measurement path. The haemodialysis 
population is highly comorbid and is disproportionately prone to amputations and tissue 
viability problems. There are many clinical conditions that are routinely seen in all 
haemodialysis units – e.g. heavily bandaged limbs, damaged skin, amputations – that 
can exclude patients from the standard BCM measurement approach. There are also 
complications that may not prevent a standard BCM measurement, but will significantly 
affect the quality of the reading – e.g. use of moisturisers, localised fluid accumulations 
or contact between body segments such as at the armpit. In either case, alternative 
pathways may allow measurements to be made on patients who would have otherwise 
have been managed without BCM. The potential for equivalent measured impedances 
across different paths was demonstrated two decades ago, when BIA measurements on 
the each side of the body was compared with cross measurements and relatively small 
differences in resistance and reactance were observed (Lukaski et al., 1985). However, 
the only investigation to apply this to BIS measurements using BCM was in preliminary 
work for this study, where it was shown that BCM-measured OH from the hand-to-hand 
path is an acceptable alternative to the standard path (Keane and Lindley, 2015).  
 
 
Segment 
Control Pre-dialysis Post-dialysis 
RE RI RE RI RE RI 
Arm_ref (%) a 52 56 50 55 48 54 
Arm_opp (%) b 52 59 52 51 50 53 
Leg_ref (%) 44 47 44 51 45 50 
Leg_opp (%) 44 48 43 55 45 52 
Trunk_ref (%) 4.0 1.4 4.3 1.6 4.1 1.3 
Trunk_opp (%) 4.0 1.3 4.0 1.5 3.8 1.6 
Trunk upper (%) 0.2 - 0.3 - 0.1 - 
Trunk lower (%) 0.01 - 0.03 - 0.03 - 
Trunk_ref-opp (%) 4.0 - 4.1 - 3.8 - 
Trunk_opp-ref (%) 4.0 - 4.1 - 3.8 - 
Table 4-13: Relative segmental resistances as a proportion of standard whole body path 
resistances. Differences between the three groups for RE and RI were assessed using one 
way analysis of variance (ANOVA), with a indicating p<0.05 for RE and b indicating p<0.05 
for RI  
 
The results from healthy controls suggest there was no significant difference in OH 
across any whole-body path other than across the legs. Changing from a whole-body 
measurement to a hand-to-hand or cross measurement will involve substitution of one 
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limb for another and a change in the pathway through the trunk. Using the 8-lead BCM, 
the impedances of each limb individually can be isolated (see section 3.2.2) and the 
relative magnitudes of RE and RI in each limb expressed in relation to the resistance of 
the reference path (whole body measurement on dominant/non-VA side) (table 4-12). 
 
For measurements of RE, it can be seen that summing the segment resistances for the 6 
whole body paths individually supports the results from the model: substituting limbs 
and trunk paths does not significantly alter the overall path RE, except the leg to leg path 
which is noticeably lower (fig. 4-6) – suggesting increased OH as seen in the model 
results. The higher resistance of the arms seems to be compensated by a lower measured 
resistance for a current crossing the trunk from arm to arm than from arm to leg.  
 
Estimation of RI has much greater uncertainty (see section 2.3.2.5) and for segmental 
measurements, especially, in the trunk, the data were largely uninformative. It was not 
possible to infer much from segmental RI data.  
 
 
Figure 4-7: Re-calculating whole-body assessments of RE expressed as a % of the standard 
measurement path (hand-to-foot on the dominant side) in healthy controls based on the 
data in table 4-8 
 
The differences in ECF distribution between healthy controls and haemodialysis 
patients before and after treatment were investigated by assessing differences in RE 
between the three groups in each limb (table 4-12). Differences in RE between controls 
and dialysis patients will be related to differences in body composition as well as fluid 
Dominant side: 100% 
Non-dominant side: 101% 
 
Cross 1: 101% 
Cross 2: 101% 
Arms: 104% 
Legs: 89% 
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status, but differences between pre- and post-dialysis measurements will be purely 
related to differences in fluid. ANOVA suggested that the only significant results were 
for RE in the dominant / non-VA arm and for RI in the non-dominant / VA arm. The 
higher RE in the dominant arm is consistent with lower OH in this segment compared to 
the vascular access arm and the legs, where fluid accumulates. Higher RI in the non-
dominant arm could be explained by a greater difference in muscle mass between the 
dominant and non-dominant sides in healthy controls compared to dialysis patients, 
which again is supported by the model results. 
 
Considering the model results for lean and adipose tissue, the dominant side has 
significantly increased lean tissue and reduced adipose tissue as compared to the non-
dominant side and the legs have increased lean tissue and reduced adipose tissue 
compared to the arms. This is consistent with previous work using BIA that 
demonstrated a decreased resistance in the dominant arm compared to the non-dominant 
arm (Bedogni et al., 2002) and a decreased resistance of the legs compared to the arms 
(Lorenzo and Andreoli, 2003). For the comparison between arms, the decreased 
resistance is consistent with greater muscle mass, due to the higher proportion of water 
in muscle than fat, while the decrease in resistance in the arms compared to the legs, the 
difference could be similarly related to differences in body composition or could be due 
to the differences in shape. Using limb cross sectional areas and lengths from a study by 
Zhu et al. and assuming the limbs to be cylinders, equation 2-8 shows that an arm has a 
resistance 1.2 times higher than a leg, assuming identical resistivities (mean arm 
circumference 26 cm and length 58 cm; mean leg circumference 39 cm and length 72 
cm) (Zhu et al., 2000). 
 
For haemodialysis patients, it has been suggested that the presence of vascular access in 
a patients’ arm can bias measurements of OH and so guidance suggests avoiding these 
paths. This evidence comes from studies using different bioimpedance analysis 
techniques. Woodrow et al. used single frequency measurements to show decreased 
resistance in the fistula arm that was accompanied by increased arm circumference, 
suggesting increased excess fluid (Woodrow et al., 1997), although this was not 
replicated in paediatrics (Avila et al., 2015). More recently, two studies from a single 
centre using segmental BIA (SBIA) have reported that water and lean tissue content is 
different in the fistula and non-fistula arms (Panorchan et al., 2015, Booth et al., 2011). 
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However, none of the techniques used in these studies can adequately distinguish excess 
fluid from lean and adipose tissue, which leaves the possibility that the differences 
observed relate to differences in lean tissue alone rather than excess fluid, particularly 
given that fistulae tend to be placed in the non-dominant arm of patients. The results 
here confirm that the presence of a vascular access tends to increase the measured 
excess fluid, both in whole-body BCM and by looking at segmental RE on fistula side 
compared to the non-fistula (table 4-9). However, the effect (0.4 litres) is similar to the 
reproducibility of the BCM (0.3 litres) so the clinical significance of this result is 
debatable. 
 
4.5.1.2 Changes in measurement over a dialysis session 
Pre- and post-dialysis BCM measurements allowed assessment of the changes in body 
composition parameters during haemodialysis, which can provide validation of the 
BCM models and provide evidence of the effect of making measurements post-dialysis.  
 
In theory, the change in OH over dialysis should equal the change in body weight, while 
there should be no change in lean tissue or adipose tissue. However, dialysis has been 
shown to perturb fluid distributions (Shulman et al., 2001) which can influence whole-
body bioimpedance measurements (Zhu et al., 1999). Fluid shifts from the limbs into 
the trunk manifest as an apparent decrease in ECF when measured by whole-body 
techniques and shifts from the trunk to the limbs as an increase in ECF (Lundvall et al., 
1996). Haemodialysis has also been reported to change sodium concentration (Rees et 
al., 1999) and temperature (Huang et al., 2000), two variables that can affect 
bioimpedance at the microscopic level.  
 
These results suggest that post-dialysis BCM-measured OH has a small bias of around 
0.3 litres with limits of agreement of -1.9 to 1.3 litres, which supports similar 
measurements done as part of the validation of the BCM (Wabel et al., 2007b). 
However, El-Kateb et al. reported a similar dataset to that presented here (El-Kateb and 
Davenport, 2016) with contrasting results, including a significant bias and limits of 
agreement three times larger than those observed in this study. This discrepancy seems 
likely to be due to a lack of experience making BCM measurements and highlights the 
need for some expertise when making measurements (Lindley et al., 2015). 
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Post dialysis measurements of lean tissue and adipose tissue have non-significant 
changes over dialysis unlike the validation literature which suggests there is a 
significant difference (Wabel et al., 2007b).  
 
Despite the good agreement between change in BCM-measured OH and change in 
weight, the model for OH did suggest there was a degree of ultrafiltration induced 
changes in fluid distributions, with a larger change in the lower limbs than the upper. 
This would suggest that more fluid is recruited from the legs than the upper body which 
is largely in agreement with previous work. Measurements over the first 75 minutes of 
dialysis using BIS (Shulman et al., 2001) and over the whole haemodialysis session 
using SBIA (Zhu et al., 2008) and SBIS (Chanchairujira and Mehta, 2001) have 
demonstrated a greater fractional change in fluid in the legs as compared to arms and 
trunk. Abbas et al (Abbas et al., 2014) showed that there is a greater % removal of ECV 
from the legs than other compartments but that as UF rate is increased, there is a 
preferential recruitment of fluid from the trunk, which correlated with RBV reduction. 
When RBV was included in the model as an interaction term, there was no significant 
difference so we were not able to replicate this finding, but the model was not powered 
to assess this effect.  
 
One of the implications of the greater removal of fluid from the legs than the arms could 
be that the legs are the last segment that fluid is recruited from. One of the alternative 
bioimpedance techniques, calf bioimpedance, is based on the normalisation of calf ECF 
as an indicator of target weight (Seibert et al., 2013, Basile et al., 2015). However, if the 
legs are the final reserve of excess fluid, there is a chance that achieving normalised 
ECF fluid status may mean excessive dehydration in other segments, leading to poor 
perfusion of organs such as the heart, gut and brain and the associated consequences.  
 
4.5.1.3 Summary 
In summary, these data can allow BCM measurement and interpretation of the results 
with greater confidence. This will allow measurement protocols to be much more 
flexible and individualised than the manufacturer’s guidance suggests and can guide 
future research. This is based on a number of key observations: 
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 Any of the whole body paths other than foot-to-foot can be used as an 
alternative to the standard path, with an acknowledgement of the additional 
uncertainty when interpreting the results. 
 The difference in OH when a fistula is present is statistically significant, but 
arguably is not clinically significant when the uncertainty in other methods of 
target weight assessment are considered.  
 Making BCM measurements post-dialysis introduces a negligible bias to OH 
measurements but does increase measurement uncertainty, which should be 
accounted for when interpreting such data. This uncertainty will be reduced 
with time after dialysis, such as asking patients to move off the dialysis station 
to be weighed, before a measurement is made. 
 
4.5.2  Characterising RBV slope and refilling 
The application of RBV to fluid management in haemodialysis has been inconsistent 
and developed on a limited evidence base. Yet, despite mixed results from studies 
looking at the use for improving fluid management, there remains significant interest in 
the technology and a number of new trials are currently being undertaken (Hecking et 
al., 2012). 
 
Interpretation of RBV has largely been based upon qualitative categorisation of curves 
by the user or automated quantitative analysis as part of biofeedback tools. In general, 
the qualitative approaches are used for assessment of target weight and the automated 
quantitative analysis is used to prevent IDH. However, both approaches could be 
thought of as related to the ‘probing’ concept for fluid management, whereby patients’ 
target weights are progressively lowered until the patient becomes symptomatic, at 
which point the target weight is increased or ultrafiltration rate reduced (Chazot et al., 
2012).  
 
The most common approach to qualitative analysis of RBV is that the patient is 
overloaded as long as they have a flat-line, or type ‘A’ curve. This prompts a reduction 
in target weight until there is evidence that vascular refill cannot keep up with 
ultrafiltration - manifested as a downward slope in the RBV curve (Lopot et al., 1996). 
Steuer et al showed that dry weight can be reduced in patients with a flat-line (Steuer et 
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al., 1998), but with the growing realisation of the harm associate with excessive 
ultrafiltration, achieving a lower weight is not an appropriate outcome measure in itself. 
There is less understanding around the other curve shapes. Santoro suggested that 
increasing ultrafiltration volume can move curves towards a D shape (Santoro et al., 
1998) and a small study showed an association between a D type curve and fluid 
overload (Bonello et al., 2007). Hothi used receiver-operator-curve (ROC) analysis to 
show that the RBV change in the first hour is the most discriminatory for predicting 
IDH and that the average shape of the curve for complicated treatments was D-type as 
compared to a C-type for uncomplicated treatments (Hothi et al., 2008). 
 
These data have for the first time demonstrated that a flat-line does not necessarily 
indicate fluid overload (fig. 4-4), which could potentially cloud one of the primary 
assumptions of RBV analysis. Robust physiological explanations of the characteristic 
shapes are lacking, however it is most likely that the ‘D’ shaped curves are related to 
redistribution effects in the early stages of a treatment session. It has been shown that 
the biggest reduction in central venous pressure occurs during the first hour of dialysis 
which is accompanied by an increase in myocardial perfusion, after which changes are 
less pronounced during dialysis and normalise afterwards (Thalhammer et al., 2015). A 
substantial proportion of the blood is contained in the splanchnic and splenic beds. Yu 
et al. were able to show that translocation of red blood cells from these beds peaks in 
the first hour of dialysis and by investigating patients with diffusion only dialysis as 
well as with ultrafiltration, they demonstrated that this change only occurred during 
ultrafiltration (Yu et al., 1997). Further work is necessary to investigate these factors as 
well as others to be able to make better use of RBV analysis. 
 
The problem with using RBV curve classification is compounded by a lack of a 
consensus on definitions for how to categorise RBV curves. For example, an ‘A’ curve 
may be  classed as a “flat-line” without any quantitative definition, while elsewhere a 
flat-line could be anything from 1.5% decrease per hour (Sinha et al., 2010) or even 5% 
per hour over dialysis (Steuer et al., 1994), This issue has led to the reporting of results 
with significant disparity. Lopot et al reported that less than 1% of recordings from their 
centre had the characteristics of a shape D slope (Lopot et al., 2000), yet Dheu et al 
report that 91% of readings in their paediatric unit had this shape (Dheu et al., 2009). In 
light of this, sensitivity analysis was undertaken to see how robust the association 
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between flat-line slopes and fluid depleted states were. This confirmed that even with 
the most conservative definition of a flat-line, up to 50% of subjects showing a flat-line 
can finish haemodialysis fluid depleted as measured by BCM (fig. 4-6). It is important 
that future work with RBV defines objective criteria for better assimilation of reported 
studies and better understanding of the technology. 
 
There was no evidence of agreement in this study between RBV slopes from serial 
measurement sessions, up to two months apart. The use of BCM concurrently with RBV 
allows the opportunity to account for some of the variability between different 
measurement sessions, with a fluid status assessment, and absolute blood volume 
measurements could further explain intra-subject variation. 
 
In summary, these data raises some questions about the perceived understanding of 
RBV dynamics during haemodialysis and highlights the need for further observational 
studies that use objective and reproducible classifications. 
 
4.6 Limitations 
The study was not powered to address the multiple comparisons made by the models - 
the sample size was based on comparisons between the two primary whole-body paths 
only. A larger sample would allow better estimates of these different effect sizes. It 
would also have been interesting to extend the analysis to a group of haemodialysis 
patients who are defined as being prone to IDH, to investigate the relationship between 
fluid distributions and dynamics and IDH. However, within the scope of this PhD, it 
was not feasible to extend the number of patients included in the study any further. 
 
The sample of HD patients came from single renal unit and the generalisability of the 
results should be considered. The unit is somewhat distinct in the routine use of 
bioimpedance to guide fluid management over a number of years and sample 
characteristics show relatively normal hydration post-dialysis (table 4-6). 
 
4.7 Conclusion and implications for practice 
These observational data provide an increased evidence base for improving confidence 
in using BCM in a wider patient group and a wider range of practical situations. 
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Measurements should preferably be made pre-dialysis and avoid vascular access sites, 
but both measurements made post-dialysis and/or across vascular access sites can still 
provide reliable information on fluid status when interpretation acknowledges the 
additional uncertainty associated with these approaches. Furthermore, all whole-body 
BCM measurements other than foot-to-foot may be considered when measuring OH in 
situations where multiple complications are present. 
 
The assumption that a flat-line RBV slope indicates fluid overload, appears to be 
incorrect, meaning that the widely accepted practice of reducing target weights in 
response to a flat-line could lead to unnecessary or harmful fluid-depletion. The use of 
BCM measurements with RBV allows changes in blood volume associated with 
intolerance to ultrafiltration to be related to a known initial fluid status. The 
complimentary nature of BCM and RBV supports further studies into how the 
information from both tests can be combined. 
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5 Characterising body composition monitor 
measurements of fluid status in subjects with 
high BMI 
 
5.1 Objective 
There are technical reasons why bioimpedance measurements in patients at high BMI 
may have increased uncertainty and a number of clinical studies have demonstrated 
associations between haemodialysis patients’ fluid status and BMI. However, the 
influence of treatment-related factors on these clinical observations has not been well 
explored and further characterisation of BCM in this group is needed. To be able to 
differentiate treatment related associations between body habitus and fluid status from 
associations relating to measurement, this study made BCM tests in subjects with 
normal renal function as well as haemodialysis patients.  
 
Research question 2: Is the tendency for high BMI haemodialysis patients to finish 
dialysis fluid depleted according to the BCM associated with an artefact in the 
mathematical model or with systematic differences in the prescription and delivery of 
treatment? 
 
5.2 Introduction 
There remains uncertainty about the use of bioimpedance in individuals with particular 
characteristics, including those at high BMI. However, much of the literature 
highlighting these issues are based on BIA devices using equations generated from 
subjects with relatively normal body habitus and these will not be accurate in extremes 
of body habitus (Das et al., 2003, Baumgartner et al., 1998). 
 
BCM measurements, based on BIS, use a different approach to analysis  which is based 
on a fluid model (Moissl et al., 2006) and a body composition model (Chamney et al., 
2007) (see section 2.3.5). This analysis does avoid the need for population specific 
regression equations, but BMI may still confound BIS results through its relationship 
with shape and/or distribution of adipose tissue. In the fluid model used by the BCM, 
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Moissl et al. introduced a BMI correction for the calculation of fluid volumes to address 
the effect of changes in body shape (Moissl et al., 2006). However, this correction was 
based on a sample with a relatively narrow range of BMI and, furthermore, validation of 
the BCM device is limited at very high BMI (Ribitsch et al., 2012). 
 
There are also a number of observational studies that describe associations between 
BMI and patients’ fluid status in haemodialysis patients. A large dataset from our 
centre, based on the first BCM measurement made on haemodialysis patients after the 
technology was introduced into the unit, showed a significant inverse association 
between BMI and BCM-measured OH at clinically defined target weight (Lindley and 
Keane, 2014). Elsewhere, both pre- and post-dialysis OH have been shown to be 
negatively associated with BMI (Antlanger et al., 2013, Ribitsch et al., 2012).  
 
The observed variation in BCM-measured OH at target weight is likely to be 
multifactorial. Patients with high BMI could be reluctant to increase target weights 
particularly if they are eligible for transplant listing if they achieve or remain below a 
specified BMI. It is also plausible that there are physiological factors involved. 
Although adipose tissue contains a much lower proportion of water than lean tissue, 
most of the water is extracellular so patients with high BMI may have a reserve of 
extracellular water that can be recruited into the circulation and effectively buffer larger 
ultrafiltration volumes. 
 
5.3 Methods 
5.3.1 Subjects 
The study population consisted of three groups of subjects:  
 A large dataset from a previous study provides a group of healthy subjects with 
normal renal function from the general population with average BMI 
(Wieskotten et al., 2013), which will be referred to as healthy subjects with 
normal BMI.  
 A second group of healthy subjects with normal renal function who have high 
BMI were recruited from outpatient clinics for bariatric surgery patients within 
the local Hospital, referred to as healthy subjects with high BMI. 
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 Finally, a group of haemodialysis patients with high BMI were recruited from 
within the two hospital and six satellite haemodialysis units under the care of a 
large Teaching Hospital. 
 
The healthy subjects with high BMI were greater than 18 years of age and had no 
history of renal failure. Renal function was assessed with an estimated glomerular 
filtration rate (eGFR), calculated by the local laboratory with the Modification of Diet in 
Renal Disease (MDRD) 4 parameter formula (Levey et al., 1999) using the most recent 
creatinine measurement for the individual (not being more than one month from the date 
of BCM measurement). Normal renal function was defined as an eGFR of greater than 
60 ml/min/1.73m2. BMI was calculated from measurement of height and weight at the 
time of data collection and patients with a BMI greater than 30 kg/m2 were considered 
for inclusion. 
 
The dialysis patients with high BMI were greater than 18 years of age, had been treated 
with haemodialysis for more than 3 months and had a BMI greater than 30 kg/m2 
calculated from the patients recorded height and their normally hydrated weight as 
defined by BCM. 
 
5.3.2 Sample size 
The sample of healthy subjects with normal BMI consisted of 1296 subjects with a 
mean BCM-measured OH of -0.1 litres and a standard deviation of 1.1 litres. Assuming 
a similar standard deviation for BCM-measured OH in healthy subjects with high BMI, 
recruiting 20 subjects will detect a difference of approximately 0.6 litres at the level of 
5% type I error with 80% power. 
 
The association between BCM-measured OH and BMI in haemodialysis is already 
established (Lindley and Keane, 2014, Ribitsch et al., 2012, Antlanger et al., 2013). A 
convenience sample of ten haemodialysis patients was based on the estimated 
prevalence of eligible patients in the study time-frame and is used for descriptive 
purposes only. 
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5.3.3 Procedure 
Data for healthy subjects with normal BMI came from a previously reported study 
(Wieskotten et al., 2013). 
 
Healthy subjects with high BMI had a standard and 8-lead BCM measurement as 
described in chapter 3. A visual assessment of body shape was made, based on changes 
in limb cross sectional area (CSA) from proximal to distal ends of the limb as described 
in figure 5-1.  
 
Figure 5-1: Visual assessment of the asymmetry of the limbs. Numerals increase with 
greater disparity between upper and lower CSA; A refers to the arms and L to the legs. 
 
 AI AII AIII 
LI Low Low*/Medium Medium/High* 
LII Low*/Medium Medium/High* High 
LIII Medium/High* High High 
Table 5-1: Calculating shape factors for analysis from the visual assessments. Control 
subjects were split into three groups (low, medium and high) whereas HD subjects were 
split between low and high as indicated by *. 
 
Dialysis patients had a standard and an 8-lead BCM measurement made pre- and post-
dialysis on a mid-week session as described in chapter 3. Ultrafiltration volume, blood 
pressure and any symptoms experienced were recorded. RBV monitoring was 
performed where possible as outlined in chapter 3, to identify patients’ capacity for 
vascular refilling. For dialysis patients, shape factor was split into two categories rather 
than three, due to low numbers.  
 
LI 
AI 
LII 
AII 
LIII 
AIII 
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5.3.4 Statistical analysis 
Continuous data was graphically assessed for whether it appeared to come from a 
normal distribution by plotting histograms. BCM-measured OH was described by mean 
(standard deviation) for normally distributed data and median (range) for non-normal 
data. A two sided Student’s t-test was used to compare BCM-measured OH in healthy 
subjects with normal BMI and healthy subjects with high BMI. 
 
The effect of shape was investigated using the Kruskal-Wallis test in the healthy 
subjects with high BMI and the Mann-Whitney test in dialysis patients. Comparisons 
were displayed using box-plots. 
 
Haemodialysis patients’ refilling capacity was categorised as adequate or insufficient 
based on the pre-dialysis BCM-measured OH, UF volume and the percentage blood 
volume drop as described in chapter 3. 
 
5.4 Results 
5.4.1 Patient characteristics 
The characteristics of the patient groups can be seen in table 5-2.  
 Healthy subjects 
with normal BMI 
Healthy subjects 
with high BMI 
Haemodialysis 
patients 
Number 1327 20 10 
Age, years 44 (17) 47 (12) 48 (37 to 73) 
Sex (% male) 47% 25% 80% 
BMI, kg/m2 26 (5) 41 (7)* 40 (35 to 51) 
Shape factor:  - low 
                   - medium 
                   - high 
- 
- 
- 
9  
6  
5 
7  
- 
3  
OH, l.  For HD:   pre 
                              post  
-0.1 (1.1) 
- 
-0.1 (1.7) 
- 
1.8 (-1.9 to 4.6) 
-1.8 (-3.8 to 0.5) 
LTM (kg) 45 (12) 33 (10)* 49 (29 to 72)) 
ATM (kg) 24 (11) 84 (23)* 66 (46 to 107) 
Ultrafiltration volume (litres) - - 2.2 (1.1 to 3.5) 
IDFG (litres) - - 1.6 (0.4 to 3.0) 
BP change (mmHg): systolic 
                                    diastolic 
- 
- 
- 
- 
4 (-30 to 48) 
3 (-15 to 28) 
Albumin (g/L) - - 40 (33 to 43) 
Table 5-2: Patient characteristics. Data are mean (sd) for normal data and median (range) 
otherwise. IDFG is the intradialytic fluid gain that preceded this session. Significant 
difference between healthy subject groups is indicated by *. 
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5.4.2 Subjects with normal renal function 
Mean BCM-measured OH for healthy subjects with high BMI was -0.1 litres which was 
not different from the mean BCM-measured OH from healthy subjects with normal 
BMI (p=0.7; 95% CI: -0.3 to 0.5). Increasing the shape factor - that is a greater 
difference in limb circumference from proximal to distal ends - was associated with a 
lower BCM-measured OH (p=0.004) and an increasing BMI (p<0.001). This is shown 
in the upper chart of figure 5-2.  
 
 
Figure 5-2: Association between shape factor and BCM-measured OH (shown in black) 
and BMI (shown in blue) for healthy subjects with high BMI (above) and dialysis patients 
with high BMI pre- and post-dialysis (below). Differences between shape factor groups 
were non-significant unless indicated. 
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5.4.3 HD patients 
The, median BCM-measured OH values for dialysis patients were 1.8 and -1.8 litres 
pre- and post-dialysis respectively. The shape factor was not associated with pre- or 
post-dialysis BCM-measured OH (p>0.5; fig. 5-2). RBV was recorded for seven of the 
dialysis patients with high BMI (fig. 5-3) and 6 of these, including all patients finishing 
dialysis dehydrated, were deemed as having adequate refill. Median systolic and 
diastolic blood pressure changes were 13 and 3 mmHg, further supporting that refill was 
maintained (table 5-2). 
 
Figure 5-3: RBV curves for HD patients with high BMI. Solid lines are from HD session 1 
and dashed lines from the repeat measurement session, HD session 2. Colours reflect 
different shapes of blood volume curve as defined in chapter 3. Not all patients had RBV 
measurements on session 1 and/or session 2. 
Dialysis Session Profile shape
1st session
2nd session
A
B
C
D
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5.5 Discussion 
Previous studies around this topic have clearly shown associations between BMI and 
fluid status in haemodialysis patients. These results suggest that this is not related to a 
systematic bias in the BCM measurements and is due to treatment related factors, such 
as patient behaviour, physiology and the way the patients are managed. 
 
The BCM assumes that the body is a series of segments which are represented as 
individual cylinders of uniform conducting material and the electrical properties of the 
segments are heavily dependent on the shape and composition of the tissue being 
measured (Foster and Lukaski, 1996). At extremes of body habitus, the shape of 
individual segments and the distribution of major body tissues such as lean and adipose 
tissue influence the measured electrical impedance. The BCM models include a factor 
to help correct for such effects (Moissl et al., 2006), which assumes that BMI is a 
surrogate measure of differences in shape and amount of adipose tissue. This correction 
has been shown to improve fluid estimation by BIS at relatively normal BMI, but there 
was a lack of validation of this BMI-based correction at high BMI.  
 
Carter et al. investigated the effect of high BMI on measures of fluid by BIS (Carter et 
al., 2005). However, the results did not consider the accuracy of absolute volumes but 
rather dialysis-induced changes in ECF and the discrepancies observed highlight the 
dependence on distribution of body tissues and fluid. This is related to the fact that arms 
and legs are shaped very differently compared to the trunk and to each other (Foster and 
Lukaski, 1996) and so localised changes in body composition have different effects on a 
whole body measurement depending on which limb it occurs in. As such, whether 
adipose tissue increases are central visceral or peripheral fat accumulation and whether 
excess fluid removal occurs uniformly from all segments are important. The differences 
observed in the study by Carter et al. are likely to be related to the dialysis induced 
effect on fluid distribution, as the authors explain (Carter et al., 2005). 
 
These results for healthy subjects with high BMI showed BCM-measured OH 
measurements that are consistent with healthy controls with normal BMI. There was no 
independent measure of the distribution of adipose tissue and the method of assessing 
shape was crude (in an attempt to minimise intrusion on participants). A significant 
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association between shape factor and BCM-measured OH in healthy subjects with high 
BMI was demonstrated which suggests that BCM-measured OH may be under-
estimated in subjects with shape factor 3. However, this shape was also associated with 
higher BMI so BMI may be a confounding factor in the relationship between shape 
factor and BCM-measured OH. Further investigation of the effect of limb shape and a 
measure of the distribution of fat, such as waist-to-hip ratio, is warranted.  
 
Haemodialysis patients with high BMI had the tendency to tolerate removal of large 
fluid volumes, finishing dialysis with extremely negative values of OH (up to -3.8 litres 
observed in this study). None of the sessions monitored during the study exhibited any 
acute symptoms of IDH and the RBV results suggest that the patients were able to 
tolerate dehydration while still being able to recruit fluid from the interstitium into the 
circulation (fig 5-3). It is possible there may be a “buffering” effect from extracellular 
fluid in the increased adipose tissue compartment (Waki et al., 1991). This suggests that 
reducing target weights in this patient group may be less likely to provoke symptoms 
and could help control excess fluid in patients with low residual renal function and large 
IDFGs.  
  
5.6 Limitations 
This study was limited in design by the lack of a gold standard measure of fluid status. 
The use of control subjects with normal renal function allowed an estimation of what 
the BCM would measure in subjects of similar body habitus were their kidney’s 
functioning. 
 
The assessment of body shape in this study was crude. The shape of limbs is likely to be 
one of the most important factors in framing measurement uncertainty with any whole-
body bioimpedance devices and warrants further investigation. However, this study was 
an assessment of the clinical significance of measurements at the extremes of body 
habitus rather than an assessment of the underlying mechanisms involved. 
 
5.7 Conclusion and implications for practice 
In summary, there was no evidence of a systematic bias in BCM-measured hydration 
status in subjects with high BMI. In dialysis patients, significant levels of fluid 
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depletion were observed post-dialysis but RBV suggested refilling was maintained and 
blood pressure was stable. These patients may have a reserve of ECF to buffer 
ultrafiltration and it is possible that this feeds into the ‘reverse epidemiology’ 
association between BMI and survival in haemodialysis patients. Although further work 
is needed to fully describe the clinical significance of this observation and help to 
optimise and individualise BCM based fluid management strategies, this study suggests 
that low post-dialysis BCM-measured OH should be managed as real fluid depletion 
which should be limited to avoid compromising residual renal function. 
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6 Characterising body composition monitor 
measurements of fluid status in malnourished 
subjects 
 
6.1 Objective 
There is a demonstrated association between haemodialysis patients’ fluid status and 
body habitus, suggesting patients with malnutrition finish dialysis overloaded. It is not 
clear to what extent this is related to differences in the prescription and delivery of 
haemodialysis treatment or whether it is commonplace for BCM to indicate fluid 
overload in malnourished individuals who have normal renal function. To be able to 
differentiate between these two effects, this study made BCM measurements in 
malnourished subjects with normal renal function as well as haemodialysis patients. 
 
Research question 3: Is the presence of malnutrition associated with BCM-measured 
fluid overload? 
 
6.2 Introduction 
As discussed in chapter 5.1, studies have demonstrated an association between BMI and 
pre- and post- dialysis BCM-measured OH (Wizemann et al., 2009, Antlanger et al., 
2013, Ribitsch et al., 2012) as well as between BMI and BCM-measured OH at 
clinically defined target weight (Lindley and Keane, 2014). In cases of malnutrition, 
overhydration defined by ECF to body weight ratio has been shown to correlate with 
subjective global assessment (SGA), a validated tool to aid interpretation of 
malnutrition risk in haemodialysis patients (Garagarza et al., 2013). Furthermore, in 
peritoneal dialysis patients, longitudinal increases in overhydration measured as 
ECF/TBW have been associated with worsening nutritional state as measured by SGA 
and by hand-grip measures (Cheng et al., 2005).  
 
Again, in parallel with patients with high BMI, the observed variation in OH at target 
weight is likely to be multifactorial. Malnourished patients are likely to be encouraged 
to improve dietary intake and avoid weight loss, which may lead to a preference to 
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maintain or increase target weight. Smaller and malnourished patients lack the adipose 
tissue reserve that may be able to buffer larger ultrafiltration volumes as described in 
chapter 5.  
 
There has been extensive validation of BCM-measured OH in subjects with normal 
renal function (Wabel et al., 2009) but the validation cohort were a generally healthy 
cohort with a limited BMI range (Ribitsch et al., 2012) and so it is of interest to 
investigate malnourished subjects with normal renal function. The BCM model has 
been applied to a malnourished indigenous population from Columbia and given values 
of OH proportional to the degree of malnutrition, getting as high as 6.2 litres (Chamney 
et al., 2007). However, this was a re-analysis of the original data which used dilution 
based estimates of ECF and ICF and was based on a population of indigenous 
Columbians from 1978 (Barac-Nieto et al., 1978). There is a need to corroborate these 
findings using BCM-measured fluid volumes and using a population more 
representative of current haemodialysis populations. 
 
Patients admitted to the wards for the care of the elderly provided a suitable population 
for the study. They are assessed for malnutrition and renal function using eGFR, and are 
monitored to ensure that their fluid intake is sufficient to ensure they are not dehydrated. 
In order to compare malnourished subjects recruited from this population with subjects 
without malnutrition, a subgroup was extracted from the database of measurements used 
in the validation study for the BCM which matched for age range. 
 
6.3 Methods 
6.3.1 Subjects 
The study population consisted of three groups of subjects:  
 Healthy subjects with unclassified body habitus: Subjects with normal renal 
function aged 80 years old or over whose measurements were used in the 
validation study for the BCM (Wieskotten et al., 2013).  
 Healthy subjects with malnutrition: Subjects with normal renal function came 
from an elderly care ward and were clinically defined as malnourished. (Note 
that in this context ‘healthy’ refers only to renal function) 
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 Haemodialysis patients with malnutrition: Haemodialysis patients from within 
the two hospital and six satellite haemodialysis units under the care of a large 
Teaching Hospital defined as malnourished by specialist dietetic input 
 
The healthy subjects with unclassified body habitus were greater than 80 years of age, 
had no history of renal failure or cardiovascular comorbidities and were drinking freely.  
 
In the healthy subjects with malnutrition, renal function was assessed using the eGFR, 
calculated by the local laboratory with the MDRD 4 parameter formula (Levey et al., 
1999) based on the most recent creatinine measurement for the individual (not being 
more than one month from the date of BCM measurement). Normal renal function was 
defined as an eGFR of greater than 45 ml/min/1.73m2 for subjects greater than 60, to 
account for the expected reduction in eGFR with aging (Glassock and Winearls, 2009). 
Definition of malnutrition was based on the Malnutrition Universal Screening Tool 
(MUST) (Kondrup et al., 2003). BMI was calculated from measurement of height and 
weight at the time of data collection. Subjects were drinking freely and had no history 
of renal failure. 
 
The malnourished dialysis patients were greater than 18 years of age and had been on 
dialysis for at least 3 months to allow time for fluid imbalance on presentation to be 
corrected. Defining malnutrition using MUST is not validated for haemodialysis 
patients. A specialist dietitian identified patients for this cohort based on the following 
criteria: 
- SGA score greater than 3 (Enia et al., 1993); 
- Presence of two of the three core nutritional variables associated with 
malnutrition (unintentional weight loss, BMI less than 20 kg/m2 and reduced 
dietary intake); 
- Scoring greater than 2 on a novel malnutrition screening tool (LTHT) developed 
locally (Bowra et al., 2015). 
BMI was calculated from the patients recorded height and their normally hydrated 
weight as defined by BCM. 
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6.3.2 Sample size 
The sample of healthy subjects with unclassified body habitus consisted of 39 subjects 
with a mean BCM-measured OH of 1.3 litres and a standard deviation of 1.1 litres. 
Assuming a similar standard deviation for measurements of BCM-measured OH in 
malnourished healthy subjects, recruiting 20 subjects will allow a difference of 
approximately 0.9 litres to be measured at the level of 5% type I error with 80% power. 
 
The association between BCM-measured OH and BMI in haemodialysis is already 
established (Lindley and Keane, 2014, Ribitsch et al., 2012, Antlanger et al., 2013). A 
convenience sample of five haemodialysis patients was based on the estimated 
prevalence of eligible patients in the study time-frame and is used for descriptive 
purposes only. 
 
6.3.3 Procedure 
Data for healthy subjects with unclassified body habitus came from a previously 
reported study (Wieskotten et al., 2013) using a standard BCM device measuring across 
the hand-to-foot path. 
 
Malnourished subjects with normal renal function had a standard and 8-lead BCM 
measurement as described in chapter 3. 
 
Malnourished haemodialysis patients had a standard and an 8-lead BCM measurement 
made pre- and post-dialysis on a midweek session as described in chapter 3. 
Ultrafiltration volume, blood pressure and any symptoms experienced were recorded.  
 
6.3.4 Statistical analysis 
Continuous data was graphically assessed for whether it appeared to come from a 
normal distribution by plotting histograms. BCM-measured OH was described by mean 
(standard deviation) for normally distributed data and median (range) for non-normal 
data. A two sided Student’s t-test was used to compare BCM-measured OH in healthy 
subjects with unclassified body habitus and malnourished healthy subjects. 
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6.4 Results 
The characteristics of the patient groups can be seen in table 6-1. The mean BCM-
measured OH for malnourished healthy subjects was 1.3 litres. Although this was 
significantly greater than the mean for the whole population of healthy subjects with 
unclassified body habitus used to validate the BCM (mean BCM-measured OH = -0.1 
litres), it was not different from the elderly subgroup aged over 80 years (p=0.5). 
 
Although the inclusion criteria for malnourished dialysis patients did not include age, 
the five patients recruited were aged between 68 and 72 years. The post-dialysis BCM-
measured OH for this group ranged from -0.1 to 4.5 litres, with a median of 1.8 litres. 
 
 Healthy 
subjects 
(unclassified) 
Healthy 
subjects 
(malnourished) 
Haemodialysis 
patients 
(malnourished) 
Number 39 20 5 
Age, years 87 (5) 87 (5) 75 (68 to 82) 
Sex (% male) 33 (%) 40% 60% 
BMI, kg/m2 23 (4) 19 (7)* 20 (16 to 22) 
OH, l.  For HD:   pre 
                              post  
1.3 (1.1) 
- 
1.3 (1.1) 
- 
2.5 (0.6 to 5.9) 
1.8 (-0.1 to 4.5) 
LTM (kg) 31 (7) 26 (7)* 27 (17 to 29) 
ATM (kg) 32 (9) 22 (20)* 25 (13 to 32) 
Ultrafiltration volume (litres) - - 1.6 (0.7 to 2.5) 
IDFG (litres) - - 1.6 (0.2 to 2.3) 
BP change (mmHg): systolic 
                                    Diastolic 
- 
- 
- 
- 
13 (-13 to 21) 
3 (-23 to 24) 
Albumin (g/L) - - 36 (27 to 43) 
Table 6-1: Patient characteristics. Data are mean (sd) for normal data and median (range) 
otherwise. IDFG is the intradialytic fluid gain that preceded this session. Significant 
difference between healthy subjects is indicated by *. 
 
6.5 Discussion 
These results suggest that some degree of fluid overload as measured by BCM is 
common in elderly subjects irrespective of whether they come from the general 
population or from a cohort with a clinical diagnosis of malnutrition.  
 
The presence of oedema and expanded fluid volumes is relatively common in protein 
deficient states of malnutrition (Alberda et al., 2006) and has been linked to 
hypoproteinemia and leaky capillaries (Guirao et al., 1994, Fiorotto and Coward, 1979). 
BCM-measured OH has been shown to be associated with the severity of malnutrition 
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by SGA in subjects with normal renal function, but despite being statistically significant 
the effect sizes were very low and clinically not of great importance (Wieskotten et al., 
2008). However, this study was not designed to assess this association and the numbers 
of subjects with high degrees of malnutrition appear to be low. It is also interesting to 
note that one patient from the group of healthy subjects with high BMI recruited for 
chapter 5 had bariatric surgery during the study and BCM measurements before and 
after surgery indicated a measured increase in OH of 3 litres over a 3 month period. 
This may have been the consequence of nutritional defects following bariatric surgery 
as reported elsewhere (Dalcanale et al., 2010) which has previously been associated 
with expanded extracellular fluid and fluid overload (Mazariegos et al., 1992, Leone et 
al., 2000).  
 
Although the BCM models include a factor to adjust OH for age, measurements in the 
subgroup of healthy subjects aged over 80 indicates that the correction is insufficient at 
this age. Further inspection of the database suggests a tendency to develop  increased 
BCM-measured OH at ages above 70 years of age (Wieskotten et al., 2013). This 
systematic increase in BCM-measured OH could be explained by changes in body 
composition that affect the average hydration of lean and/or adipose tissue, the 
fundamental constants in the BCM model (Chamney et al., 2007). Variation in the 
constants could result from changes in the proportion of the different tissues that make 
up the total lean and adipose tissue or from changes in the ECF and ICF content of the 
tissue at normal hydration. Measurements of FFM using DEXA and body cell mass 
using total body potassium counting have suggested that there is a normal increase in 
the hydration of lean tissue with age (Gallagher et al., 1996). There is also a trend of 
increasing number of comorbidities with age (Tomson et al., 2007) and an association 
between  number of comorbidities and BCM-measured OH (Antlanger et al., 2013), 
which suggests that comorbidities are another important variable when trying to explain 
these relationships. A possible explanation of this is an increase in the fat within 
muscle, intermuscular and intramuscular adipose tissue (IMAT). Age, disease, injury, 
inactivity and obesity are all associated with increased levels of IMAT (Addison et al., 
2014). If IMAT has a higher ECF content than subcutaneous or other visceral fat, this 
ECF will be interpreted as over-hydration when IMAT levels are higher than expected 
by the BCM model. 
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If BCM-measured OH is associated with IMAT, the increase in IMAT associated with 
muscle wastage would be expected to lead to a higher BCM-measured OH in 
malnourished subjects. However, for elderly subjects without renal failure BCM-
measured OH was not significantly different in the group with malnutrition defined by 
the MUST score and the unselected group who would be expected to have a range of 
nutritional states. To obtain a conclusive answer to the original research question would 
require the collection of BCM-measured OH in a younger cohort with a diagnosis of 
malnutrition and without any concomitant disease, injury or restriction on activity 
which are likely to confound the results. Such a cohort would be difficult to find and 
unrepresentative of the haemodialysis population.  
 
The small sample of haemodialysis patients classified as malnourished in this study had 
BCM-measured OH when at their target weight that is consistent with previously 
reported data for patients with low BMI (Lindley and Keane, 2014). To some extent, the 
wide variation in their post-dialysis BCM-measured OH may be explained by the 
differences in the many factors associated with age and fluid status.  
 
If some or all of the measured excess fluid is actually confined within muscle it will not 
increase cardiovascular risk, as with intravascular excess fluid. Consequently, attempts 
to reduce target weights in these patients to levels of ‘normal’ hydration as measured by 
BCM or below may not be necessary and indeed may be excessive with the potential to 
cause IDH episodes. In the absence of experimental measurements of the actual ECF 
and ICF in IMAT and in subcutaneous and visceral adipose tissue, it should be possible 
to establish whether or not the measured excess fluid is able to transfer into the 
circulation and lead to harmful excessive intravascular volumes. Further investigations 
making use of absolute and relative blood volume measurements can help to explore the 
degree of BCM-measured OH that can be considered ‘normal’ for these subjects and 
what information is required for individualised fluid management. 
 
6.6 Limitations  
As described in section 5.6, the lack of a gold-standard assessment of OH limited this 
study. 
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The sample of malnourished control subjects was predominantly elderly, which was 
related to the hospital wards that were used to recruit these subjects. Ultimately, the 
effect of malnutrition on BCM-measured OH could not be distinguished from the 
association between age and BCM-measured OH in subjects greater than around 70 
years of age. However, recruiting younger malnourished subjects poses practical and 
ethical issues. 
 
6.7 Conclusion and implications for practice 
Although the study failed to answer the original research, the data collected and the 
subgroup analysis of the BCM validation study indicate that the presence of excess fluid 
as measured by BCM is common in elderly subjects. There will be some differences 
depending on individual comorbidities, however in general, older, and more comorbid 
patients, and patients with muscle wastage due to inactivity, should not be expected to 
achieve a post-dialysis fluid status as low as younger, fitter, more active patients. Fluid 
management strategies using BCM-measured OH that are designed for use across all 
patients may be inappropriate in these individuals. A patient with left-sided heart failure 
will usually need to achieve the lowest tolerable hydration post-dialysis to avoid 
breathlessness during the interdialytic period. In this case, the BCM-measured OH is 
mainly used to guide patients back to target after weight gain or loss. For other patients, 
especially those with a low IDFG, as if often the case for those with low BMI or poor 
nutritional state (Kalantar-Zadeh et al., 2009), a degree of BCM-measured 
overhydration post-dialysis may not be a problem, whereas IDH is known to be a risk. 
Use of intravascular blood volume measurements with RBV should help confirm to 
what degree this excess fluid is confined to the tissues or is recruited to the circulation. 
There is a real need for further work to help individualise fluid management in the 
cohorts discussed here.  
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7 Managing localised oedema in haemodialysis: 
can it be monitored by BCM and mobilised by 
simple interventions 
 
7.1 Objective 
Patients with heavily localised oedema present a problem both to the use of BCM for 
guiding fluid management and to achieving prescribed ultrafiltration goals during 
treatment. To inform management strategies, there is a need for a better understanding 
of the effect of localised fluid on different BCM measurement paths and of whether it is 
possible to monitor changes in localised oedema during haemodialysis. For successful 
implementation of these strategies, there is a need for better understanding of the ability 
to mobilise and remove oedematous fluid during haemodialysis. This preliminary study 
addressed these two knowledge gaps and additionally evaluated the efficacy of two 
simple interventions for mobilising localised fluid into the circulation by assessing 
tolerance of ultrafiltration and the reduction in localised fluid. 
 
Research question 4: (a) Can BCM measurements be used to assess and monitor 
localised oedema and (b) Can easily administered, non-invasive interventions mobilise 
persistent localised oedema so that it can be recruited into the circulation? 
 
7.2 Introduction 
7.2.1 Fluid accumulation in haemodialysis patients 
Haemodialysis is an intermittent replacement of kidney function which is based on 
several treatment sessions separated by longer periods in which toxins and fluid will 
accumulate in the body to different degrees depending on an individual’s residual renal 
function.  
 
The fluid in the intracellular compartment remains relatively stable and the excess fluid 
accumulation is predominantly located in the ECF, including in the plasma volume 
(Fisch and Spiegel, 1996). However, the plasma volume has a finite capacity so the 
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majority of the excess fluid accumulates in the interstitium, where the skin and 
subcutaneous tissue initially act as a reservoir (Gunga et al., 1994) and not until excess 
fluid becomes around 10% of body weight is clinically perceptible oedema  manifested 
(Mees, 1995).  
 
Disruption to the normal mechanisms involved in fluid homeostasis, including poor 
lymphatics, damaged microvascular membranes and elevated hydrostatic pressures can 
cause localised oedema formation. These localised accumulations often present in the 
lower limbs, due to the effect of gravity, and can cause problems for both the use of 
BCM as a diagnostic tool and to the management of fluid status.  
 
7.2.2 Localised oedema and bioimpedance 
Localised fluid accumulations are most likely to occur in the arms and legs because of 
the limited drainage capacity (Board and Harlow, 2002). As the arms and legs have 
significantly smaller cross sectional areas than the trunk, localised changes in the 
impedance in these segments can disproportionately affect whole-body bioimpedance, 
leading to measurements made across oedematous limbs which indicate unrealistically 
high ultrafiltration volumes for patients.  
 
It is also much more likely that measurements across oedematous tissue will suffer from 
artefacts, causing the display of an error message or inaccurate results. There are a 
number of reasons for this. The swollen tissue is more likely to cause a short circuit for 
the measurement signal between the legs or at the underarm. The tissue viability issues 
relating to oedematous tissue can cause sores, broken skin or use of heavy moisturiser 
on the site of electrode placement, all of which are issues.  
 
The effect of measuring across different paths in subjects with localised oedema has not 
been well described. This information can feed into individualised fluid management 
strategies to be used alongside clinical assessments which can help to avoid 
inappropriate decision making in these subjects. 
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7.2.3 Mobilisation of localised oedema during haemodialysis 
To understand how best to manage the fluid status in patients with localised oedema, 
there is a need to examine whether the established risk factors that drive prescription of 
target weights are applicable in this group. In particular, the evidence relating to the 
association between fluid overload and cardiovascular risk, and between excessive fluid 
removal and multiple end-organ damage, may not be directly applicable to this 
population. 
 
The cardiovascular risk associated with fluid excess is primarily due to left ventricular 
hypertrophy and arterial disease (Meeus et al., 2000). Although there are many factors 
involved in these processes, both are significantly associated with fluid overload 
(Seibert et al., 2013, Lin et al., 2005). Left ventricular hypertrophy is an adaptation 
associated with increased work in response to volume and pressure overload (Meeus et 
al., 2000). Hypervolemia is associated with arterial dilation and hypertrophy of the 
vessels, leading to reduced compliance (London et al., 1996), and these have been 
linked to all cause mortality in haemodialysis patients (Blacher et al., 1998). Without 
knowing the refilling characteristics of oedematous tissue it is not clear to what extent 
localised fluid is involved in arterial dilation, volume and pressure overload and other 
processes involved in the cardiac and arterial damage. As such, the influence of 
localised, extravascular fluid overload on cardiovascular risk is not known.  
 
At the other extreme, risk factors associated with excessive fluid removal are primarily 
related to intravascular fluid depletion and poor perfusion of end-organs (McIntyre, 
2010). An improved understanding of the mobilisation of localised oedema is key to 
managing these subjects in such a way that intravascular fluid depletion is avoided.  
 
7.2.4 Improving mobilisation from localised oedema 
As discussed in section 2.1.2.4, oedema is the result of capillary filtration rate exceeding 
lymphatic drainage and it manifests as localised fluid accumulation. Established 
physical therapies for treating oedema include compression hosiery, intermittent 
pneumatic compression (IPC), massage, exercise and elevation (Lymphology, 2003, 
Ogawa, 2012). Compression hosiery and elevation are part of routine care for 
haemodialysis patients with oedema, while massage alone is deemed to be ineffective 
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and potentially harmful (Lymphology, 2003). Exercise and IPC are not part of routine 
management of oedema in haemodialysis patients and provide further opportunities to 
mobilise fluid in these patients. 
 
IPC involves the cycling of positive pressure to the limb via the inflation of a cuff, 
sleeve or boot, increasing the hydrostatic pressure of the interstitial fluid. This leads to 
an increased arterio-venous pressure gradient, increased arterial flow, cardiac venous 
return and refilling of the blood volume (Tai et al., 2013, Chen et al., 2001). IPC has 
been applied to haemodialysis patients previously. A case series has described how four 
patients who regularly suffered from cramp were given IPC during dialysis which 
completely stopped the symptoms in all cases (Ahsan et al., 2004). A randomised 
control trial of IPC for preserving central blood volume (CBV) during haemodialysis 
(Tai et al., 2013), stratified patients by intradialytic hypotension-prone status, finding no 
effect on preservation of CBV but a significant impact on the volume of fluid removed 
during dialysis.  
 
Exercise can improve fluid mobilisation through activation of the muscle pump 
improving venous and lymphatic return. The movement of the limbs creates pressure 
changes in the tissue, providing a rhythmic opening of the lymphatics and increasing 
lymph transport (Partsch, 2008). Exercise also increases capillary filtration in exercising 
tissue, which raises the interstitial pressure and drives lymph flow. The lymphatics 
which encircle muscles are subjected to arterial pulsations due to increased cardiac 
output during exercise and also the contracting muscle fibers help to propel fluid away 
from exercising muscle (Korthuis, 2011). The lymph vessels are lined with smooth 
muscle cells and have one-way valves which aid the flow of lymph to the central 
circulation (Korthuis, 2011). 
 
There has been little published on the effect of exercise on microvascular fluid 
exchange. Olszewski showed that during two hours of ergometer cycling there was an 
83% increase in lymph flow - ascribed to the muscle pump driving lymph flow and an 
increase in skin lymph formation due to the exercise - and that a two hour period of 
venous stasis caused by limiting the muscle pump reduced lymph flow by 50% 
(Olszewski et al., 1977). Stick et al. looked at reductions in venous pressure due to 
muscle pump activation and showed that ergometer exercise decreased venous pressures 
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(Stick et al., 1993a). A more passive approach to activation of the muscle pump is the 
use of electrical stimulation to mimic the action potentials associated with muscle 
contraction. Plantar stimulation of the calf in haemodialysis patients with consistent 
intradialytic hypotensive episodes improved vascular refilling and achievement of 
ultrafiltration targets (Madhavan et al., 2009). In chronic heart failure patients, daily 
stimulation of the calf muscle reduced oedema by on average 0.5 kg over one month 
(Pierce and McLeod, 2009). Stimulation of lower leg muscles minimised the increase in 
lower limb volume after motionless standing, illustrating the activation of the muscle 
pump in the stationary position (W Man et al., 2003). 
 
7.2.5 Study aims 
This study aimed to provide better evidence for making and interpreting BCM 
measurements and to evaluate simple interventions for improving fluid mobilisation in 
patients with localised oedema. This was based upon three principle objectives: 
- Characterise differences in BCM measurement paths in subjects with localised 
lower-limb oedema. 
- To evaluate whether localised lower-limb oedema is mobilised during 
haemodialysis. 
- To evaluate whether simple interventions can improve fluid mobilisation from 
localised lower-limb oedema during haemodialysis.  
The results will feed into fluid management strategies for this group of patients. 
 
7.3 Methods 
7.3.1 Study design 
This study was designed as a preliminary investigation into three knowledge gaps in the 
management of fluid status in subjects with localised oedema, without intending to 
explore the mechanistic effects involved. This objective was consistent with the 
overarching aim of this thesis to improve the evidence base underpinning routine BCM 
based fluid management.  
 
A feasibility cross-over study design allowed the potential of the interventions to 
mobilise localised fluid to be evaluated while providing observational data to address 
the other two objectives. The cross-over design is particularly suited to this study in a 
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population with a chronic condition. For pilot or feasibility studies, a sample size of 12 
has been suggested as a minimum target for parallel arm trials (Julious, 2005). The 
same study demonstrates that, for cross over studies, the gain in precision for a unit 
increase in sample size at around 6 subjects in cross over studies is similar to parallel 
arm trials with 12 subjects. As such, 6 was taken as the target sample size for this study. 
 
7.3.2 Participants 
Participants were recruited from the haemodialysis units of a large Teaching Hospitals 
Trust. Eligible patients had lower limb oedema as defined by pitting and were identified 
by staff responsible for their care as having problems with routine fluid management. 
 
Exclusion criteria included having less than 3 months haemodialysis vintage, being less 
than 18 years of age, the inability to be weighed, amputations and the presence of 
metallic implants. 
 
To achieve the planned sample size, units were approached successively and nurses, 
dietitians and doctors responsible for care in each unit were asked to identify individuals 
who had evident lower limb oedema. These patients were then screened against the 
inclusion/exclusion criteria and approached if appropriate.  
 
7.3.3 Study protocol 
The study period ran for 16 weeks as described in figure 7-1 and 7-2. Monitoring and 
interventions took place on the middle session of the week. Two weeks of baseline 
measurements and two weeks of follow up measurements where participants received 
treatment as normal formed the control period. In between, the two arms alternately had 
compression followed by stimulation or, stimulation followed by compression, with 
concurrent monitoring. The intervention periods were followed by a two week washout 
period.  Participants were randomised to one of the two arms, A and B, by use of 
concealed envelopes. 
 
During the IPC phase, participants received compression of the lower limbs using a 
Flowtron Hydroven 3 (Arjo-Huntleigh, Bedfordshire UK). The compression sleeve was 
placed around the calves of both legs, with the bottom of the sleeves positioned around 
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the participants’ ankles. The amplitude of the contractions was set to 40 mmHg based 
on manufacturer’s recommendations. Patients were encouraged to use the devices for as 
much of the haemodialysis session as possible and adherence was recorded. 
 
Figure 7-1: Study protocol 
 
During the stimulation phase, participants were encouraged to use the device for two 
sessions of 30 minutes of stimulation, not being during the first hour of dialysis. The 
primary device used to deliver stimulation was the Circulation Booster (Actegy Health, 
Bracknell, UK), which consists of a plate with two pads that can be placed under a 
subjects’ feet. It produces a series of phases of stimulation, which target different 
muscle groups in the lower leg. It has a remote control to change signal amplitude and is 
very user friendly. Where this device was not suitable, the more flexible Neurotrac 
Sports XL (Verity Medical, Hampshire, UK) was used. This is based on applying 
adhesive electrodes above specific muscle groups on the lower leg and applying a signal 
via a battery operated control box. Electrodes were placed as per manufacturer’s 
guidance to target the calf muscles and a pre-programmed stimulation cycle that was 
designed to improve blood flow. For both devices, the strength of the stimulations was 
slowly increased until the participant starts to feel some form of discomfort and then the 
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setting was reduced by two units. The participant could control the strength of the 
contractions at all times and could reduce this if they felt any discomfort. 
 
At each measurement session, a number of observations were recorded: 
 Standard and 8-lead BCM measurements were made pre- and post-dialysis 
 The Crit-line blood volume monitor was used to measure RBV change and 
refilling capacity as described in chapter 3 
 The extent of oedema was recorded pre- and post-dialysis by measuring lower-
limb circumference at a reproducible location on the lower calf.  
 Patient symptoms 
 
 
Figure 7-2: Study flow diagram 
 
7.3.4 Outcome measures 
7.3.4.1 Characterising BCM measurements in patients with localised 
oedema 
Reliability of BCM measurements in these patients was assessed by reviewing all 
measurements for artefacts and calculating the proportion of measurements that were 
artefact free. Significant artefacts included measurements that had: 
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- divergence of data points from the fitted curve 
- a curve with no clear parabolic shape 
- abnormally high reactance 
and that also had unexpected body composition values. 
 
The results from chapter 4 describe minimal differences in BCM-measured OH between 
the main whole body paths. Given the similarities between the two sides and the cross 
measurements, to characterise BCM-measured OH in patients with localised oedema it 
was sufficient simply to characterise the difference between hand-to-foot measurements 
across the effected region and hand-to-hand measurements. This difference in OH was 
called the oedema bias and was calculated as described in equation 7-1. 
 
Equation 7-1:                oedema bias = OHHand to foot  – OHHand to hand  
 
7.3.4.2 Mobilisation of lower limb oedema for ultrafiltration during 
haemodialysis 
The ability to mobilise the lower limb oedema was measured by: 
Reduction in limb circumference – The extent of oedema was assessed pre- and post- 
dialysis by circumferential measure of the oedema at a reproducible point close to the 
site of most prominent oedema. 
Vascular refilling capacity – Absolute change in RBV and a classification of refilling 
(see chapter 3) were recorded. 
Fluid shift – The difference between the change in BCM-measured OH using the hand-
to-hand path (ΔH_H) and the change in BCM-measured OH using the standard whole-
body path (ΔH_F) during dialysis (equation 7-2). 
 
Equation 7-2                          𝑭𝒍𝒖𝒊𝒅 𝒔𝒉𝒊𝒇𝒕 =  ∆𝑯_𝑭 − ∆𝑯_𝑯 
 
7.3.4.3 Interventions for improving fluid mobilisation from localised 
oedema 
The potential of each intervention as a therapy was assessed by: 
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Rate of recruitment – The rate of recruitment was based on the proportion of patients 
screened that were suitable for inclusion and consented to the study. 
Adherence to the interventions – Adherence of the participants to the interventions was 
measured using the fractional time of prescribed treatment that was carried out over the 
sessions of interest. For compression, this meant the proportion of the total treatment 
time during the four sessions that compression was used was recorded. For stimulation, 
this was the proportion of the hour of prescribed treatment from each study session. 
Post-dialysis fluid status – BCM-measured OH from the post-dialysis measurement. 
Patient symptoms – Any interventions given for treatment of IDH were recorded. 
Patients were asked at the end of every session if they experienced any symptoms 
related to IDH (cramping, dizziness, nausea or excessive tiredness). If any of these 
markers were present, the session was classed as a symptomatic session. 
Adverse events – Any adverse events that occurred during the interventions were 
recorded. 
 
Results were summarised with descriptive statistics. 
 
7.4 Results 
7.4.1 Included subjects 
 
 
 
Subject 
 
Age 
(years) 
 
 
Sex 
 
 
Comorbidities 
 
Primary renal 
diagnosis 
RRT  
vintage  
(months) 
 
 
Ethnicity 
1 70 M N/a CKD (unknown) 30 White 
2 81 F Malignancy Traumatic or 
surgical renal loss 
48 White 
3 59 F Smoking 
Cerebral palsy 
Pyelonephritis 99 White 
4 45 F N/a Pyelonephritis 65 White 
5 57 M Heart failure 
Diabetes 
Neuropathic ulcers 
Diabetic neuropathy 21 Black 
6 58 F Myocardial infarction 
Claudication 
Renovascular 
disease 
22 White 
Table 7-1: Patient characteristics 
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The characteristics of the patients included in the study can be seen in table 7-1. Even 
with relatively strict inclusion criteria, it can be seen that the sample includes patients 
with very different comorbidities and individual needs. Only two of the patients were 
fully ambulatory, with three predominantly using wheelchairs and one subject unable to 
move the lower limbs at all. 
 
7.4.2 Characterising BCM measurements in patients with 
localised oedema 
Considering the primary 6 whole body paths measured using the 8-lead BCM, at least 
one of the Cole plots had clear artefacts in 12% of measurements. The prevalence of 
artefacts for each subject individually can be seen in table 7-2, along with suggested 
sources of the artefact. 
There was a consistent bias when measuring hand-to-foot compared to hand-to-hand in 
subjects with localised oedema, both pre- and post-dialysis (table 7-3). The mean bias 
from the 6 subjects for each phase and for all phases were tested against a null of zero 
difference and each case was significant other than one subject with missing data. 
 
Subject Prevalence of artefacts Proposed source of artefacts 
1 17% Heavy use of moisturiser; flaky skin. 
2 12% Use of moisturiser; high BMI leading to ‘short 
circuit’ effects between the legs and under the arms. 
3 33% Use of moisturiser; poor mobility secondary to 
cerebral palsy leading to ‘short circuit’ effects 
between the legs and under the arms. 
4 0% N/a 
5 21% Poor foot care; significant tissue viability issues; 
previous foot ulcers and scarring. 
6 0% N/a 
Table 7-2: Details of the prevalence of artefacts on 8-lead BCM measurements 
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Phase Measure 1 2 3 4 5 6 All 
subjects 
Control 
oedema bias 
(Pre) (litres) 
1.9 1.0 1.2 1.5 1.4 1.1 1.4* 
oedema bias 
(Post) (litres) 
1.8 1.4 1.2 1.6 0.4 0.7 1.1* 
fluid shift (litres) 0.1 -0.3 1.0 0.0 0.8 0.2 0.3 
IPC 
oedema bias 
(Pre) (litres) 
1.9 2.5 1.4 2.0 0.8 1.2 1.7* 
oedema bias 
(Post) (litres) 
1.7 3.8 0.3 2.1 2.2 0.9 2.0* 
fluid shift (litres) 0.6 -1.3 1.1 0.1 -0.6 0.2 0.0 
Stimulation 
oedema bias 
(Pre) (litres) 
1.6 2.1  2.7   2.1* 
oedema bias 
(Post) (litres) 
0.3 1.7  2.4   1.4 
fluid shift (litres) 1.0 0.8  0.3   0.7 
All phases 
oedema bias 
(Pre) (litres) 
1.7 1.9 1.1 2.3 0.9 1.2 1.6* 
oedema bias 
(Post) (litres) 
1.3 2.3 1.8 2.2 0.3 0.8 1.6* 
fluid shift (litres) 0.7 -0.3 1.1 0.2 0.1 0.4 0.3 
Table 7-3: Pre- and post-dialysis oedema bias is defined in equation 7-1. This gives an 
indication of the extent of the localised fluid in the lower limb. Fluid shift is defined in 
equation 7-2 and gives an indication of the extent of mobilisation of fluid during dialysis 
from the localised oedema into the blood volume. Values are the mean of the four 
measurement sessions.  Statistical significance is indicated by * 
 
7.4.3 Mobilisation of lower limb oedema for ultrafiltration during 
haemodialysis 
Reduction in limb circumference – There was a moderate change in limb circumference 
in the control phase, with a median reduction of 8.5 mm and a range from 2 to 28 mm. 
During both interventional phases there was a trend for a greater reduction in limb 
circumference, with a median 4 mm increase in the stimulation phase (range -3 to 6mm) 
and a median 6mm increase (range -4 to 13 mm) in the compression phase compared to 
the control phase. The median absolute reduction was greatest in the compression phase 
at 14 mm.  
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Vascular refilling capacity – Only three of the six participants were monitored for 
vascular refilling capacity. A recall of all Crit-line monitors on 21st July 2015 (MHRA, 
2015) meant that vascular refilling could not be defined in subjects 5 and 6. Subject 4 
was being treated with pre-dilution haemodiafiltration which interferes with the blood 
line before the cuvette used for RBV detection. In the three subjects who were 
monitored, good refilling was observed (as defined in chapter 3) in all measured 
sessions. 
Fluid distribution changes – Fluid distribution changes can be indicated by considering 
the relative changes in BCM-measured OH in both the hand-to-foot path (ΔH_F) and 
the hand-to-hand path (ΔH_H). There was no significant difference between ΔH_F and 
ΔH_H across the subjects for any phase individually or all phases together, indicating 
there was no greater mobilisation of fluid for ultrafiltration from the lower limbs than 
across the upper body (table 7-3). 
 
7.4.4 Interventions for improving fluid mobilisation from 
oedematous tissue 
Rate of recruitment – Figure 6-2 describes the number of patients at each stage of the 
study. Three units were used to recruit the 6 participants: two satellite dialysis units and 
the main hospital unit (evening shifts were not included for practical reasons). 257 
patients were considered for inclusion, based on the population of these units. Of these, 
8 were identified as meeting the inclusion criteria, two of which declined to take part in 
the study and 6 of whom gave informed consent and were randomised. This gave a 
recruitment rate of around 2% of prevalent haemodialysis patients in the units 
considered. 
Adherence to the interventions – All 6 participants completed the compression phase. 
Adherence varied between 50%, in one individual, up to 100% in three of the six 
participants. None of the participants found the intervention uncomfortable or painful. 
Only three of the six participants completed the stimulation period. One of the 
participants moved away during the trial before this period. Two of the participants, had 
comorbid conditions that prevented effective use of the stimulators. In the case of 
subject 3, the cerebral palsy and kyphoscoliosis left the lower limbs in such a condition 
that it was impossible to place the feet on the pads of the Circulation Booster. For the 
NeuroTrac, issues with skin integrity and the heavy use of moisturisers prevented 
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sufficiently good contact with the disposable electrodes and no stimulation was evident. 
Subject 6 had undergone surgery on one foot which again prevented full contact with 
the Circulation Booster pads and neuropathic ulcers on the leg prevented effective 
placement of disposable electrodes. 
Post-dialysis fluid status – There was a large range of values for fluid status in the 
cohort, from 4.4 litres fluid depleted up to 2.1 litres overloaded. The median post-
dialysis OH was -0.8 litres in the control phase and increased in both stimulation and 
compression phases by 0.4 and 1.1 litres respectively. 
Symptoms – Two of the subjects were symptom free in the control phase, two 
experienced symptoms in half of the sessions, one in a quarter of sessions and one in 
three quarters. The frequency of having symptomatic sessions was reduced in both 
intervention phases: with stimulation, two patients were less symptomatic and one had 
similar results to the control period; and with compression, five patients had similar 
results to the control phase and one had reduced frequency of symptoms. 
Adverse events – There were no adverse events. 
 
 Subject 
1 
Subject 
2 
Subject  
3 
Subject  
4 
Subject  
5 
Subject 
6 
Median 
 
Control 
Post-HD OH 
(l) 
-4.4 -1.6 2.1 0.1 -0.3 -1.3 -0.8 
Δcirc (mm) 2 28 15 5 9 8 8.5 
Refilling 100% 100% 100%    100% 
Symptoms 50% 25% 75% 0% 0% 50% 38% 
 
NMES 
Adherence 75% 90%  100%   90% 
Post-HD OH 
(l) 
-4.6 
(+0.2) 
-0.4 
(+1.2) 
 0.1 
(0) 
  -0.4 
(+04) 
Δcirc (mm) 8 (6) 32 (4)  2 (-3)   8 (4) 
Refilling 100% 
(0%) 
100% 
(0%) 
    100% 
(0%) 
Symptoms 25%  
(-25%) 
0% 
(-25%) 
 100% 
(0%) 
  25% 
(-25%) 
 
 
IPC 
Adherence %) 100% 90% 50% 100% 100% 80% 95% 
Post-HD OH 
(l) 
-3.8 
(+0.6) 
0.2 
(+1.8) 
1.2  
(-0.9) 
1.1 
(+1) 
0.4 
(0.7) 
-1.2 
(+0.1) 
0.3 
(1.1) 
Δcirc (mm) 14 (12) 28 (-4) 28 (13) 11 (6) 9 (0) 13 (5) 14 (6) 
Refilling 100% 
(0%) 
100% 
(0%) 
100% 
(0%) 
    
Symptoms 50%  
(0%) 
25%  
(0%) 
50% 
(-25%) 
0% 
(0%) 
0%  
(0%) 
0% 
(0%) 
38% 
(-13%) 
Table 7-4: Study results. Δcirc refers to reduction in calf circumference over dialysis. 
Numbers in brackets show the effect size, being the difference with the control period. 
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7.5 Discussion 
7.5.1 Characterising BCM measurements in patients with 
localised oedema 
The characterisation of BCM measurement configurations in chapter 4 show that in 
healthy controls and haemodialysis patients without localised fluid accumulation, 
measurements from hand-to-hand give comparable results to the standard measurement 
path. Similar analysis in this group of patients with localised lower limb oedema 
displays a significant disparity between BCM-measured OH using the reference path 
and the hand-to-hand path. 
 
Based on the lack of clear evidence from this study that localised fluid can be 
mobilised, the difference between the two measurement paths could potentially be used 
to set target weights that maximise the removal of oedematous fluid from the lower 
limbs without making the upper body too fluid depleted. Given that localised fluid is not 
preferentially removed, monitoring the body segments that have lower fluid status will 
give better protection against potential perfusion defects, IDH and end organ damage. 
However, as there are significant differences between patients with this indication, 
hand-to-foot measurements can be used to monitor and maximise the relative reduction 
in lower limb volumes when the upper body does not appear to be fluid depleted. The 
use of RBV measurements in combination with BCM may also allow monitoring of the 
plasma volume to avoid symptomatic fluid depletion. 
 
7.5.2 Mobilisation of lower limb oedema for ultrafiltration during 
haemodialysis 
Oedema is a standard indicator of fluid overload that traditionally would lead to a 
reduction in target weight to try and reduce the oedema (Charra et al., 1996). However, 
it is not known to what extent localised oedema is accessible during haemodialysis or to 
what extent it influences cardiovascular risk factors. If mobilisation of oedematous fluid 
is poor, ultrafiltration as a method of reducing the extent of oedema could put patients at 
risk of IDH.  
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For interpretation of the BCM results and individualising fluid management strategies in 
this patient group, it is important that a better idea of the refilling characteristics of 
localised oedema is established. Plasma refilling is difficult to directly assess, but 
information on refilling capacity was obtained indirectly from three other assessments.  
 
The circumferential change in the lower limb showed a reduction in limb circumference 
in all phases but the extent of the reductions observed was moderate. Haemodialysis 
patients have been shown to have 14 mm change in calf circumference simply from 
sleeping and remaining supine for an extended period (Elias et al., 2012) and stable, 
non-oedematous patients have lower limb circumference reductions typically above 
10mm during a standard haemodialysis session (Zhu et al., 2011). This suggests that 
despite, in some cases, patients dialysing to target weights that leave them significantly 
fluid depleted or symptomatic, there was no indication of notable changes in the extent 
of lower limb oedema. 
 
Assessment of vascular refilling capacity was hampered by the recall of the Crit-line 
device, meaning there was a lack of data. Of the patients that were monitored, none of 
the dialysis sessions indicated a drop in blood volume that would be defined as 
suggesting a lack of vascular refilling as defined in chapter 3. Subject 1 tended to be 
managed to finish dialysis with significant fluid depletion, suffered severe cramping on 
occasions and regularly achieved ultrafiltration volumes above 3 litres, yet did not have 
any RBV charts classified as having poor refilling. Subject 3, on the other hand was 
managed to finish dialysis with a degree of fluid overload, suffered regularly from 
cramp and had characteristic ‘A’ shaped RBV curves at all sessions. This is potentially 
linked to comorbidities and inability to move her lower limbs. It is hard to form 
conclusions from this limited dataset and further categorisation of RBV in these patients 
is warranted. 
 
The difference between hand-to-foot and hand-to hand BCM measurements give an 
indication of the relative reduction in excess fluid in the lower half of the body 
compared to the upper body and is an important consideration when interpreting BCM 
measurements on subjects with localised fluid. The results here that there is a minimal 
difference in measurements across the two paths suggest that there is a lack of 
significant mobilisation of fluid from the localised oedema.  
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The results here are not able to demonstrate a clear and noticeable mobilisation of lower 
limb fluid for ultrafiltration during haemodialysis. However it must be acknowledged 
that the study is exploratory in nature and has a diverse cohort of subjects so cannot 
categorically define this capacity. Basing fluid management strategies on hand-to-hand 
BCM measurements may be advisable in the first instance to reduce the risk of IDH, but 
additional hand-to-foot measurements can allow the identification of preferential 
removal of fluid from the lower limbs in an individual case and alteration of 
management accordingly. 
 
7.5.3 Assessing the feasibility of IPC and neuromuscular 
stimulation for mobilisation of lower limb oedema 
The issue of haemodynamic stability in haemodialysis is a poorly understood area. 
Methods of monitoring haemodynamics have been developed but very few 
interventions have been proposed. The use of compression devices has been trialled as a 
method of improving central blood volume, but with inconclusive results (Tai et al., 
2013). Cool dialysate and midodrine have been shown to improve haemodynamic 
stability (Hoeben et al., 2002), but this is related more to compensatory mechanisms of 
the cardiovascular system than the mobilisation of excess fluid. Anti-embolism 
stockings have been shown to have some effects on haemodynamic variables early in 
haemodialysis sessions, but with no clear improvement over the treatment as a whole 
(Kim et al., 2010). 
 
This study assessed the feasibility of compression or stimulation as methods of 
mobilising localised lower limb oedema by improving venous and lymphatic return. 
The outcomes around feasibility are discussed here. 
 
Rate of recruitment – The rate of recruitment was low at around 2% of the local 
population. Previous reports have estimated around 23% of haemodialysis patients as 
having pitting oedema (Agarwal et al., 2008) while it is estimated that up to a 30% of 
HD treatments include IDH (Palmer and Henrich, 2008). There are a number of possible 
explanations for this disparity. Firstly, the study was undertaken in a unit with a 
particular interest in avoiding excessive dehydration and where BCM has been part of 
routine care for a number of years. Also, the identification of IDH was not based on BP 
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measurements but on nursing staff recording episodes of IDH, which may not always 
happen. Previous interventional studies have been able to recruit patients into studies 
based on suffering IDH in 30% or more sessions over one month (Tai et al., 2013). In 
the department in which the research was carried out, using the recorded metrics for 
IDH, only 13% of subjects would meet these particular inclusion criteria. 
Adherence to the interventions – Adherence to the interventions was good. During the 
compression phase, half of the patients were happy to wear the cuffs throughout 
treatment. Other patients liked to have some breaks, when the cuffs started to itch or get 
warm. During the stimulation phase, adherence to the prescribed time was only slightly 
lower. Most participants experienced a strange sensation but none reported it to be 
uncomfortable. However, for two patients, no response - in terms of patient sensation or 
visual observation of muscle movement was possible from either stimulator. Patients 
found both interventions to be minimally burdensome and in fact of the six patients 
recruited, one patient purchased a compression device and one patient purchased a 
stimulation device for home use because of the benefits they perceived from the 
devices. 
Clinical outcome measures - The study highlighted issues that need to be considered 
when designing trials with outcome measures relating to fluid status. BCM 
measurements are rarely made for routine management with the frequency that they 
were undertaken here for recording outcome measures, so blinding is important. 
However, this is also ethically challenging. In this study, there was no blinding and the 
results were used to alter target weights when felt there was an indication. This is likely 
to result in fewer IDH episodes and less chance of patients target weight becoming 
inappropriate. The results also highlighted the diurnal variations in lower limb oedema 
that can impact upon outcome measures. During the transition from compression to 
stimulation with subject 4, the patient changed from having dialysis in the afternoons to 
being treated in the morning. Given that fluid accumulates in the lower limbs during the 
day, as patients are more likely to be upright, and then reduces at night when supine, the 
extent of the oedema was much reduced during the stimulation phase and this was 
reflected by a lower reduction in limb circumference than the control period. 
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7.6 Limitations 
There are a number of limitations to this study. This study was also limited by issues 
around availability of blood volume monitor chambers part way through the study. 
However, in the patients that were monitored, there were no instances of poor refilling 
observed which, as discussed, may be related to the high degree of care the patients 
received in relation to fluid management.  
 
This study did not investigate or optimise the application of the compression device for 
the purpose of this trial. The devices used in the trial are intended for use in preventing 
deep vein thrombosis. There are other devices that encompass the whole leg and that 
have difference settings to maximise fluid removal. However, these devices are much 
less commonly available and much more expensive. The simple device was chosen as a 
pragmatic solution that could be reproduced easily in most centres, due to the ease of 
use, patient acceptability and prevalence of the devices across the country. However, it 
has been shown that different settings on the device have significantly different effects 
(Grieveson, 2003). The fact that the region of compression was just the calves may 
mean that the fluid does not move adequately out of the region of intervention towards 
non-swollen tissues, for maximum vascular refilling (Olszewski et al., 2011). 
 
A better assessment of IDH would have given a more sensitive outcome measure for the 
trial. One method of doing this is repeated blood pressure measurements throughout 
treatment, although this can be of some discomfort to the patients. 
 
 
7.7 Conclusion and implications for practice 
Use of the BCM in patients with localised oedema allows the potential for better 
tailoring of target weights to best reduce the morbidity associated with oedema and 
normalise fluid status without provoking IDH. Standard measurement paths give a 
biased assessment of whole-body fluid status and achievable ultrafiltration volumes and 
there is no clear evidence that all this fluid is readily mobilised into the vascular space. 
However, even within this small group of six subjects, there was a great degree of 
variability in tolerance of ultrafiltration, comorbidities and ability to obtain valid BCM 
measurements amongst other things. This highlights the need for an individualised 
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approach to BCM based fluid management in these subjects. Post-dialysis hand-to-hand 
measurements and RBV monitoring can be used to ensure the upper body does not 
become fluid depleted and hand-to-foot measurements pre- and post-dialysis can help to 
guide the extent to which lower limb oedema can be mobilised. An understanding of the 
differences in BCM measurement path and timings can allow users to adapt to the 
clinical situation and have confidence in reporting the results. 
 
Clear feasibility for a study to categorically assess the interventions for improving the 
process of fluid removal on haemodialysis has not been demonstrated. The low 
prevalence of patients meeting the inclusion criteria would mean a study would have to 
be multi-centre, and necessitate standardisation of centre-to-centre practice pattern 
differences. The majority of patients eligible were happy to consent, which may be 
related to the morbidity associated with lower limb oedema and patients’ desire to 
intervene. 
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8 Conclusion 
8.1 Unmet clinical need 
This research aimed to address the need for a greater evidence base to underpin the 
development of bioimpedance and RBV monitoring beyond the research setting and 
into routine care. For this, they must become practical and effective tools that can be 
used to provide individualised fluid management across the haemodialysis population.  
 
The results have characterised the uncertainties associated with measuring outside the 
standard protocol suggesting that, despite the many practical and clinical complications 
common in haemodialysis units, BCM can obtain useful diagnostic information in most 
scenarios. The results inform the development of individualised approach to 
interpretation of BCM measurements in certain patient groups and the need for further 
research to dissect the associations of fluid overload and fluid depletion with mortality. 
The combined use of RBV and BCM has indicated that existing management strategies 
based on RBV may need to be altered, as the ‘flat-line’ (‘A’) curve that has been 
assumed to indicate fluid overload has been observed in many patients who are 
normally hydrated or fluid depleted based on the BCM measurements.  
 
The findings provide both a grounding for development of measurement protocols to 
improve fluid management strategies and a reference for further research aimed at 
describing the underlying mechanisms. 
 
8.2 Research questions 
Here the main conclusions from each research question are summarised and 
implications for clinical practice outlined. 
 
Research question 1: Can characterisation of alternative measurement paths and timing 
for the BCM, and the use of simultaneous RBV monitoring, lead to more individualised 
and effective fluid management? 
With use of an 8-lead BCM, measurements across all configurations of electrodes 
placed at the wrist and ankle allowed the characterisation of BCM measurements in 
relation to the standard path. Measurements made on control subjects with normal renal 
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function – where euhydration and no perturbations from normal fluid distributions were 
assumed – showed that measurements on all of the primary whole body paths other than 
foot-to-foot gave similar fluid status. 8-lead BCM measurements in haemodialysis 
patients pre-dialysis, showed similar patterns except for a small increase in BCM-
measured fluid overload associated with the presence of vascular access. Finally, 
measurements made post-dialysis demonstrated that there was minimal bias compared 
to pre-dialysis measurements and that post-dialysis measurements should not be ruled 
out. Having a reference for the variation in BCM-measured OH using alternative 
electrode configurations and timings will have a significant impact on the flexibility and 
inclusivity of routine BCM measurements. Importantly, BCM measurements can be 
made after dialysis sessions during which patients have experienced severe symptoms 
allowing excessive fluid depletion to be identified and the patient to be reassured that a 
simple increase in their target weight will prevent recurrence. 
 
The simultaneous measurement of BCM and RBV measurements gave a new insight 
into some of the fundamental assumptions of RBV monitoring for fluid management. It 
is widely accepted that a flat-line (‘A’) curve suggests the need for a reduction in target 
weight. While this approach has been shown to reduce weight and improve blood 
pressure in interventional studies (Agarwal et al., 2009),the sole robust clinical trial 
investigating the use RBV found higher mortality in the RBV managed group than in 
standard care (Reddan et al., 2005). There has been no good explanation for these 
unexpected findings but based on the results presented here, it is possible that reducing 
target weights based on RBV flat-lines increases fluid depletion in these patients, which 
is associated with a number of deleterious effects including loss of residual renal 
function (Jansen et al., 2002) and cardiovascular stress (McIntyre, 2010). This 
highlights the complexity of RBV measurements used for fluid management and the 
urgent need for further studies in this area. Of particular benefit would be a better 
understanding of how whole-body and segmental BCM-measured fluid volumes, RBV 
and absolute blood volume are related to risk factors and how these factors differ 
between patient groups. 
 
Research question 2: Is the tendency for high BMI haemodialysis patients to finish 
dialysis fluid depleted according to the BCM associated with an artefact in the 
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mathematical model or with systematic differences in the prescription and delivery of 
treatment? 
Observational studies have demonstrated a clear link between post-dialysis fluid 
depletion as defined by BCM and high BMI and this has raised doubt about the validity 
of BCM in subjects with high BMI. However, these studies are unable to define whether 
the observations relate to systematic bias in the BCM modelling or are treatment related 
effects.  
 
BCM measurements on high BMI subjects with normal renal function showed these 
subjects to be normally hydrated suggesting the BCM models are valid in subjects with 
BMI up to 50 kg/m2. The fluid depletion observed in very large haemodialysis patients 
is likely to be related to a combination of factors, including patient’s desire to minimise 
weight and a large ECF volume that can buffer plasma volume changes. Indeed, RBV 
measurements on high BMI dialysis patients show that refilling was maintained, despite 
high levels of fluid depletion.  
 
Research question 3: Is the presence of malnutrition associated with BCM-measured 
fluid overload? 
 
Mirroring the association between high BMI and fluid depletion, observational data 
suggest that low BMI is associated with post-dialysis fluid overload. In this study it was 
shown that a degree of excess fluid as measured by BCM is common in elderly subjects 
with normal renal function irrespective of whether they were classified as malnourished 
or of unclassified body habitus. Without recruiting a cohort of younger malnourished 
subjects with normal renal function, it is not possible to define the effect of malnutrition 
on BCM-measured OH isolated from confounding factors. However, the results support 
the tailoring of fluid management strategies in patient with increasing combinations of 
ageing, malnutrition, comorbidities and frailty to account for the fact that a degree of 
excess fluid as measured by BCM appears to be common in these groups. 
 
Research question 4: (a) Can BCM measurements be used to assess and monitor 
localised fluid oedema and (b) Can easily administered, non-invasive interventions 
mobilise persistent localised oedema so that it can be recruited into the circulation? 
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Standard hand-to-foot measurement paths should not be used in isolation for managing 
patients with localised oedema. These patients can have differing needs and no single 
approach to measurement and interpretation of results is sufficient. By using standard 
and alternative measurement paths and, if appropriate both pre- and post-dialysis 
measurements, users should be able to optimise any possible reduction in oedema while 
minimising the risk of fluid depletion to other parts of the body.  
 
The feasibility of IPC and neuromuscular stimulation as interventions for increasing 
refilling and improving both fluid removal and patient experience during dialysis was 
assessed. A conclusive trial to evaluate these devices would likely be difficult to design 
and deliver, mainly due to the difference in the presentation and response of patients 
with localised oedema. However the interventions were well tolerated and two of the six 
patients in the feasibility study wanted to purchase the devices as they perceived a 
benefit. 
 
8.3 Further work 
The practicality of measurements with BCM and the potential for use across the 
haemodialysis population has been demonstrated. This focus on measurement should be 
followed up by work that develops the interpretation of BCM results and the evidence 
base for management strategies. A number of interventional studies, including 
randomised controlled trials and prospective cohort studies, have showed that using 
BCM to guide populations to target OH values has improved hard outcomes, including 
fluid status, blood pressure, arterial stiffness and survival (Onofriescu et al., 2014, 
Onofriescu et al., 2012, Moissl et al., 2013). However, these are based on universal 
strategies and neglect personalised approaches.  
 
To better understand the mechanisms behind the morbidity and mortality associated 
with both fluid overload and fluid depletion, intravascular fluid status is likely to be 
important. BCM and RBV are complementary measurements - BCM provides tissue 
hydration information and quantifies fluid status, while RBV gives information on 
intravascular fluid changes and can help patients avoid IDH.  But there is also a need for 
an absolute measure of blood volume for assessment of intravascular hydration. Recent 
work has demonstrated a simple method for measuring absolute blood volume (ABV) 
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from a dialysis machine and a RBV measurement device. Simultaneous assessments of 
BCM, RBV and ABV would allow a more complete picture of the characteristics of 
fluid accumulation and removal in dialysis patients and potentially develop the 
conclusions from this piece of work. 
 
Training materials for BCM use in the large proportion of dialysis patients with special 
needs are lacking and this work can form the basis of practical training tools. More 
focussed research using information from BCM and RBV is clearly needed to improve 
methods of interpretation of RBV data. 
 
8.4 Summary 
This study provides important information to support flexible and individualised routine 
use of BCM for fluid management in haemodialysis. Based on manufacturer’s guidance, 
a significant subset of patients would be excluded from measurement or measurements 
would give inappropriate results. These data show that alternative measurement 
approaches are valid and supports individualised interpretation of BCM-measured OH. 
Further work is needed to better understand how to use RBV measurements in routine 
practice.  
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9 Appendix 
9.1 8-lead BCM measurement specification 
Path Current Current Voltage Voltage Segments measured 
1 Right hand Right foot Right hand Right foot Right arm, Right trunk, Right leg 
2 Left hand Left foot Left hand Left foot Left arm, Left trunk, Left leg 
3 Right hand Left foot Right hand Left foot Right arm, R-L trunk, Left leg 
4 Left hand Right foot Left hand Right foot Left arm, L-R trunk, Right leg 
5 Right hand Left hand Right hand Left hand Right arm, Top trunk, Left arm 
6 Right foot Left foot Right foot Left foot Right leg, Low trunk, Left leg 
7 Right hand Right foot Right hand Left foot Right arm + Right trunk 
8 Left hand Left foot Left hand Right foot Left arm + Left trunk 
9 Right hand Right foot Left hand Right foot Right leg + Right trunk 
10 Left hand Left foot Right hand Left foot Left leg + Left trunk 
11 Right hand Left hand Right hand Right foot Right arm only 
12 Right hand Left hand Left hand Left foot Left arm only 
13 Right foot Left foot Right hand Right foot Right leg only 
14 Right foot Left foot Left hand Left foot Left leg only 
15 Right hand Right foot Left hand Left foot Right trunk only 
16 Left hand Left foot Right hand Right foot Left trunk only 
17 L&R hand L&R foot L&R hand L&R foot Full whole body 
 
9.2 Mixed regression model assumption checks 
Section 4-4 presented results from mixed regression models investigating OH, lean 
tissue and adipose tissue. Here, the results from checks of the models investigation lean 
tissue (figure 9-1) and adipose tissue (figure 9-2) are presented. Visual inspection of the 
residual plots suggested random scatter. Although Q-Q plots showed some dispersion 
from normality; sensitivity analyses were done by checking the outliers for errors, but 
no clear problems with the data were found. 
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Figure 9-1: Plot of residuals (left) and a ‘Q-Q’ plot of the residuals (right) for mixed-
effects model of LTM in healthy controls (above) and haemodialysis patients (below) 
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Figure 9-2: Plot of residuals (left) and a ‘Q-Q’ plot of the residuals (right) for mixed-
effects model of ATM in healthy controls (above) and haemodialysis patients (below) 
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9.3 Repeatability of regression model 
Repeat measurements were made for 36 of the 48 dialysis patients to assess the 
reproducibility of the regression model. The analysis was done in exactly the same way 
and the results can be seen in tables 9-1 to 9-3. The model had lower power than the 
primary analysis, which can explain why some of the results that were significant in the 
primary analysis are no longer significant here. However, the trends are consistent and 
the effect sizes similar, suggesting good reproducibility of the model. 
 
 
Measurement  
Path 
OH  
(litres) 
Bias  
(litres) 
 
p-value 
Approx. 95% 
CI 
Pre-
dialysis 
Non-VA side 1.6 - 0.19 -0.20 to 3.3 
VA-side - 0.01 0.02 -0.45 to 0.48 
Cross1 - 0.07 0.91 -0.39 to 0.54 
Cross2 - -0.12 0.02 0.59 to 0.34 
Arms - -0.51 0.23 -0.55 to 0.13 
Legs - 1.6 <0.01 1.1 to 2.1 
Post-
dialysis 
Non-VA side -0.33 - 0.45 -0.81 to 0.26 
VA-side - 0.31 0.37 -0.35 to 0.97 
Cross1 - 0.01 0.98 -0.65 to 0.67 
Cross2 - 0.37 0.28 -0.29 to 1.0 
Arms - 0.52 0.13 -0.13 to 1.2 
Legs - -0.43 0.20 -1.1 to 0.22 
Table 9-1: Repeat OH measurements for dialysis patients. Reference path is non-VA side. 
Data are presented for a 60 year old female, where the adjustment for age was 0.06 per 
year (p=0.6; 95% CI: -0.02 to 0.03) and for sex was -0.38 for male (p=0.4; 95% CI: -1.3 to 
0.5) 
 
 
Measurement  
Path 
LTM  
(kg) 
Bias  
(kg) 
 
p-value 
Approx. 95% 
CI 
Pre-
dialysis 
Non-VA side 23 - <0.01 5 to 41 
VA-side - 1.0 0.45 -0.81 to 2.8 
Cross1 - -0.12 0.61 -1.9 to 1.7 
Cross2 - 1.3 0.12 -0.5 to 3.1 
Arms - 1.7 0.08 -0.13 to 3.5 
Legs - 1.9 0.04 0.06 to 3.7 
Post-
dialysis 
Non-VA side 22 - <0.01 20 to 24 
VA-side - -0.81 0.69 -3.4 to 1.8 
Cross1 - -0.03 0.90 -2.6 to 2.5 
Cross2 - -0.94 0.41 -3.5 to 1.6 
Arms - -0.36 0.82 -2.9 to 2.2 
Legs - -0.44 0.89 -3.0 to 2.1 
Table 9-2: Repeat measurements for LTM with dialysis patients. Reference path is non-
VA side. Data are presented for a 60 year old female, where the adjustment for age was -
0.16 per year (p=0.25; 95% CI: -0.44 to 0.11) and for sex was -2.6 for male (p=0.6; 95% 
CI: -12 to 6.8) 
125 
 
 
 
 
Measurement  
Path 
ATM  
(kg) 
Bias  
(kg) 
 
p-value 
Approx. 95% 
CI 
Pre-
dialysis 
Non-VA side 36 - <0.01 11 to 60 
VA-side - -1.0 0.26 -2.8 to 0.7 
Cross1 - 0.05 0.98 -1.7 to 1.8 
Cross2 - -1.1 0.20 -2.9 to 0.6 
Arms - -1.1 0.21 -2.9 to 0.6 
Legs - 3.6 <0.01 -5.3 to -1.8 
Post-
dialysis 
Non-VA side 37 - <0.01 12 to 61 
VA-side - 0.49 0.70 -2.0 to 2.9 
Cross1 - 0.02 0.99 -2.4 to 2.5 
Cross2 - 0.56 0.66 -1.9 to 3.0 
Arms - -0.18 0.88 -2.6 to 2.3 
Legs - 0.90 0.48 -1.6 to 3.4 
Table 9-3: Repeat measurements ATM model results for dialysis patients. Reference path 
is non-VA side. Data are presented for a 60 year old female, where the adjustment for age 
was 0.06 per year (p=0.8; 95% CI: -0.14 to 0.58) and for sex was 6.6 for male (p=0.3; 95% 
CI: -9.0 to 14) 
 
9.4 Complete RBV results 
Table 9-4 presents the complete set of RBV results for all 48 patients and over both 
sessions. Where a shape factor is presented in brackets, this is the result of the 
sensitivity analysis.  
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Session 1 Session 2 
Pre-HD OH UF vol. Refilling Shape Pre-HD OH UF vol. Refilling Shape 
-0.7 1.5 1 A (C) 3.8 3.4 0 C 
3 1.4 1 D - - - - 
4.4 2.1 0 D 4.5 2.7 0 D 
-1.4 0.7 1 D 0.4 2.5 1 D 
- - - - - - - - 
3.2 3 0 D (C) -0.1 2.6 0 C 
1.6 1.5 0 C - - - - 
-0.5 0.4 1 C -0.8 0.9 1 A 
1.4 3.3 1 C 2.5 3.8 1 C 
1 2.2 1 D (C) - - - - 
1.1 1.3 0 D 0.5 0.6 0 D 
0.9 1.7 1 D 1.6 1.6 1 D 
2 3.1 1 A (D) - - - - 
-1 0.5 0 C -0.6 0.8 1 A (C) 
0.5 1.4 1 D 0.8 2.4 1 D 
1.5 1.7 0 C 3.4 2.5 0 D 
-0.9 1.5 1 A (D) 0.7 1.8 1 C 
2.2 3.5 1 C - - - - 
2.6 0.6 1 D 0.7 0.4 0 D 
2.4 2.1 0 C 1.4 1.9 0 C 
    0.7 1.1 1 D 
-0.8 1.1 1 A -1.2 0.9 1 D 
3.2 1.4 1 A 0.9 1.9 1 C 
0.6 1.3 0 D -0.9 0.6 1 A 
- - - - -0.6 1.0 1 A (B) 
2 1.7 1 A (B) 1.9 2.8 1 A (C) 
- - - - 1.4 2.6 1 A 
1.8 2.9 1 A (C) 1.4 2.6 1 D (C) 
- - - - 2.8 4 1 C 
-0.7 0.7 1 A -0.7 1.2 1 A (C) 
- - - - 2.9 3.0 1 C 
1.5 1.2 0 D - - - - 
4 3.2 1 D 5.6 3.2 0 D 
1.1 0.8 0 D 1 1.2 1 A (C) 
0.7 1.6 1 D -0.8 1.5 0 D 
4.1 3 1 C 5.8 4 1 C 
0.9 2.4 1 C 0.1 1.6 1 C 
2.1 2.1 1 A 2.1 2.4 1 D (C) 
2.7 2.7 1 B - - - - 
0.5 2 1 C 0.7 1.2 1 B 
0.4 1.2 1 A 1.8 1.1 1 A (C) 
1.1 1.7 1 A (C) 0.9 1.4 1 D 
2.1 1.4 1 A (B) 0.9 0.4 1 A (C) 
3.3 3 1 A (c) - - - - 
3.8 3 1 D 1.9 2.6 1 D 
2.8 1.4 1 C - - - - 
3.9 3.5 1 C - - - - 
- - - - 4.1 2.5 0 C 
Table 9-4: Complete RBV results 
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